Treatment	O
of	O
allergic	O
airway	O
inflammation	O
and	O
hyperresponsiveness	O
by	O
antisense-induced	O
local	O
blockade	O
of	O
GATA-3	B-DNA
expression	O
.	O

Recent	O
studies	O
in	O
transgenic	O
mice	O
have	O
revealed	O
that	O
expression	O
of	O
a	O
dominant	O
negative	O
form	O
of	O
the	O
transcription	B-protein
factor	I-protein
GATA-3	I-protein
in	O
T	B-cell_type
cells	I-cell_type
can	O
prevent	O
T	B-cell_type
helper	I-cell_type
cell	I-cell_type
type	I-cell_type
2	I-cell_type
(	O
Th2	B-cell_type
)	O
-mediated	O
allergic	O
airway	O
inflammation	O
in	O
mice	O
.	O

However	O
,	O
it	O
remains	O
unclear	O
whether	O
GATA-3	B-protein
plays	O
a	O
role	O
in	O
the	O
effector	O
phase	O
of	O
allergic	O
airway	O
inflammation	O
and	O
whether	O
antagonizing	O
the	O
expression	O
and/or	O
function	O
of	O
GATA-3	B-DNA
can	O
be	O
used	O
for	O
the	O
therapy	O
of	O
allergic	O
airway	O
inflammation	O
and	O
hyperresponsiveness	O
.	O

Here	O
,	O
we	O
analyzed	O
the	O
effects	O
of	O
locally	O
antagonizing	O
GATA-3	B-protein
function	O
in	O
a	O
murine	O
model	O
of	O
asthma	O
.	O

We	O
could	O
suppress	O
GATA-3	O
expression	O
in	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-4	I-protein
-producing	O
T	B-cell_type
cells	I-cell_type
in	O
vitro	O
and	O
in	O
vivo	O
by	O
an	O
antisense	O
phosphorothioate	O
oligonucleotide	O
overlapping	O
the	O
translation	B-DNA
start	I-DNA
site	I-DNA
of	O
GATA-3	B-DNA
,	O
whereas	O
nonsense	O
control	O
oligonucleotides	O
were	O
virtually	O
inactive	O
.	O

In	O
a	O
murine	O
model	O
of	O
asthma	O
associated	O
with	O
allergic	O
pulmonary	O
inflammation	O
and	O
hyperresponsiveness	O
in	O
ovalbumin	O
(	O
OVA	O
)	O
-sensitized	O
mice	O
,	O
local	O
intranasal	O
administration	O
of	O
fluorescein	O
isothiocyanate-labeled	O
GATA-3	O
antisense	O
oligonucleotides	O
led	O
to	O
DNA	O
uptake	O
in	O
lung	B-cell_type
cells	I-cell_type
associated	O
with	O
a	O
reduction	O
of	O
intracellular	O
GATA-3	O
expression	O
.	O

Such	O
intrapulmonary	O
blockade	O
of	O
GATA-3	O
expression	O
caused	O
an	O
abrogation	O
of	O
signs	O
of	O
lung	O
inflammation	O
including	O
infiltration	O
of	O
eosinophils	B-cell_type
and	O
Th2	B-cell_type
cytokine	O
production	O
.	O

Furthermore	O
,	O
treatment	O
with	O
antisense	O
but	O
not	O
nonsense	O
oligonucleotides	O
induced	O
a	O
significant	O
reduction	O
of	O
airway	O
hyperresponsiveness	O
in	O
OVA-sensitized	O
mice	O
to	O
levels	O
comparable	O
to	O
saline-treated	O
control	O
mice	O
,	O
as	O
assessed	O
by	O
both	O
enhanced	O
pause	O
(	O
PenH	O
)	O
responses	O
and	O
pulmonary	O
resistance	O
determined	O
by	O
body	O
plethysmography	O
.	O

These	O
data	O
indicate	O
a	O
critical	O
role	O
for	O
GATA-3	B-DNA
in	O
the	O
effector	O
phase	O
of	O
a	O
murine	O
asthma	O
model	O
and	O
suggest	O
that	O
local	O
delivery	O
of	O
GATA-3	O
antisense	O
oligonucleotides	O
may	O
be	O
a	O
novel	O
approach	O
for	O
the	O
treatment	O
of	O
airway	O
hyperresponsiveness	O
such	O
as	O
in	O
asthma	O
.	O

This	O
approach	O
has	O
the	O
potential	O
advantage	O
of	O
suppressing	O
the	O
expression	O
of	O
various	O
proinflammatory	B-protein
Th2	I-protein
cytokines	I-protein
simultaneously	O
rather	O
than	O
suppressing	O
the	O
activity	O
of	O
a	O
single	O
cytokine	B-protein
.	O

Treatment	NULL
of	NULL
Allergic	NULL
Airway	NULL
Inflammation	NULL
and	NULL
Hyperresponsiveness	NULL
by	NULL
Antisense-induced	NULL
Local	NULL
Blockade	NULL
of	NULL
GATA-3	NULL
Expression	NULL
By	NULL
Susetta	NULL
Finotto	NULL
,	NULL
*	NULL
George	NULL
T.	NULL
De	NULL
Sanctis	NULL
,	NULL
!	NULL
)	NULL

Hans	NULL
A.	NULL
Lehr	NULL
,	NULL
#	NULL
Udo	NULL
Herz	NULL
,	NULL
**	NULL
Michael	NULL
Buerke	NULL
,	NULL
$	NULL
Mechthild	NULL
Schipp	NULL
,	NULL
*	NULL
Brigitte	NULL
Bartsch	NULL
,	NULL
*	NULL
Raja	NULL
Atreya	NULL
,	NULL
*	NULL
Edgar	NULL
Schmitt	NULL
,	NULL
)	NULL
Peter	NULL
R.	NULL
Galle	NULL
,	NULL
*	NULL
Harald	NULL
Renz	NULL
,	NULL
**	NULL
and	NULL
Markus	NULL
E	NULL
Neurath*	NULL
From	NULL
the	NULL
*Laboratory	NULL
of	NULL
Immunology	NULL
,	NULL
the	NULL
*Institute	NULL
of	NULL
Pathology	NULL
,	NULL
the	NULL
Medical	NULL
Clinic	NULL
II	NULL
,	NULL
and	NULL
the	NULL
Institute	NULL
of	NULL
Immunology	NULL
,	NULL
University	NULL
of	NULL
Mainz	NULL
,	NULL
55099	NULL
Mainz	NULL
,	NULL
Germany	NULL
;	NULL
the	NULL
Division	NULL
of	NULL
Pulmonary	NULL
and	NULL
Critical	NULL
Care	NULL
Medicine	NULL
,	NULL
Brigham	NULL
and	NULL
Women	NULL
's	NULL
Hospital	NULL
,	NULL
Harvard	NULL
Medical	NULL
School	NULL
,	NULL
Boston	NULL
,	NULL
Massachusetts	NULL
02115	NULL
;	NULL
and	NULL
the	NULL
**	NULL
Institute	NULL
of	NULL
Laboratory	NULL
Medicine	NULL
,	NULL
University	NULL
of	NULL
Marburg	NULL
,	NULL
D-35033	NULL
Marburg	NULL
,	NULL
Germany	NULL
Abstract	NULL
Recent	NULL
studies	NULL
in	NULL
transgenic	NULL
mice	NULL
have	NULL
revealed	NULL
that	NULL
expression	NULL
of	NULL
a	NULL
dominant	NULL
negative	NULL
form	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
GATA-3	NULL
in	NULL
T	NULL
cells	NULL
can	NULL
prevent	NULL
T	NULL
helper	NULL
cell	NULL
type	NULL
2	NULL
(	NULL
Th2	NULL
)	NULL
-mediated	NULL
allergic	NULL
airway	NULL
inflammation	NULL
in	NULL
mice	NULL
.	NULL

However	NULL
,	NULL
it	NULL
remains	NULL
unclear	NULL
whether	NULL
GATA-3	NULL
plays	NULL
a	NULL
role	NULL
in	NULL
the	NULL
effector	NULL
phase	NULL
of	NULL
allergic	NULL
airway	NULL
inflammation	NULL
and	NULL
whether	NULL
antagonizing	NULL
the	NULL
expression	NULL
and/or	NULL
function	NULL
of	NULL
GATA-3	NULL
can	NULL
be	NULL
used	NULL
for	NULL
the	NULL
therapy	NULL
of	NULL
allergic	NULL
airway	NULL
inflammation	NULL
and	NULL
hyperresponsiveness	NULL
.	NULL

Here	NULL
,	NULL
we	NULL
analyzed	NULL
the	NULL
effects	NULL
of	NULL
locally	NULL
antagonizing	NULL
GAT	NULL
function	NULL
in	NULL
a	NULL
murine	NULL
model	NULL
of	NULL
asthma	NULL
.	NULL

We	NULL
could	NULL
suppress	NULL
GATA-3	NULL
expression	NULL
in	NULL
interleukin	NULL
(	NULL
IL	NULL
)	NULL
-4-pro-ducing	NULL
T	NULL
cells	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
by	NULL
an	NULL
antisense	NULL
phosphorothioate	NULL
oligonucleotide	NULL
overlapping	NULL
the	NULL
translation	NULL
start	NULL
site	NULL
of	NULL
GATA-3	NULL
,	NULL
whereas	NULL
nonsense	NULL
control	NULL
oligonucleotides	NULL
were	NULL
virtually	NULL
inactive	NULL
.	NULL

In	NULL
a	NULL
murine	NULL
model	NULL
of	NULL
asthma	NULL
associated	NULL
with	NULL
allergic	NULL
pulmonary	NULL
inflammation	NULL
and	NULL
hyperresponsiveness	NULL
in	NULL
ovalbumin	NULL
(	NULL
OVA	NULL
)	NULL
-sensitized	NULL
mice	NULL
,	NULL
local	NULL
intranasal	NULL
administration	NULL
of	NULL
fluorescein	NULL
isothiocyanate-labeled	NULL
GATA-3	NULL
antisense	NULL
oligonucleotides	NULL
led	NULL
to	NULL
DNA	NULL
uptake	NULL
in	NULL
lung	NULL
cells	NULL
associated	NULL
with	NULL
a	NULL
reduction	NULL
of	NULL
intracellular	NULL
GATA-3	NULL
expression	NULL
.	NULL

Such	NULL
intrapulmonary	NULL
blockade	NULL
of	NULL
GATA-3	NULL
expression	NULL
caused	NULL
an	NULL
abrogation	NULL
of	NULL
signs	NULL
of	NULL
lung	NULL
inflammation	NULL
including	NULL
infiltration	NULL
of	NULL
eosinophils	NULL
and	NULL
Th2	NULL
cytokine	NULL
production	NULL
.	NULL

Furthermore	NULL
,	NULL
treatment	NULL
with	NULL
antisense	NULL
but	NULL
not	NULL
nonsense	NULL
oligonucleotides	NULL
induced	NULL
a	NULL
significant	NULL
reduction	NULL
of	NULL
airway	NULL
hyperresponsiveness	NULL
in	NULL
OVA-sensitized	NULL
mice	NULL
to	NULL
levels	NULL
comparable	NULL
to	NULL
saline-treated	NULL
control	NULL
mice	NULL
,	NULL
as	NULL
assessed	NULL
by	NULL
both	NULL
enhanced	NULL
pause	NULL
(	NULL
PenH	NULL
)	NULL
responses	NULL
and	NULL
pulmonary	NULL
resistance	NULL
determined	NULL
by	NULL
body	NULL
plethysmography	NULL
.	NULL

These	NULL
data	NULL
indicate	NULL
a	NULL
critical	NULL
role	NULL
for	NULL
GATA-3	NULL
in	NULL
the	NULL
effector	NULL
phase	NULL
of	NULL
a	NULL
murine	NULL
asthma	NULL
model	NULL
and	NULL
suggest	NULL
that	NULL
local	NULL
delivery	NULL
of	NULL
GATA-3	NULL
antisense	NULL
oligonucleotides	NULL
may	NULL
be	NULL
a	NULL
novel	NULL
approach	NULL
for	NULL
the	NULL
treatment	NULL
of	NULL
airway	NULL
hyperresponsiveness	NULL
such	NULL
as	NULL
in	NULL
asthma	NULL
.	NULL

This	NULL
approach	NULL
has	NULL
the	NULL
potential	NULL
advantage	NULL
of	NULL
suppressing	NULL
the	NULL
expression	NULL
of	NULL
various	NULL
proinflammatory	NULL
Th2	NULL
cytokines	NULL
simultaneously	NULL
rather	NULL
than	NULL
suppressing	NULL
the	NULL
activity	NULL
of	NULL
a	NULL
single	NULL
cytokine	NULL
.	NULL

Key	NULL
words	NULL
:	NULL
-	NULL
GATA-3	NULL
*	NULL
antisense	NULL
DNA	NULL
*	NULL
asthma	NULL
*T	NULL
cells	NULL
Â«	NULL
Th2	NULL
cytokines	NULL
Introduction	NULL
Allergic	NULL
asthma	NULL
is	NULL
a	NULL
chronic	NULL
pulmonary	NULL
disease	NULL
associated	NULL
with	NULL
bronchoconstriction	NULL
and	NULL
chronic	NULL
inflammation	NULL
of	NULL
the	NULL
airways	NULL
(	NULL
1-3	NULL
)	NULL
.	NULL

In	NULL
allergic	NULL
asthma	NULL
,	NULL
there	NULL
is	NULL
a	NULL
polarization	NULL
of	NULL
T	NULL
Address	NULL
correspondence	NULL
to	NULL
Susetta	NULL
Finotto	NULL
,	NULL
Division	NULL
of	NULL
Pulmonary	NULL
and	NULL
Critical	NULL
Care	NULL
Medicine	NULL
,	NULL
Brigham	NULL
and	NULL
Women	NULL
's	NULL
Hospital	NULL
and	NULL
Harvard	NULL
Medical	NULL
School	NULL
,	NULL
75	NULL
Francis	NULL
St.	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
02115	NULL
.	NULL

Phone	NULL
:	NULL
617-278-0729	NULL
or	NULL
-0763	NULL
;	NULL
Fax	NULL
:	NULL
617-232-4623	NULL
;	NULL
E-mail	NULL
:	NULL
sfinotto	NULL
@	NULL
rics.bwh.harvard.edu	NULL
1247	NULL
lymphocyte	NULL
responses	NULL
and	NULL
enhanced	NULL
secretion	NULL
of	NULL
cytokines	NULL
involved	NULL
in	NULL
regulation	NULL
of	NULL
IgE	NULL
,	NULL
mast	NULL
cells	NULL
,	NULL
basophils	NULL
,	NULL
and	NULL
eosinophils	NULL
,	NULL
ultimately	NULL
leading	NULL
to	NULL
inflammation	NULL
and	NULL
disease	NULL
(	NULL
4	NULL
)	NULL
.	NULL

The	NULL
proinflammatory	NULL
cytokines	NULL
produced	NULL
by	NULL
T	NULL
cells	NULL
contribute	NULL
to	NULL
the	NULL
initiation	NULL
and	NULL
perpetuation	NULL
of	NULL
allergic	NULL
asthma	NULL
(	NULL
1-3	NULL
)	NULL
.	NULL

In	NULL
particular	NULL
,	NULL
it	NULL
has	NULL
been	NULL
shown	NULL
that	NULL
allergic	NULL
airway	NULL
inflammation	NULL
in	NULL
patients	NULL
with	NULL
asthma	NULL
and	NULL
animal	NULL
models	NULL
of	NULL
allergic	NULL
airway	NULL
inflammation	NULL
is	NULL
associated	NULL
with	NULL
increased	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

Â©	NULL
The	NULL
Rockefeller	NULL
University	NULL
Press	NULL
Â«	NULL
0022-1007/2001/06/1247/14	NULL
$	NULL
5.00	NULL
Volume	NULL
193	NULL
,	NULL
Number	NULL
11	NULL
,	NULL
June	NULL
4	NULL
,	NULL
2001	NULL
1247-1260	NULL
http	NULL
:	NULL
//www.jem.org/cgi/content/full/193/11/1247	NULL
Th2	NULL
(	NULL
IL-4	NULL
,	NULL
IL-5	NULL
,	NULL
IL-13	NULL
)	NULL
cytokine	NULL
production	NULL
(	NULL
5-8	NULL
)	NULL
.	NULL

In	NULL
this	NULL
regard	NULL
,	NULL
IL-4	NULL
has	NULL
been	NULL
postulated	NULL
to	NULL
be	NULL
critical	NULL
for	NULL
the	NULL
development	NULL
of	NULL
Th2	NULL
T	NULL
cells	NULL
in	NULL
asthmatic	NULL
airways	NULL
and	NULL
the	NULL
reduced	NULL
expression	NULL
of	NULL
the	NULL
IL-12	NULL
receptor	NULL
B2	NULL
chain	NULL
on	NULL
lung	NULL
Th1	NULL
cells	NULL
(	NULL
6	NULL
,	NULL
9	NULL
,	NULL
10	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
it	NULL
is	NULL
believed	NULL
to	NULL
induce	NULL
IgE	NULL
isotype	NULL
switching	NULL
in	NULL
B	NULL
cells	NULL
in	NULL
asthma	NULL
and	NULL
promotes	NULL
goblet	NULL
cell	NULL
metaplasia	NULL
,	NULL
mucus	NULL
hypersecretion	NULL
,	NULL
and	NULL
the	NULL
recruitment	NULL
of	NULL
eosinophils	NULL
by	NULL
upregulating	NULL
vascular	NULL
cell	NULL
adhesion	NULL
molecule	NULL
1	NULL
expression	NULL
in	NULL
pulmonary	NULL
endothelial	NULL
cells	NULL
(	NULL
10	NULL
)	NULL
.	NULL

The	NULL
importance	NULL
of	NULL
IL-4	NULL
is	NULL
also	NULL
underlined	NULL
by	NULL
the	NULL
observation	NULL
that	NULL
inhalation	NULL
of	NULL
IL-4	NULL
causes	NULL
the	NULL
development	NULL
of	NULL
sputum	NULL
eosinophilia	NULL
and	NULL
increased	NULL
responsiveness	NULL
of	NULL
the	NULL
airways	NULL
and	NULL
the	NULL
finding	NULL
that	NULL
neutralizing	NULL
antibodies	NULL
to	NULL
IL-4	NULL
are	NULL
therapeutically	NULL
effective	NULL
for	NULL
asthma	NULL
(	NULL
1	NULL
,	NULL
11	NULL
,	NULL
12	NULL
)	NULL
.	NULL

GATA-3	NULL
is	NULL
a	NULL
pleiotropic	NULL
transcription	NULL
factor	NULL
of	NULL
the	NULL
C4	NULL
zinc	NULL
finger	NULL
family	NULL
expressed	NULL
in	NULL
T	NULL
cells	NULL
,	NULL
mast	NULL
cells	NULL
,	NULL
eosinophils	NULL
,	NULL
basophils	NULL
,	NULL
and	NULL
embryonic	NULL
brain	NULL
and	NULL
kidney	NULL
that	NULL
binds	NULL
to	NULL
a	NULL
5-WGATAR-3	NULL
``	NULL
'	NULL
consensus	NULL
DNA	NULL
sequence	NULL
(	NULL
13-16	NULL
)	NULL
.	NULL

GATA-3	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
essential	NULL
for	NULL
the	NULL
development	NULL
of	NULL
the	NULL
earliest	NULL
T	NULL
cell	NULL
progenitor	NULL
cells	NULL
(	NULL
17	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
GATA-3	NULL
was	NULL
found	NULL
to	NULL
be	NULL
selectively	NULL
expressed	NULL
in	NULL
Th2	NULL
but	NULL
not	NULL
in	NULL
Th1	NULL
cells	NULL
and	NULL
to	NULL
play	NULL
an	NULL
important	NULL
role	NULL
in	NULL
cytokine	NULL
gene	NULL
expression	NULL
in	NULL
T	NULL
cells	NULL
(	NULL
18-21	NULL
)	NULL
.	NULL

In	NULL
particular	NULL
,	NULL
GAT	NULL
is	NULL
important	NULL
for	NULL
the	NULL
expression	NULL
of	NULL
IL-5	NULL
in	NULL
T	NULL
cells	NULL
by	NULL
transactivation	NULL
of	NULL
the	NULL
IL-5	NULL
promoter	NULL
together	NULL
with	NULL
Ets-1	NULL
and	NULL
Ets-2	NULL
proteins	NULL
(	NULL
20	NULL
,	NULL
21	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
GATA-3	NULL
weakly	NULL
transactivates	NULL
the	NULL
IL-4	NULL
promoter	NULL
in	NULL
T	NULL
cells	NULL
(	NULL
22	NULL
)	NULL
.	NULL

These	NULL
functions	NULL
of	NULL
GATA-3	NULL
on	NULL
Th2	NULL
cytokine	NULL
gene	NULL
promoters	NULL
can	NULL
be	NULL
suppressed	NULL
by	NULL
repressor	NULL
of	NULL
GATA	NULL
(	NULL
ROG	NULL
)	NULL
,	NULL
a	NULL
recently	NULL
cloned	NULL
lymphoid-specific	NULL
repressor	NULL
of	NULL
GATA-3-induced	NULL
transactivation	NULL
(	NULL
23	NULL
)	NULL
.	NULL

Finally	NULL
,	NULL
ectopic	NULL
expression	NULL
of	NULL
GATA-3	NULL
in	NULL
developing	NULL
Th1	NULL
cells	NULL
leads	NULL
to	NULL
upregulation	NULL
of	NULL
IL-4	NULL
and	NULL
IL-5	NULL
and	NULL
downregulation	NULL
of	NULL
IFN-y	NULL
.	NULL

The	NULL
latter	NULL
effect	NULL
appears	NULL
to	NULL
be	NULL
partly	NULL
due	NULL
to	NULL
downregulation	NULL
of	NULL
the	NULL
IL-12	NULL
receptor	NULL
B2	NULL
chain	NULL
(	NULL
18	NULL
,	NULL
19	NULL
,	NULL
24	NULL
)	NULL
.	NULL

Activation	NULL
studies	NULL
in	NULL
retroviral	NULL
infected	NULL
T	NULL
cells	NULL
have	NULL
shown	NULL
that	NULL
the	NULL
activation	NULL
of	NULL
GAT	NULL
in	NULL
T	NULL
cells	NULL
occurs	NULL
upon	NULL
activation	NULL
of	NULL
the	NULL
IL-4/signal	NULL
transducer	NULL
and	NULL
activator	NULL
of	NULL
transcription	NULL
(	NULL
STAT	NULL
)	NULL
'-6	NULL
signaling	NULL
pathway	NULL
(	NULL
25	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
exposure	NULL
of	NULL
naive	NULL
T	NULL
cells	NULL
to	NULL
IL-4	NULL
may	NULL
be	NULL
a	NULL
very	NULL
early	NULL
event	NULL
that	NULL
induces	NULL
GATA-3	NULL
activation	NULL
and	NULL
Th2	NULL
cell	NULL
differentiation	NULL
.	NULL

However	NULL
,	NULL
GATA-3	NULL
can	NULL
fully	NULL
reconstitute	NULL
Th2	NULL
development	NULL
in	NULL
STAT-6-deficient	NULL
T	NULL
cells	NULL
,	NULL
suggesting	NULL
that	NULL
it	NULL
is	NULL
a	NULL
master	NULL
switch	NULL
both	NULL
in	NULL
STAT-6-dependent	NULL
and	NULL
-inde-pendent	NULL
Th2	NULL
development	NULL
(	NULL
26	NULL
)	NULL
.	NULL

Finally	NULL
,	NULL
GATA-3	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
exert	NULL
STAT-6-independent	NULL
autoactivation	NULL
,	NULL
creating	NULL
a	NULL
feedback	NULL
pathway	NULL
stabilizing	NULL
Th2	NULL
commitment	NULL
(	NULL
26	NULL
)	NULL
.	NULL

Based	NULL
on	NULL
the	NULL
above	NULL
data	NULL
,	NULL
it	NULL
was	NULL
of	NULL
particular	NULL
interest	NULL
to	NULL
analyze	NULL
the	NULL
expression	NULL
and	NULL
functional	NULL
role	NULL
of	NULL
GATA-3	NULL
in	NULL
patients	NULL
with	NULL
atopic	NULL
asthma	NULL
.	NULL

Indeed	NULL
,	NULL
in	NULL
a	NULL
recent	NULL
study	NULL
Na-kamura	NULL
and	NULL
co-workers	NULL
(	NULL
27	NULL
)	NULL
showed	NULL
an	NULL
increased	NULL
expres-	NULL
Abbreviations	NULL
used	NULL
in	NULL
this	NULL
paper	NULL
:	NULL
BAL	NULL
,	NULL
bronchioalveolar	NULL
lavage	NULL
;	NULL
BALF	NULL
,	NULL
BAL	NULL
fluid	NULL
;	NULL
DEX	NULL
,	NULL
dexamethasone	NULL
;	NULL
EMSA	NULL
,	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
;	NULL
HPF	NULL
,	NULL
high	NULL
power	NULL
field	NULL
;	NULL
MACS	NULL
,	NULL
magnetic	NULL
cell	NULL
sorting	NULL
;	NULL
MCh	NULL
,	NULL
methacho-line	NULL
;	NULL
PAS	NULL
,	NULL
periodic	NULL
acid-Schiff	NULL
;	NULL
PenH	NULL
,	NULL
enhanced	NULL
pause	NULL
;	NULL
RL	NULL
,	NULL
pulmonary	NULL
resistance	NULL
;	NULL
STAT	NULL
,	NULL
signal	NULL
transducer	NULL
and	NULL
activator	NULL
of	NULL
transcription	NULL
.	NULL

1248	NULL
sion	NULL
of	NULL
GATA-3	NULL
mRNA	NULL
in	NULL
asthmatic	NULL
airways	NULL
,	NULL
suggesting	NULL
that	NULL
GATA-3	NULL
may	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
Th2	NULL
cytokine	NULL
responses	NULL
in	NULL
asthma	NULL
.	NULL

Based	NULL
on	NULL
this	NULL
observation	NULL
,	NULL
we	NULL
analyzed	NULL
in	NULL
the	NULL
present	NULL
study	NULL
the	NULL
role	NULL
of	NULL
GATA-3	NULL
in	NULL
a	NULL
mouse	NULL
model	NULL
of	NULL
asthma	NULL
(	NULL
28	NULL
)	NULL
using	NULL
an	NULL
antisense	NULL
DNA	NULL
strategy	NULL
.	NULL

We	NULL
observed	NULL
increased	NULL
local	NULL
production	NULL
of	NULL
GATA-3	NULL
in	NULL
this	NULL
model	NULL
and	NULL
demonstrate	NULL
that	NULL
local	NULL
treatment	NULL
with	NULL
GATA-3	NULL
antisense	NULL
oligonucleotides	NULL
could	NULL
be	NULL
successfully	NULL
used	NULL
to	NULL
downregulate	NULL
Th2-induced	NULL
pulmonary	NULL
inflammation	NULL
and	NULL
airway	NULL
hyperresponsiveness	NULL
.	NULL

Materials	NULL
and	NULL
Methods	NULL
Reagents	NULL
.	NULL

The	NULL
following	NULL
reagents	NULL
were	NULL
used	NULL
:	NULL
water-soluble	NULL
dexamethasone	NULL
(	NULL
DEX	NULL
)	NULL
and	NULL
aluminum	NULL
potassium	NULL
sulfate	NULL
(	NULL
alum	NULL
;	NULL
Sigma-Aldrich	NULL
)	NULL
;	NULL
crystalline	NULL
OVA	NULL
(	NULL
Pierce	NULL
Chemical	NULL
Co.	NULL
)	NULL
;	NULL
biotinylated	NULL
monoclonal	NULL
anti-mouse	NULL
IL-4	NULL
(	NULL
BD	NULL
PharMingen	NULL
)	NULL
,	NULL
monoclonal	NULL
and	NULL
polyclonal	NULL
goat	NULL
antibody	NULL
anti-GATA-3	NULL
,	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
,	NULL
Inc.	NULL
)	NULL
and	NULL
monoclonal	NULL
antiactin	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
,	NULL
Inc.	NULL
)	NULL
;	NULL
horseradish	NULL
peroxidase-conjugated	NULL
anti-rabbit	NULL
Ig	NULL
and	NULL
anti-mouse	NULL
Ig	NULL
(	NULL
Amersham	NULL
Pharmacia	NULL
Biotech	NULL
)	NULL
,	NULL
the	NULL
ECL	NULL
Western	NULL
blotting	NULL
system	NULL
(	NULL
Amersham	NULL
Pharmacia	NULL
Biotech	NULL
)	NULL
;	NULL
biotinylated	NULL
anti-goat	NULL
IgG	NULL
(	NULL
Vector	NULL
Laboratories	NULL
)	NULL
;	NULL
Cy3/AMCA	NULL
Streptavidin	NULL
conjugated	NULL
(	NULL
Dianova	NULL
)	NULL
;	NULL
and	NULL
phosphorothicate	NULL
oligonucleotides	NULL
(	NULL
Roth	NULL
GmbH	NULL
and	NULL
GIBCO	NULL
BRL	NULL
)	NULL
.	NULL

Phosphorothioate	NULL
Oligonucleotides	NULL
.	NULL

-	NULL
Oligonucleotides	NULL
were	NULL
synthesized	NULL
with	NULL
a	NULL
phosphorothioate	NULL
backbone	NULL
to	NULL
improve	NULL
resistance	NULL
to	NULL
endonucleases	NULL
.	NULL

The	NULL
antisense	NULL
oligonucleotides	NULL
consisted	NULL
of	NULL
18-mer	NULL
analogues	NULL
to	NULL
the	NULL
5	NULL
end	NULL
of	NULL
the	NULL
murine	NULL
GATA-3	NULL
sequence	NULL
which	NULL
spans	NULL
the	NULL
translation	NULL
initiation	NULL
site	NULL
.	NULL

This	NULL
sequence	NULL
had	NULL
no	NULL
C	NULL
plus	NULL
G	NULL
dinucleotide	NULL
or	NULL
a	NULL
quadruple	NULL
G	NULL
sequence	NULL
element	NULL
that	NULL
are	NULL
known	NULL
to	NULL
cause	NULL
unspecific	NULL
effects	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
several	NULL
control	NULL
(	NULL
mismatched	NULL
and	NULL
nonsense	NULL
)	NULL
oligonucleotides	NULL
were	NULL
prepared	NULL
.	NULL

The	NULL
nonsense	NULL
oligonucleotides	NULL
contained	NULL
the	NULL
same	NULL
nucleotide	NULL
composition	NULL
as	NULL
the	NULL
antisense	NULL
oligonucleotides	NULL
.	NULL

The	NULL
sequences	NULL
were	NULL
as	NULL
follows	NULL
(	NULL
mismatches	NULL
are	NULL
underlined	NULL
)	NULL
:	NULL
GATA-3	NULL
antisense	NULL
DNA	NULL
(	NULL
with	NULL
or	NULL
without	NULL
FITC	NULL
)	NULL
,	NULL
CAC	NULL
CTC	NULL
CAT	NULL
GTC	NULL
CTC-3	NULL
'	NULL
;	NULL
GATA-3	NULL
nonsense	NULL
DNA	NULL
,	NULL
TGT	NULL
CAT	NULL
CCG	NULL
CTC	NULL
CAC-3	NULL
'	NULL
;	NULL
GATA-3	NULL
mismatched	NULL
DNA	NULL
,	NULL
5	NULL
!	NULL

-AGC	NULL
CAC	NULL
CTA	NULL
CAT	NULL
TTC	NULL
CTA-3	NULL
'	NULL
;	NULL
and	NULL
GATA-3	NULL
mismatched	NULL
DNA	NULL
2	NULL
,	NULL
5-AGC	NULL
CAC	NULL
CTA	NULL
GGC	NULL
ATC	NULL
CTC-3	NULL
'	NULL
.	NULL

Coincubation	NULL
of	NULL
DNA	NULL
with	NULL
Murine	NULL
Spleen	NULL
CD4*	NULL
Th2	NULL
Cells	NULL
.	NULL

Naive	NULL
splenic	NULL
CD4*	NULL
T	NULL
cells	NULL
(	NULL
purity	NULL
>	NULL
97	NULL
%	NULL
)	NULL
were	NULL
obtained	NULL
using	NULL
monoclonal	NULL
antibodies	NULL
to	NULL
CD4	NULL
coupled	NULL
to	NULL
magnetic	NULL
beads	NULL
(	NULL
Miltenyi	NULL
Biotec	NULL
)	NULL
according	NULL
to	NULL
the	NULL
protocol	NULL
provided	NULL
by	NULL
the	NULL
manufacturer	NULL
.	NULL

Cells	NULL
were	NULL
cultured	NULL
on	NULL
10	NULL
pg/ml	NULL
anti-CD3-coated	NULL
wells	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
2	NULL
g/ml	NULL
anti-CD28	NULL
,	NULL
100	NULL
U/ml	NULL
rmIL-2	NULL
,	NULL
and	NULL
1,000	NULL
U/ml	NULL
rmIL-4	NULL
for	NULL
3	NULL
d.	NULL
Cells	NULL
were	NULL
then	NULL
cultured	NULL
for	NULL
an	NULL
additional	NULL
2	NULL
d	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
rmIL-2	NULL
and	NULL
IL-4	NULL
only	NULL
.	NULL

During	NULL
the	NULL
last	NULL
12	NULL
h	NULL
cells	NULL
were	NULL
challenged	NULL
with	NULL
50	NULL
ng/ml	NULL
PMA	NULL
and	NULL
1	NULL
pg/ml	NULL
ionomycin	NULL
.	NULL

For	NULL
coincubation	NULL
experiments	NULL
phosphorothioate	NULL
oligonucleotides	NULL
(	NULL
12-15	NULL
pM	NULL
)	NULL
were	NULL
preincubated	NULL
for	NULL
45	NULL
min	NULL
with	NULL
Lipofectamine	NULL
(	NULL
Life	NULL
Technologies/	NULL
GIBCO	NULL
BRL	NULL
)	NULL
.	NULL

At	NULL
days	NULL
2	NULL
and	NULL
4	NULL
the	NULL
oligonucleotides	NULL
were	NULL
added	NULL
to	NULL
the	NULL
cell	NULL
cultures	NULL
.	NULL

Cells	NULL
treated	NULL
with	NULL
FITC-conjugated	NULL
antisense	NULL
DNA	NULL
were	NULL
washed	NULL
,	NULL
fixed	NULL
in	NULL
4	NULL
%	NULL
paraformaldehyde	NULL
,	NULL
and	NULL
analyzed	NULL
by	NULL
FACSÂ®	NULL
analysis	NULL
for	NULL
uptake	NULL
efficiency	NULL
.	NULL

Cell	NULL
viability	NULL
was	NULL
assessed	NULL
by	NULL
trypan	NULL
blue	NULL
staining	NULL
and	NULL
supernatants	NULL
were	NULL
analyzed	NULL
for	NULL
IL-4	NULL
and	NULL
IL-9	NULL
production	NULL
by	NULL
ELISA	NULL
.	NULL

Enrichment	NULL
of	NULL
Antisense-transfected	NULL
Cells	NULL
by	NULL
Immunomagnetic	NULL
Cell	NULL
Sorting	NULL
.	NULL

To	NULL
enrich	NULL
for	NULL
antisense-transfected	NULL
T	NULL
cells	NULL
,	NULL
T	NULL
cells	NULL
were	NULL
cotransfected	NULL
on	NULL
day	NULL
4	NULL
with	NULL
the	NULL
pMACS	NULL
KÂ®.II	NULL
vector	NULL
(	NULL
Miltenyi	NULL
Antisense	NULL
DNA	NULL
to	NULL
GATA-3	NULL
Abrogates	NULL
Airway	NULL
Hyperresponsiveness	NULL
Biotec	NULL
)	NULL
expressing	NULL
a	NULL
truncated	NULL
H2-KÂ®	NULL
molecule	NULL
(	NULL
that	NULL
is	NULL
not	NULL
expressed	NULL
in	NULL
BALB/c	NULL
mice	NULL
)	NULL
and	NULL
FITC-labeled	NULL
or	NULL
unlabeled	NULL
phosphorothicate	NULL
oligonucleotides	NULL
.	NULL

Cells	NULL
were	NULL
harvested	NULL
48	NULL
h	NULL
after	NULL
cotransfection	NULL
,	NULL
resuspended	NULL
in	NULL
PBE	NULL
(	NULL
PBS	NULL
with	NULL
5	NULL
mM	NULL
EDTA	NULL
)	NULL
buffer	NULL
,	NULL
and	NULL
incubated	NULL
with	NULL
MACSelect	NULL
KÂ®	NULL
microbeads	NULL
(	NULL
Miltenyi	NULL
Biotec	NULL
)	NULL
followed	NULL
by	NULL
magnetic	NULL
separation	NULL
.	NULL

FITC-positive	NULL
cells	NULL
were	NULL
visualized	NULL
by	NULL
fluorescence	NULL
microscopy	NULL
or	NULL
confocal	NULL
laser	NULL
microscopy	NULL
using	NULL
a	NULL
Bio-Rad	NULL
Laboratories	NULL
MRC-1024/MP	NULL
microscope	NULL
.	NULL

To	NULL
assess	NULL
enrichment	NULL
of	NULL
antisense-transfected	NULL
cells	NULL
,	NULL
T	NULL
cell	NULL
nuclei	NULL
were	NULL
counterstained	NULL
with	NULL
DAPI	NULL
(	NULL
Vector	NULL
Laboratories	NULL
)	NULL
and	NULL
the	NULL
percentage	NULL
of	NULL
FITC-positive	NULL
cells	NULL
was	NULL
determined	NULL
by	NULL
counting	NULL
12	NULL
randomly	NULL
selected	NULL
high	NULL
power	NULL
fields	NULL
(	NULL
HPFs	NULL
)	NULL
in	NULL
three	NULL
samples	NULL
per	NULL
condition	NULL
by	NULL
fluorescence	NULL
microscopy	NULL
.	NULL

Cytokine	NULL
production	NULL
in	NULL
magnetic	NULL
cell	NULL
sorting	NULL
(	NULL
MACS	NULL
)	NULL
-selected	NULL
T	NULL
cells	NULL
was	NULL
assessed	NULL
after	NULL
18	NULL
h	NULL
stimulation	NULL
with	NULL
50	NULL
ng/ml	NULL
PMA	NULL
plus	NULL
1	NULL
jug/ml	NULL
iono-mycin	NULL
by	NULL
ELISA	NULL
.	NULL

Allergen	NULL
Sensitization/Challenge	NULL
Protocol	NULL
.	NULL

Female	NULL
BALB/c	NULL
mice	NULL
(	NULL
6-8	NULL
wk	NULL
of	NULL
age	NULL
)	NULL
received	NULL
an	NULL
intraperitoneal	NULL
injection	NULL
of	NULL
100	NULL
g/ml	NULL
OVA	NULL
(	NULL
0.2	NULL
ml	NULL
of	NULL
500	NULL
jug/ml	NULL
in	NULL
normal	NULL
saline	NULL
)	NULL
complexed	NULL
with	NULL
alum	NULL
on	NULL
days	NULL
0	NULL
and	NULL
14	NULL
.	NULL

On	NULL
days	NULL
25	NULL
,	NULL
26	NULL
,	NULL
and	NULL
27	NULL
,	NULL
the	NULL
mice	NULL
underwent	NULL
anesthesia	NULL
with	NULL
0.2	NULL
ml	NULL
of	NULL
avertine	NULL
intraperitoneally	NULL
(	NULL
1	NULL
mg/ml	NULL
of	NULL
tryplomethan	NULL
in	NULL
amylalcohol	NULL
;	NULL
2.5	NULL
%	NULL
in	NULL
PBS	NULL
)	NULL
before	NULL
receiving	NULL
50	NULL
pg	NULL
OVA	NULL
in	NULL
saline	NULL
intranasally	NULL
.	NULL

Control	NULL
animals	NULL
received	NULL
saline	NULL
intraperitoneally	NULL
with	NULL
alum	NULL
on	NULL
days	NULL
0	NULL
and	NULL
14	NULL
and	NULL
50	NULL
ul	NULL
of	NULL
saline	NULL
intravenously	NULL
on	NULL
days	NULL
25	NULL
,	NULL
26	NULL
,	NULL
and	NULL
27	NULL
.	NULL

Antisense	NULL
GATA-3	NULL
or	NULL
DEX	NULL
Treatment	NULL
in	NULL
OVA-sensitized	NULL
Mice	NULL
.	NULL

To	NULL
assess	NULL
the	NULL
effect	NULL
of	NULL
antisense	NULL
GATA-3	NULL
treatment	NULL
in	NULL
airway	NULL
inflammation	NULL
,	NULL
antisense	NULL
or	NULL
control	NULL
oligonucleotides	NULL
were	NULL
given	NULL
by	NULL
intranasal	NULL
administration	NULL
(	NULL
200	NULL
jug/treatment	NULL
)	NULL
at	NULL
days	NULL
24	NULL
,	NULL
25	NULL
,	NULL
26	NULL
,	NULL
and	NULL
27	NULL
(	NULL
30	NULL
min	NULL
before	NULL
intravenous	NULL
injection	NULL
of	NULL
OVA	NULL
)	NULL
to	NULL
OVA-sensitized	NULL
mice	NULL
.	NULL

To	NULL
localize	NULL
antisense	NULL
oligonucleotides	NULL
in	NULL
vivo	NULL
,	NULL
we	NULL
performed	NULL
the	NULL
last	NULL
intranasal	NULL
administration	NULL
with	NULL
FITC-labeled	NULL
antisense	NULL
oligonucleotides	NULL
.	NULL

To	NULL
compare	NULL
the	NULL
efficiency	NULL
of	NULL
antisense	NULL
GATA-3	NULL
treatment	NULL
to	NULL
the	NULL
classical	NULL
treatment	NULL
with	NULL
glucocorticoids	NULL
,	NULL
a	NULL
group	NULL
of	NULL
OVA-treated	NULL
mice	NULL
was	NULL
given	NULL
1	NULL
mg	NULL
(	NULL
50	NULL
pul	NULL
vol	NULL
)	NULL
of	NULL
water	NULL
soluble	NULL
DEX	NULL
intravenously	NULL
in	NULL
saline	NULL
on	NULL
days	NULL
24	NULL
,	NULL
25	NULL
,	NULL
26	NULL
,	NULL
and	NULL
27	NULL
.	NULL

Collection	NULL
and	NULL
Analysis	NULL
of	NULL
Bronchioalveolar	NULL
Lavage	NULL
Fluid	NULL
,	NULL
Cytospins	NULL
,	NULL
and	NULL
ELISA	NULL
for	NULL
IFN-y	NULL
and	NULL
IL-4	NULL
.	NULL

24	NULL
h	NULL
after	NULL
the	NULL
last	NULL
intranasal	NULL
challenge	NULL
with	NULL
either	NULL
OVA	NULL
or	NULL
saline	NULL
at	NULL
day	NULL
27	NULL
,	NULL
bronchicalveolar	NULL
lavage	NULL
(	NULL
BAL	NULL
)	NULL
of	NULL
the	NULL
right	NULL
lung	NULL
was	NULL
performed	NULL
after	NULL
tying	NULL
off	NULL
the	NULL
left	NULL
lung	NULL
at	NULL
the	NULL
mainstem	NULL
bronchus	NULL
.	NULL

Total	NULL
BAL	NULL
fluid	NULL
(	NULL
BALF	NULL
;	NULL
1	NULL
ml	NULL
of	NULL
saline	NULL
three	NULL
times	NULL
)	NULL
was	NULL
collected	NULL
and	NULL
cells	NULL
were	NULL
counted	NULL
using	NULL
a	NULL
100-pl	NULL
aliquot	NULL
.	NULL

Samples	NULL
were	NULL
centrifuged	NULL
at	NULL
1,200	NULL
rpm	NULL
for	NULL
5	NULL
min	NULL
at	NULL
4Â°C	NULL
,	NULL
and	NULL
cell	NULL
pellets	NULL
were	NULL
resuspended	NULL
in	NULL
PBS	NULL
.	NULL

Cytospins	NULL
were	NULL
made	NULL
by	NULL
centrifugation	NULL
at	NULL
450	NULL
rpm	NULL
for	NULL
5	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

Eosinophils	NULL
were	NULL
detected	NULL
by	NULL
staining	NULL
according	NULL
to	NULL
May-Griinwald	NULL
Giemsa	NULL
and	NULL
subsequently	NULL
analyzed	NULL
with	NULL
a	NULL
ZEISS	NULL
microscope	NULL
at	NULL
400	NULL
X	NULL
.	NULL

To	NULL
determine	NULL
cytokine	NULL
concentrations	NULL
in	NULL
BALF	NULL
,	NULL
samples	NULL
were	NULL
centrifuged	NULL
at	NULL
1,200	NULL
rpm	NULL
for	NULL
5	NULL
min	NULL
at	NULL
4Â°C	NULL
.	NULL

Supernatants	NULL
were	NULL
analyzed	NULL
by	NULL
specific	NULL
ELISA	NULL
for	NULL
content	NULL
of	NULL
IFN-y	NULL
and	NULL
IL-4	NULL
using	NULL
commercially	NULL
available	NULL
kit	NULL
systems	NULL
(	NULL
BD	NULL
PharMingen	NULL
)	NULL
.	NULL

Lung	NULL
Histology	NULL
.	NULL

_	NULL
24	NULL
h	NULL
after	NULL
the	NULL
last	NULL
intranasal	NULL
challenge	NULL
with	NULL
either	NULL
OVA	NULL
or	NULL
saline	NULL
,	NULL
lungs	NULL
were	NULL
analyzed	NULL
by	NULL
histology	NULL
(	NULL
day	NULL
28	NULL
)	NULL
.	NULL

The	NULL
right	NULL
lung	NULL
was	NULL
frozen	NULL
immediately	NULL
and	NULL
stored	NULL
in	NULL
liquid	NULL
nitrogen	NULL
until	NULL
use	NULL
.	NULL

The	NULL
left	NULL
lung	NULL
was	NULL
fixed	NULL
in	NULL
10	NULL
%	NULL
formaline	NULL
,	NULL
dehy-drated	NULL
,	NULL
mounted	NULL
in	NULL
paraffin	NULL
,	NULL
sectioned	NULL
,	NULL
and	NULL
stained	NULL
with	NULL
hema-toxylin/eosin	NULL
.	NULL

Eosinophils	NULL
in	NULL
the	NULL
lungs	NULL
were	NULL
quantified	NULL
blindly	NULL
by	NULL
the	NULL
same	NULL
pathologist	NULL
(	NULL
H.A	NULL
.	NULL

Lehr	NULL
)	NULL
using	NULL
a	NULL
Leitz	NULL
D33	NULL
microscope	NULL
,	NULL
a	NULL
JVC1	NULL
chip	NULL
camera	NULL
,	NULL
the	NULL
program	NULL
PhotoshopÂ®	NULL
,	NULL
and	NULL
an	NULL
Image	NULL
Processing	NULL
Tool	NULL
Kit	NULL
(	NULL
v2.1	NULL
)	NULL
.	NULL

Three	NULL
HPFs	NULL
in	NULL
the	NULL
area	NULL
of	NULL
peripheral	NULL
1249	NULL
Finotto	NULL
et	NULL
al	NULL
.	NULL

bronchi	NULL
were	NULL
randomly	NULL
selected	NULL
for	NULL
quantification	NULL
.	NULL

Counts	NULL
are	NULL
given	NULL
as	NULL
eosinophils	NULL
per	NULL
square	NULL
millimeter	NULL
.	NULL

Airway	NULL
mucus	NULL
was	NULL
identified	NULL
by	NULL
the	NULL
alcian	NULL
blue/periodic	NULL
acid-Schiff	NULL
(	NULL
PAS	NULL
)	NULL
reaction	NULL
by	NULL
using	NULL
a	NULL
standard	NULL
protocol	NULL
in	NULL
use	NULL
in	NULL
our	NULL
Department	NULL
of	NULL
Pathology	NULL
.	NULL

PAS-positive	NULL
mucosubstances	NULL
in	NULL
the	NULL
small	NULL
and	NULL
large	NULL
airways	NULL
were	NULL
also	NULL
assessed	NULL
by	NULL
semiquantitative	NULL
analysis	NULL
in	NULL
four	NULL
to	NULL
five	NULL
mice	NULL
per	NULL
group	NULL
using	NULL
the	NULL
following	NULL
grading	NULL
scale	NULL
:	NULL
-=	NULL
,	NULL
no	NULL
mucosubstances	NULL
;	NULL
+	NULL
,	NULL
mucosubstances	NULL
detectable	NULL
;	NULL
++	NULL
,	NULL
high	NULL
amount	NULL
of	NULL
mucosubstances	NULL
.	NULL

Immunohistochemistry	NULL
.	NULL

_	NULL
Immunohistochemistry	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
29-31	NULL
)	NULL
.	NULL

In	NULL
brief	NULL
,	NULL
frozen	NULL
sections	NULL
were	NULL
fixed	NULL
in	NULL
4	NULL
%	NULL
paraformaldehyde	NULL
and	NULL
immunostained	NULL
for	NULL
GATA-3	NULL
and	NULL
IL-4	NULL
.	NULL

In	NULL
brief	NULL
,	NULL
sections	NULL
were	NULL
preincubated	NULL
with	NULL
2	NULL
%	NULL
normal	NULL
rabbit	NULL
serum	NULL
in	NULL
PBS/1	NULL
%	NULL
BSA/0.4	NULL
%	NULL
saponin	NULL
for	NULL
45	NULL
min	NULL
followed	NULL
by	NULL
an	NULL
incubation	NULL
with	NULL
anti-GATA-3	NULL
goat	NULL
polyclonal	NULL
antibodies	NULL
(	NULL
5	NULL
g/m	NULL
!	NULL
)	NULL

in	NULL
PBS/1	NULL
%	NULL
BSA/0.4	NULL
%	NULL
saponion/2	NULL
%	NULL
normal	NULL
rabbit	NULL
serum	NULL
overnight	NULL
at	NULL
4Â°C	NULL
.	NULL

The	NULL
next	NULL
day	NULL
sections	NULL
were	NULL
incubated	NULL
with	NULL
biotinylated	NULL
rabbit	NULL
anti-goat	NULL
IgG	NULL
(	NULL
1:100	NULL
dilution	NULL
)	NULL
followed	NULL
by	NULL
Streptavidin-Cy3	NULL
(	NULL
1:1,000	NULL
dilution	NULL
)	NULL
.	NULL

For	NULL
IL-4	NULL
staining	NULL
studies	NULL
,	NULL
sections	NULL
were	NULL
then	NULL
incubated	NULL
overnight	NULL
with	NULL
an	NULL
anti-IL-4	NULL
biotinylated	NULL
antibody	NULL
(	NULL
10	NULL
pg/ml	NULL
;	NULL
BD	NULL
PharMingen	NULL
)	NULL
in	NULL
PBS/1	NULL
%	NULL
BSA/0.4	NULL
%	NULL
saponin	NULL
followed	NULL
by	NULL
the	NULL
Streptavidin-conjugated	NULL
Cy3	NULL
complex	NULL
(	NULL
1:1,000	NULL
in	NULL
PBS	NULL
}	NULL
.	NULL

Sections	NULL
were	NULL
analyzed	NULL
with	NULL
an	NULL
Olympus	NULL
fluorescence	NULL
microscope	NULL
.	NULL

Morphometric	NULL
Analysis	NULL
.	NULL

_	NULL
GATA-3-	NULL
and	NULL
IL-4-positive	NULL
cells	NULL
in	NULL
the	NULL
lungs	NULL
were	NULL
quantified	NULL
blindly	NULL
by	NULL
the	NULL
same	NULL
pathologist	NULL
using	NULL
an	NULL
Olympus	NULL
microscope	NULL
and	NULL
an	NULL
Image	NULL
Processing	NULL
Tool	NULL
Kit	NULL
(	NULL
v2.1	NULL
)	NULL
.	NULL

10	NULL
HPFs	NULL
in	NULL
the	NULL
area	NULL
of	NULL
peripheral	NULL
bronchi	NULL
were	NULL
randomly	NULL
selected	NULL
in	NULL
4-5	NULL
mice	NULL
per	NULL
group	NULL
for	NULL
quantification	NULL
.	NULL

Counts	NULL
are	NULL
given	NULL
as	NULL
positive	NULL
cells	NULL
per	NULL
HPF	NULL
.	NULL

Protein	NULL
Analysis	NULL
.	NULL

-	NULL
Lung	NULL
tissues	NULL
were	NULL
homogenized	NULL
by	NULL
using	NULL
an	NULL
electrical	NULL
homogeneizator	NULL
,	NULL
and	NULL
proteins	NULL
were	NULL
extracted	NULL
in	NULL
PBS	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
protease	NULL
inhibitors	NULL
(	NULL
6.75	NULL
%	NULL
aprotinin	NULL
,	NULL
312	NULL
jug/ml	NULL
trypsin	NULL
inhibitor	NULL
)	NULL
and	NULL
0.62	NULL
%	NULL
NP-40	NULL
.	NULL

Protein	NULL
concentrations	NULL
were	NULL
determined	NULL
by	NULL
a	NULL
protein	NULL
assay	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
(	NULL
Bio-Rad	NULL
Laboratories	NULL
)	NULL
.	NULL

The	NULL
standard	NULL
curve	NULL
was	NULL
performed	NULL
by	NULL
using	NULL
0	NULL
,	NULL
4	NULL
,	NULL
8	NULL
,	NULL
and	NULL
16	NULL
jg	NULL
of	NULL
BSA	NULL
per	NULL
milliliter	NULL
.	NULL

Under	NULL
our	NULL
experimental	NULL
conditions	NULL
~4	NULL
mg	NULL
of	NULL
proteins	NULL
per	NULL
lung	NULL
could	NULL
be	NULL
recovered	NULL
.	NULL

Western	NULL
Blot	NULL
Analysis	NULL
.	NULL

50	NULL
jug	NULL
of	NULL
total	NULL
proteins	NULL
isolated	NULL
from	NULL
the	NULL
whole	NULL
lung	NULL
was	NULL
separated	NULL
by	NULL
15	NULL
%	NULL
SDS-PAGE	NULL
and	NULL
blotted	NULL
onto	NULL
a	NULL
nitrocellulose	NULL
membrane	NULL
overnight	NULL
(	NULL
31	NULL
)	NULL
.	NULL

Equal	NULL
loading	NULL
was	NULL
assessed	NULL
with	NULL
Ponceau	NULL
's	NULL
solution	NULL
(	NULL
Sigma-Aldrich	NULL
)	NULL
.	NULL

The	NULL
membrane	NULL
was	NULL
then	NULL
incubated	NULL
in	NULL
blocking	NULL
solution	NULL
(	NULL
5	NULL
%	NULL
dry	NULL
milk	NULL
in	NULL
PBS/0.05	NULL
%	NULL
Tween	NULL
20	NULL
)	NULL
for	NULL
1	NULL
h	NULL
at	NULL
room	NULL
temperature	NULL
,	NULL
and	NULL
subsequently	NULL
exposed	NULL
to	NULL
0.8	NULL
pg/ml	NULL
of	NULL
monoclonal	NULL
antibodies	NULL
anti-GATA-3	NULL
or	NULL
anti-B-actin	NULL
overnight	NULL
at	NULL
4Â°C	NULL
.	NULL

The	NULL
day	NULL
after	NULL
,	NULL
the	NULL
membrane	NULL
was	NULL
incubated	NULL
with	NULL
peroxidase-conjugated	NULL
anti-mouse	NULL
Igs	NULL
(	NULL
1:2,500	NULL
)	NULL
for	NULL
1	NULL
h	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

Finally	NULL
,	NULL
enzyme	NULL
activity	NULL
was	NULL
detected	NULL
with	NULL
the	NULL
ECL-Plus	NULL
Western	NULL
blotting	NULL
detection	NULL
system	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
(	NULL
Amersham	NULL
Pharmacia	NULL
Biotech	NULL
)	NULL
.	NULL

Electrophoretic	NULL
Mobility	NULL
Shift	NULL
Assay	NULL
.	NULL

-	NULL
Electrophoretic	NULL
-	NULL
mobility	NULL
shift	NULL
assay	NULL
(	NULL
EMSA	NULL
)	NULL
was	NULL
carried	NULL
out	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
25,000	NULL
cpm	NULL
radiolabeled	NULL
GATA-3	NULL
,	NULL
OCT	NULL
-1	NULL
,	NULL
and	NULL
SP1	NULL
consensus	NULL
DNA	NULL
probes	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
,	NULL
Inc.	NULL
)	NULL
to	NULL
the	NULL
binding	NULL
reaction	NULL
that	NULL
also	NULL
contained	NULL
1	NULL
jug	NULL
synthetic	NULL
DNA	NULL
duplex	NULL
of	NULL
poly	NULL
(	NULL
dIdC	NULL
)	NULL
,	NULL
30	NULL
jug	NULL
of	NULL
total	NULL
lung	NULL
proteins	NULL
,	NULL
and	NULL
binding	NULL
buffer	NULL
(	NULL
32	NULL
)	NULL
.	NULL

Complex	NULL
formation	NULL
was	NULL
allowed	NULL
to	NULL
proceed	NULL
for	NULL
30	NULL
min	NULL
.	NULL

Finally	NULL
,	NULL
the	NULL
complexes	NULL
were	NULL
separated	NULL
from	NULL
unbound	NULL
DNA	NULL
by	NULL
native	NULL
PAGE	NULL
on	NULL
5	NULL
%	NULL
gels	NULL
.	NULL

The	NULL
GATA-3	NULL
bands	NULL
on	NULL
the	NULL
EMSA	NULL
gels	NULL
were	NULL
analyzed	NULL
by	NULL
densitome-try	NULL
as	NULL
specified	NULL
in	NULL
Results	NULL
.	NULL

For	NULL
supershift	NULL
analysis	NULL
,	NULL
1	NULL
jug	NULL
GATA	NULL
3-specific	NULL
antibodies	NULL
and	NULL
control	NULL
antibodies	NULL
(	NULL
obtained	NULL
from	NULL
Santa	NULL
thysmography	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
33	NULL
)	NULL
.	NULL

In	NULL
brief	NULL
,	NULL
mice	NULL
were	NULL
Cruz	NULL
Biotechnology	NULL
,	NULL
Inc.	NULL
)	NULL
were	NULL
used	NULL
as	NULL
specified	NULL
in	NULL
Results	NULL
.	NULL

placed	NULL
in	NULL
four	NULL
body	NULL
plethysmographs	NULL
attached	NULL
to	NULL
an	NULL
exposure	NULL
Assessment	NULL
of	NULL
Airway	NULL
Reactivity	NULL
by	NULL
Body	NULL
Plethysmography	NULL
.	NULL

_	NULL
Air-	NULL
chamber	NULL
(	NULL
Crown	NULL
Glass	NULL
)	NULL
.	NULL

Airflow	NULL
was	NULL
measured	NULL
with	NULL
a	NULL
PTM	NULL
378/	NULL
way	NULL
reactivity	NULL
was	NULL
assessed	NULL
in	NULL
12	NULL
mice	NULL
per	NULL
group	NULL
by	NULL
head-out	NULL
ple-	NULL
1.2	NULL
pneumotachograph	NULL
(	NULL
Hugo	NULL
Sachs	NULL
Electronics	NULL
)	NULL
and	NULL
an	NULL
8-T2	NULL
A	NULL
E	NULL
15.00	NULL
tan	NULL
ree	NULL
.	NULL

mo	NULL
10.00	NULL
5.00	NULL
IL-9	NULL
(	NULL
ng/ml	NULL
)	NULL
~	NULL
&	NULL
H	NULL
7	NULL
0.00	NULL
zoo	NULL
Â«	NULL
00	NULL
sco	NULL
soo	NULL
1900	NULL
.	NULL

.-men	NULL
B	NULL
-	NULL
-	NULL
|	NULL
|	NULL
BF	NULL
5.00	NULL
4.00	NULL
3.00	NULL
v	NULL
a	NULL
R	NULL
2.00	NULL
|	NULL
-|	NULL
N-	NULL
-	NULL
~	NULL
F	NULL
GATA3+	NULL
cells	NULL
/HPF	NULL
1.00	NULL
0.00	NULL
|	NULL
--	NULL
8	NULL
eal	NULL
-	NULL
>	NULL
:	NULL
~~	NULL
m	NULL
___	NULL
FITC	NULL
positive	NULL
cells	NULL
(	NULL
%	NULL
)	NULL
unsel	NULL
.	NULL

selected	NULL
=C	NULL
.	NULL

2	NULL
&	NULL
&	NULL
hang	NULL
Â§	NULL
3	NULL
2	NULL
<	NULL
&	NULL
2	NULL
2	NULL
;	NULL
$	NULL
5	NULL
5g	NULL
&	NULL
E	NULL
E	NULL
Â£0220	NULL
Â£	NULL
t	NULL
U	NULL
E	NULL
5	NULL
<	NULL
s	NULL
s	NULL
2	NULL
s	NULL
$	NULL
a	NULL
-	NULL
-o	NULL
Â»	NULL
mam	NULL
um	NULL
GATA-3	NULL
--	NULL
Nest	NULL
!	NULL
)	NULL

ase	NULL
``	NULL
am	NULL
Â»	NULL
-	NULL
[	NULL
}	NULL
-ACtiN	NULL
CN	NULL
UN	NULL
ASGATA	NULL
-	NULL
NSGATA	NULL
-	NULL
MMGATA	NULL
untreated	NULL
AS-GATA3	NULL
MM-GATA3	NULL
MM2-GATA3	NULL
NS-GATA3	NULL
Western	NULL
Figure	NULL
1	NULL
.	NULL

-	NULL
Suppression	NULL
of	NULL
IL-4	NULL
production	NULL
and	NULL
GATA-3	NULL
expression	NULL
in	NULL
Th2	NULL
T	NULL
cells	NULL
by	NULL
a	NULL
specific	NULL
phosphorothioate	NULL
oligonucleotide	NULL
to	NULL
the	NULL
translation	NULL
start	NULL
site	NULL
of	NULL
GATA-3	NULL
.	NULL

To	NULL
induce	NULL
Th2	NULL
T	NULL
cell	NULL
development	NULL
naive	NULL
splenic	NULL
CD4*	NULL
T	NULL
cells	NULL
(	NULL
purity	NULL
>	NULL
97	NULL
%	NULL
)	NULL
were	NULL
cultured	NULL
on	NULL
anti-CD3-coated	NULL
wells	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
soluble	NULL
anti-CD28	NULL
,	NULL
rmIL-2	NULL
,	NULL
and	NULL
rmIL-4	NULL
for	NULL
3	NULL
d.	NULL
Cells	NULL
were	NULL
then	NULL
cultured	NULL
for	NULL
an	NULL
additional	NULL
2	NULL
d	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
rmIL-2	NULL
and	NULL
IL-4	NULL
only	NULL
.	NULL

During	NULL
the	NULL
last	NULL
12	NULL
h	NULL
,	NULL
cells	NULL
were	NULL
challenged	NULL
with	NULL
PMA	NULL
(	NULL
50	NULL
ng/m	NULL
!	NULL
)	NULL

/ionomycin	NULL
(	NULL
1	NULL
ug/ml	NULL
)	NULL
.	NULL

At	NULL
days	NULL
2	NULL
and	NULL
4	NULL
,	NULL
oligonucleotides	NULL
were	NULL
preincubated	NULL
with	NULL
Lipofectamine	NULL
and	NULL
added	NULL
to	NULL
the	NULL
cell	NULL
cultures	NULL
as	NULL
indicated	NULL
.	NULL

In	NULL
vitro-differentiated	NULL
Th2	NULL
cells	NULL
showed	NULL
high	NULL
viability	NULL
under	NULL
all	NULL
experimental	NULL
conditions	NULL
(	NULL
UN	NULL
,	NULL
85-95	NULL
%	NULL
;	NULL
ASGATA3	NULL
,	NULL
90-98	NULL
%	NULL
;	NULL
NSGATA3	NULL
,	NULL
75-95	NULL
%	NULL
)	NULL
in	NULL
three	NULL
independent	NULL
experiments	NULL
as	NULL
assessed	NULL
by	NULL
trypan	NULL
blue	NULL
exclusion	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Coincubation	NULL
with	NULL
FITC-labeled	NULL
antisense	NULL
oligonucleotides	NULL
to	NULL
GATA-3	NULL
led	NULL
to	NULL
a	NULL
high	NULL
degree	NULL
of	NULL
DNA	NULL
uptake	NULL
(	NULL
50-70	NULL
%	NULL
of	NULL
cells	NULL
)	NULL
as	NULL
assessed	NULL
by	NULL
FACSÂ®	NULL
analysis	NULL
(	NULL
A	NULL
)	NULL
and	NULL
quantitative	NULL
fluorescence	NULL
microscopy	NULL
using	NULL
nuclear	NULL
counterstaining	NULL
with	NULL
DAPI	NULL
(	NULL
B	NULL
)	NULL
.	NULL

Antisense	NULL
oligonucleotides	NULL
to	NULL
GATA-3	NULL
led	NULL
to	NULL
a	NULL
significant	NULL
(	NULL
P	NULL
<	NULL
0.05	NULL
)	NULL
reduction	NULL
of	NULL
the	NULL
number	NULL
of	NULL
GATA-3-expressing	NULL
Th2	NULL
cells	NULL
,	NULL
whereas	NULL
control	NULL
nonsense	NULL
oligonucleotides	NULL
had	NULL
no	NULL
such	NULL
effect	NULL
(	NULL
C	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
mismatched	NULL
oligonucleotides	NULL
led	NULL
to	NULL
a	NULL
reduction	NULL
in	NULL
the	NULL
number	NULL
of	NULL
GATA-3-expressing	NULL
cells	NULL
,	NULL
although	NULL
this	NULL
effect	NULL
was	NULL
not	NULL
statistically	NULL
significant	NULL
.	NULL

Cytokine	NULL
production	NULL
from	NULL
untreated	NULL
and	NULL
GATA-3	NULL
antisense	NULL
or	NULL
control-treated	NULL
cells	NULL
was	NULL
assessed	NULL
by	NULL
ELISA	NULL
.	NULL

The	NULL
treatment	NULL
with	NULL
antisense	NULL
DNA	NULL
to	NULL
GATA-3	NULL
significantly	NULL
(	NULL
P	NULL
<	NULL
0.05	NULL
)	NULL
reduced	NULL
IL-4	NULL
production	NULL
(	NULL
D	NULL
)	NULL
compared	NULL
with	NULL
untreated	NULL
cells	NULL
but	NULL
,	NULL
in	NULL
contrast	NULL
,	NULL
IL-9	NULL
release	NULL
remained	NULL
unaffected	NULL
after	NULL
antisense	NULL
GATA-3	NULL
treatment	NULL
(	NULL
E	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
control	NULL
oligonucleotides	NULL
had	NULL
no	NULL
significant	NULL
effect	NULL
on	NULL
both	NULL
IL-4	NULL
and	NULL
IL-9	NULL
production	NULL
,	NULL
although	NULL
mismatched	NULL
DNA	NULL
caused	NULL
a	NULL
reduction	NULL
of	NULL
the	NULL
average	NULL
IL-4	NULL
production	NULL
.	NULL

(	NULL
F	NULL
)	NULL
High	NULL
GATA-3	NULL
expression	NULL
in	NULL
in	NULL
vitro-differentiated	NULL
Th2	NULL
cells	NULL
.	NULL

(	NULL
G	NULL
)	NULL
To	NULL
enrich	NULL
for	NULL
antisense-transfected	NULL
Th2	NULL
cells	NULL
,	NULL
we	NULL
used	NULL
a	NULL
cotransfection	NULL
system	NULL
with	NULL
a	NULL
plasmid	NULL
expressing	NULL
a	NULL
truncated	NULL
H2-K*	NULL
molecule	NULL
followed	NULL
by	NULL
magnetic	NULL
selection	NULL
of	NULL
transfected	NULL
cells	NULL
(	NULL
see	NULL
Materials	NULL
and	NULL
Methods	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
by	NULL
confocal	NULL
laser	NULL
microscopy	NULL
(	NULL
G	NULL
,	NULL
left	NULL
)	NULL
,	NULL
there	NULL
was	NULL
a	NULL
high	NULL
DNA	NULL
uptake	NULL
in	NULL
MACS-selected	NULL
cells	NULL
,	NULL
and	NULL
quantification	NULL
of	NULL
FITC-positive	NULL
cells	NULL
showed	NULL
an	NULL
enrichment	NULL
of	NULL
cells	NULL
transfected	NULL
with	NULL
FITC-labeled	NULL
antisense	NULL
DNA	NULL
compared	NULL
with	NULL
unselected	NULL
cells	NULL
(	NULL
G	NULL
,	NULL
right	NULL
)	NULL
.	NULL

There	NULL
was	NULL
a	NULL
downregulation	NULL
of	NULL
GATA-3	NULL
expression	NULL
in	NULL
MACS-selected	NULL
,	NULL
antisense-transfected	NULL
cells	NULL
compared	NULL
with	NULL
untreated	NULL
MACS-selected	NULL
T	NULL
cells	NULL
as	NULL
shown	NULL
by	NULL
Western	NULL
blot	NULL
analysis	NULL
(	NULL
H	NULL
,	NULL
left	NULL
)	NULL
.	NULL

Such	NULL
downregulation	NULL
was	NULL
not	NULL
observed	NULL
after	NULL
treatment	NULL
with	NULL
GATA-3	NULL
nonsense	NULL
DNA	NULL
and	NULL
two	NULL
mismatched	NULL
oligonucleotides	NULL
and	NULL
was	NULL
associated	NULL
with	NULL
a	NULL
marked	NULL
downregulation	NULL
of	NULL
IL-4	NULL
production	NULL
as	NULL
assessed	NULL
by	NULL
ELISA	NULL
(	NULL
H	NULL
,	NULL
right	NULL
)	NULL
.	NULL

AS	NULL
,	NULL
antisense	NULL
;	NULL
ASGATA3	NULL
,	NULL
GATA-3	NULL
antisense	NULL
DNA	NULL
;	NULL
NSGATA3	NULL
,	NULL
GATA-3	NULL
nonsense	NULL
DNA	NULL
;	NULL
NS	NULL
,	NULL
nonsense	NULL
DNA	NULL
;	NULL
MM	NULL
,	NULL
mismatched	NULL
oligonucleotides	NULL
;	NULL
UN	NULL
,	NULL
untreated	NULL
cells	NULL
;	NULL
CN	NULL
,	NULL
unstimulated	NULL
control	NULL
.	NULL

1250	NULL
Antisense	NULL
DNA	NULL
to	NULL
GATA-3	NULL
Abrogates	NULL
Airway	NULL
Hyperresponsiveness	NULL
differential	NULL
pressure	NULL
transducer	NULL
(	NULL
Gaeltec	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
airflow	NULL
was	NULL
analyzed	NULL
in	NULL
response	NULL
to	NULL
various	NULL
concentrations	NULL
of	NULL
methacholine	NULL
(	NULL
MCh	NULL
)	NULL
(	NULL
25	NULL
,	NULL
50	NULL
,	NULL
75	NULL
,	NULL
100	NULL
,	NULL
150	NULL
mg/ml	NULL
for	NULL
1	NULL
min	NULL
)	NULL
delivered	NULL
by	NULL
a	NULL
jet	NULL
nebulizer	NULL
(	NULL
Pari-Boy	NULL
;	NULL
Pariwerke	NULL
)	NULL
.	NULL

Finally	NULL
,	NULL
the	NULL
concentration	NULL
of	NULL
MCh	NULL
that	NULL
caused	NULL
a	NULL
50	NULL
%	NULL
reduction	NULL
in	NULL
expiratory	NULL
airflow	NULL
(	NULL
MCh3	NULL
,	NULL
)	NULL
was	NULL
determined	NULL
.	NULL

In	NULL
an	NULL
additional	NULL
series	NULL
of	NULL
experiments	NULL
,	NULL
airway	NULL
responsiveness	NULL
was	NULL
assessed	NULL
by	NULL
analyzing	NULL
enhanced	NULL
pause	NULL
(	NULL
PenH	NULL
)	NULL
responses	NULL
of	NULL
sa-line-	NULL
or	NULL
OVA-treated	NULL
mice	NULL
in	NULL
a	NULL
body	NULL
plethysmograph	NULL
(	NULL
model	NULL
PLY	NULL
3211	NULL
;	NULL
Buxco	NULL
Electronics	NULL
,	NULL
Inc.	NULL
)	NULL
(	NULL
34	NULL
)	NULL
.	NULL

Measurements	NULL
of	NULL
MCh	NULL
responsiveness	NULL
were	NULL
obtained	NULL
by	NULL
exposing	NULL
mice	NULL
for	NULL
5	NULL
min	NULL
to	NULL
200	NULL
expressed	NULL
as	NULL
the	NULL
peak	NULL
of	NULL
fold-increase	NULL
of	NULL
PenH	NULL
within	NULL
5	NULL
min	NULL
after	NULL
MCh	NULL
treatment	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
pulmonary	NULL
resistance	NULL
(	NULL
RL	NULL
)	NULL
was	NULL
measured	NULL
in	NULL
the	NULL
same	NULL
cohort	NULL
of	NULL
untreated	NULL
and	NULL
treated	NULL
OVA-sensitized	NULL
mice	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
35	NULL
,	NULL
36	NULL
)	NULL
.	NULL

In	NULL
brief	NULL
,	NULL
dose-response	NULL
curves	NULL
to	NULL
MCh	NULL
were	NULL
obtained	NULL
in	NULL
anesthetized	NULL
mice	NULL
after	NULL
administering	NULL
increasing	NULL
doses	NULL
of	NULL
intravenous	NULL
MCh	NULL
(	NULL
33-1,000	NULL
ug/kg	NULL
)	NULL
.	NULL

Data	NULL
were	NULL
expressed	NULL
as	NULL
mean	NULL
values	NULL
of	NULL
RL	NULL
*	NULL
SEM	NULL
.	NULL

Statistical	NULL
Analysis	NULL
.	NULL

Differences	NULL
were	NULL
evaluated	NULL
for	NULL
significance	NULL
(	NULL
P	NULL
<	NULL
0.05	NULL
)	NULL
by	NULL
the	NULL
Student	NULL
's	NULL
two-tailed	NULL
f	NULL
test	NULL
for	NULL
independent	NULL
events	NULL
(	NULL
Statworks	NULL
)	NULL
.	NULL

Data	NULL
are	NULL
given	NULL
as	NULL
mean	NULL
val	NULL
ues	NULL
-	NULL
SEM	NULL
.	NULL

mg/ml	NULL
of	NULL
aerosolized	NULL
MCh	NULL
and	NULL
monitoring	NULL
PenH	NULL
.	NULL

Results	NULL
were	NULL
25	NULL
15	NULL
10	NULL
L-	NULL
mme	NULL
ae	NULL
-	NULL
=	NULL
msd	NULL
GATA3+	NULL
cells/	NULL
HPF	NULL
Saline	NULL
OVA	NULL
AS-GATA	NULL
_	NULL
NS-GATA	NULL
-	NULL
MM-GATA	NULL
Figure	NULL
2	NULL
.	NULL

-	NULL
Increased	NULL
number	NULL
of	NULL
GATA-3-producing	NULL
lung	NULL
cells	NULL
in	NULL
OVA-sensitized	NULL
mice	NULL
and	NULL
inhibition	NULL
of	NULL
GATA-3	NULL
protein	NULL
expression	NULL
after	NULL
local	NULL
administration	NULL
of	NULL
antisense	NULL
oligonucleotides	NULL
.	NULL

Sections	NULL
of	NULL
OVA-immunized	NULL
(	NULL
B	NULL
)	NULL
and	NULL
saline-treated	NULL
control	NULL
mice	NULL
(	NULL
A	NULL
)	NULL
were	NULL
stained	NULL
with	NULL
an	NULL
antibody	NULL
against	NULL
GATA-3	NULL
(	NULL
Cy3	NULL
)	NULL
.	NULL

OVA	NULL
immunization	NULL
caused	NULL
an	NULL
upregulation	NULL
of	NULL
GATA-3	NULL
(	NULL
B	NULL
)	NULL
expression	NULL
.	NULL

Intranasal	NULL
administration	NULL
of	NULL
GATA-3	NULL
antisense	NULL
oligonucleotides	NULL
suppressed	NULL
GATA-3	NULL
(	NULL
C	NULL
)	NULL
expression	NULL
in	NULL
the	NULL
lung	NULL
of	NULL
OVA-immunized	NULL
mice	NULL
(	NULL
original	NULL
magnification	NULL
:	NULL
X400	NULL
)	NULL
.	NULL

The	NULL
same	NULL
field	NULL
analyzed	NULL
for	NULL
FITC-labeled	NULL
antisense	NULL
DNA	NULL
uptake	NULL
is	NULL
shown	NULL
in	NULL
F	NULL
(	NULL
FITC	NULL
;	NULL
emission	NULL
wavelength	NULL
,	NULL
520	NULL
nm	NULL
)	NULL
.	NULL

Double	NULL
staining	NULL
showed	NULL
the	NULL
absence	NULL
of	NULL
GATA-3	NULL
protein	NULL
expression	NULL
in	NULL
cells	NULL
with	NULL
intracellular	NULL
FITC-labeled	NULL
antisense	NULL
DNA	NULL
to	NULL
GATA-3	NULL
(	NULL
compare	NULL
C	NULL
and	NULL
F	NULL
)	NULL
.	NULL

Local	NULL
treatment	NULL
with	NULL
control	NULL
oligonucleotides	NULL
did	NULL
not	NULL
change	NULL
significantly	NULL
the	NULL
number	NULL
of	NULL
GATA-3-positive	NULL
cells	NULL
in	NULL
the	NULL
lung	NULL
compared	NULL
with	NULL
OVA-sensibilized	NULL
airways	NULL
(	NULL
nonsense	NULL
and	NULL
mismatched	NULL
oligonucleotide	NULL
treatment	NULL
is	NULL
shown	NULL
in	NULL
E	NULL
and	NULL
D	NULL
,	NULL
respectively	NULL
)	NULL
,	NULL
although	NULL
mismatched	NULL
DNA	NULL
led	NULL
to	NULL
a	NULL
reduction	NULL
in	NULL
the	NULL
average	NULL
number	NULL
of	NULL
GATA-3-expressing	NULL
cells	NULL
per	NULL
HPF	NULL
(	NULL
bottom	NULL
panel	NULL
)	NULL
.	NULL

In	NULL
these	NULL
quantitative	NULL
studies	NULL
,	NULL
GATA-3-positive	NULL
cells	NULL
in	NULL
OVA-immunized	NULL
mice	NULL
,	NULL
GATA-3	NULL
antisense	NULL
,	NULL
mismatched	NULL
,	NULL
and	NULL
nonsense-treated	NULL
OVA-immunized	NULL
mice	NULL
,	NULL
and	NULL
saline-treated	NULL
control	NULL
mice	NULL
were	NULL
assessed	NULL
by	NULL
immunohistochemistry	NULL
.	NULL

GATA-3-expressing	NULL
cells	NULL
in	NULL
the	NULL
lungs	NULL
were	NULL
quantified	NULL
blindly	NULL
by	NULL
the	NULL
same	NULL
observer	NULL
(	NULL
see	NULL
Materials	NULL
and	NULL
Methods	NULL
)	NULL
.	NULL

10	NULL
HPFs	NULL
in	NULL
the	NULL
area	NULL
of	NULL
peripheral	NULL
bronchi	NULL
were	NULL
randomly	NULL
selected	NULL
in	NULL
nine	NULL
lung	NULL
sections	NULL
from	NULL
each	NULL
mouse	NULL
(	NULL
five	NULL
mice	NULL
per	NULL
group	NULL
)	NULL
for	NULL
quantification	NULL
.	NULL

Counts	NULL
are	NULL
given	NULL
as	NULL
cells	NULL
per	NULL
HPF	NULL
.	NULL

AS-GATA	NULL
,	NULL
GATA-3	NULL
antisense	NULL
;	NULL
MM-GATA	NULL
,	NULL
mismatched	NULL
GATA-3	NULL
;	NULL
NS-GATA	NULL
,	NULL
nonsense	NULL
GATA-3	NULL
;	NULL
OVA	NULL
,	NULL
OVA-immunized	NULL
mice	NULL
.	NULL

1251	NULL
Finotto	NULL
et	NULL
al	NULL
.	NULL

For	NULL
the	NULL
analysis	NULL
of	NULL
RL	NULL
data	NULL
MANOVA	NULL
(	NULL
Wilks	NULL
Lambda	NULL
)	NULL
was	NULL
used	NULL
.	NULL

the	NULL
multivariate	NULL
analysis	NULL
Results	NULL
Suppression	NULL
of	NULL
IL-4	NULL
but	NULL
Not	NULL
IL-9	NULL
Release	NULL
in	NULL
Th2	NULL
CD4*	NULL
T	NULL
Cells	NULL
by	NULL
a	NULL
Specific	NULL
Antisense	NULL
Phosphorothicate	NULL
Oligonucleotide	NULL
to	NULL
the	NULL
Translation	NULL
Start	NULL
Site	NULL
of	NULL
GATA-3	NULL
.	NULL

In	NULL
an	NULL
attempt	NULL
to	NULL
specifically	NULL
downregulate	NULL
expression	NULL
of	NULL
GATA-3	NULL
in	NULL
T	NULL
lymphocytes	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
,	NULL
we	NULL
used	NULL
an	NULL
antisense	NULL
DNA	NULL
strategy	NULL
.	NULL

Accordingly	NULL
,	NULL
we	NULL
designed	NULL
specific	NULL
CpG-lacking	NULL
antisense	NULL
phosphorothioate	NULL
oligonucleotides	NULL
targeting	NULL
the	NULL
translation	NULL
start	NULL
site	NULL
of	NULL
murine	NULL
GATA-3	NULL
(	NULL
see	NULL
Materials	NULL
and	NULL
Methods	NULL
)	NULL
.	NULL

Then	NULL
we	NULL
tested	NULL
the	NULL
ability	NULL
of	NULL
such	NULL
oligonucleotides	NULL
to	NULL
specifically	NULL
downregulate	NULL
GATA-3	NULL
expression	NULL
in	NULL
CD4*	NULL
cells	NULL
isolated	NULL
from	NULL
the	NULL
spleen	NULL
during	NULL
Th2	NULL
cell	NULL
differentiation	NULL
in	NULL
vitro	NULL
.	NULL

We	NULL
observed	NULL
in	NULL
coincubation	NULL
studies	NULL
an	NULL
efficient	NULL
uptake	NULL
of	NULL
FITC-labeled	NULL
antisense	NULL
oligonucleotides	NULL
A	NULL
OVA-treated	NULL
mice	NULL
lung	NULL
extract	NULL
P4	NULL
2s	NULL
Â§	NULL
3	NULL
>	NULL
i	NULL
3	NULL
f	NULL
Â£	NULL
it	NULL
Â§	NULL
2s	NULL
83	NULL
50	NULL
â¬	NULL
$	NULL
oo	NULL
P	NULL
hpt	NULL
ie	NULL
F3	NULL
&	NULL
85	NULL
<	NULL
4	NULL
a	NULL
OL	NULL
3	NULL
OS	NULL
6	NULL
E	NULL
E	NULL
E	NULL
5	NULL
$	NULL
o	NULL
f	NULL
$	NULL
i	NULL
GATA3	NULL
wh	NULL
|	NULL
}	NULL
8	NULL
g	NULL
Â§	NULL
5	NULL
EMSA	NULL
free	NULL
probe	NULL
EMSA	NULL
B	NULL
OVA-treated	NULL
mice	NULL
=	NULL
uv	NULL
â¬	NULL
6	NULL
8	NULL
I	NULL
4	NULL
S	NULL
5	NULL
Â£	NULL
8	NULL
$	NULL
o	NULL
9	NULL
9	NULL
7	NULL
5G	NULL
iff	NULL
Â©	NULL
E	NULL
8	NULL
2	NULL
5	NULL
0	NULL
0	NULL
0	NULL
3	NULL
Gata-s	NULL
-	NULL
r=	NULL
W	NULL
>	NULL
ae	NULL
wes	NULL
a	NULL
i	NULL
<	NULL
6	NULL
OCT-1	NULL
=	NULL
=s	NULL
LJ	NULL
tos	NULL
tinh	NULL
teat	NULL
3	NULL
&	NULL
s	NULL
g	NULL
.	NULL

PoP	NULL
;	NULL
:	NULL
ig	NULL
.	NULL

|	NULL
3	NULL
p	NULL
as	NULL
I	NULL
â	NULL
S	NULL
Sp	NULL
*Qï¬h	NULL
EMSA	NULL
5	NULL
5	NULL
5	NULL
5	NULL
C	NULL
go	NULL
:	NULL
I	NULL
so	NULL
$	NULL
oj	NULL
$	NULL
:	NULL
Â«	NULL
3	NULL
+2	NULL
hes	NULL
0	NULL
p	NULL
E	NULL
=	NULL
s	NULL
2	NULL
2	NULL
==	NULL
Â£3	NULL
.	NULL

Ã©	NULL
oo	NULL
e	NULL
0	NULL
9	NULL
o	NULL
Â§	NULL
<	NULL
<	NULL
I	NULL
<	NULL
4	NULL
3	NULL
E	NULL
i=	NULL
bs	NULL
Eo	NULL
E	NULL
T	NULL
t	NULL
<	NULL
<	NULL
4	NULL
0	NULL
5	NULL
0	NULL
0	NULL
0	NULL
0	NULL
GATA	NULL
'	NULL
3	NULL
Â«	NULL
enne	NULL
Gump	NULL
|	NULL
um	NULL
-	NULL
#	NULL
096	NULL
Western	NULL
blot	NULL
beta-actin	NULL
|	NULL
Cin	NULL
Â»	NULL
ame	NULL
Â»	NULL
ame	NULL
comm	NULL
1252	NULL
in	NULL
cultured	NULL
and	NULL
already	NULL
differentiated	NULL
Th2	NULL
cells	NULL
(	NULL
day	NULL
6	NULL
:	NULL
50-70	NULL
%	NULL
of	NULL
cells	NULL
)	NULL
and	NULL
Jurkat	NULL
cell	NULL
lines	NULL
(	NULL
>	NULL
65	NULL
%	NULL
as	NULL
assessed	NULL
by	NULL
FACSÂ®	NULL
analysis	NULL
and	NULL
immunofluorescence	NULL
;	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
A	NULL
and	NULL
B	NULL
)	NULL
24	NULL
h	NULL
after	NULL
the	NULL
treatment	NULL
with	NULL
antisense	NULL
oligonucleotides	NULL
to	NULL
GATA-3	NULL
.	NULL

This	NULL
finding	NULL
was	NULL
associated	NULL
with	NULL
a	NULL
downregulation	NULL
of	NULL
GATA-3	NULL
expression	NULL
and	NULL
a	NULL
significant	NULL
reduction	NULL
of	NULL
IL-4	NULL
release	NULL
12	NULL
h	NULL
after	NULL
incubation	NULL
with	NULL
PMA	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
C	NULL
and	NULL
D	NULL
,	NULL
respectively	NULL
)	NULL
.	NULL

However	NULL
,	NULL
IL-9	NULL
production	NULL
by	NULL
spleen	NULL
T	NULL
cells	NULL
remained	NULL
unchanged	NULL
after	NULL
antisense	NULL
GATA-3	NULL
treatment	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
E	NULL
)	NULL
.	NULL

It	NULL
should	NULL
be	NULL
noted	NULL
that	NULL
the	NULL
observed	NULL
50	NULL
%	NULL
reduction	NULL
of	NULL
PMA	NULL
plus	NULL
ionomycin-inducible	NULL
IL-4	NULL
production	NULL
upon	NULL
antisense	NULL
treatment	NULL
is	NULL
remarkable	NULL
,	NULL
as	NULL
only	NULL
50-70	NULL
%	NULL
of	NULL
the	NULL
spleen	NULL
cells	NULL
showed	NULL
DNA	NULL
uptake	NULL
.	NULL

Indeed	NULL
,	NULL
cotransfection-	NULL
based	NULL
enrichment	NULL
of	NULL
antisense-transfected	NULL
T	NULL
cells	NULL
led	NULL
to	NULL
a	NULL
more	NULL
pronounced	NULL
downregulation	NULL
of	NULL
IL-4	NULL
production	NULL
by	NULL
Th2	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

Treatment	NULL
with	NULL
control	NULL
nonsense	NULL
oligonucleotides	NULL
did	NULL
not	NULL
affect	NULL
GATA-3	NULL
expression	NULL
or	NULL
IL-4	NULL
and	NULL
IL-9	NULL
release	NULL
un	NULL
Figure	NULL
3	NULL
.	NULL

Detection	NULL
of	NULL
GATA-3	NULL
in	NULL
the	NULL
lungs	NULL
of	NULL
OVA-immunized	NULL
mice	NULL
by	NULL
gel	NULL
retardation	NULL
assay	NULL
(	NULL
EMSA	NULL
)	NULL
and	NULL
Western	NULL
blot	NULL
analysis	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Expression	NULL
of	NULL
GATA-3	NULL
in	NULL
cellular	NULL
extracts	NULL
from	NULL
lung	NULL
cells	NULL
was	NULL
assessed	NULL
by	NULL
EMSA	NULL
using	NULL
a	NULL
GATA-3-specific	NULL
reference	NULL
binding	NULL
site	NULL
.	NULL

Unbound	NULL
radiolabeled	NULL
probe	NULL
was	NULL
separated	NULL
from	NULL
DNA-protein	NULL
complexes	NULL
by	NULL
gel	NULL
elec-trophoresis	NULL
under	NULL
nondenaturing	NULL
conditions	NULL
.	NULL

OVA	NULL
immunization	NULL
led	NULL
to	NULL
a	NULL
strong	NULL
increase	NULL
of	NULL
GATA-3	NULL
expression	NULL
in	NULL
the	NULL
lung	NULL
compared	NULL
with	NULL
lungs	NULL
from	NULL
saline-treated	NULL
control	NULL
mice	NULL
.	NULL

Whereas	NULL
treatment	NULL
with	NULL
GATA-3	NULL
antisense	NULL
oligonucleotides	NULL
caused	NULL
a	NULL
suppression	NULL
of	NULL
GATA-3	NULL
expression	NULL
,	NULL
treatment	NULL
with	NULL
GATA-3	NULL
nonsense	NULL
DNA	NULL
or	NULL
corticosteroids	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
GATA-3	NULL
expression	NULL
.	NULL

Specificity	NULL
of	NULL
the	NULL
GATA-3	NULL
signal	NULL
was	NULL
shown	NULL
by	NULL
competition	NULL
assays	NULL
using	NULL
unlabeled	NULL
GATA-3	NULL
oligonucleotides	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
and	NULL
supershift	NULL
assays	NULL
with	NULL
specific	NULL
antibodies	NULL
to	NULL
GATA-3	NULL
.	NULL

Whereas	NULL
a	NULL
control	NULL
antibody	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
GATA-3	NULL
complex	NULL
in	NULL
EMSA	NULL
,	NULL
a	NULL
complete	NULL
abrogation	NULL
of	NULL
the	NULL
retarded	NULL
complex	NULL
was	NULL
observed	NULL
upon	NULL
addition	NULL
of	NULL
the	NULL
GATA-3-specific	NULL
antibody	NULL
(	NULL
right	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Specificity	NULL
of	NULL
the	NULL
effects	NULL
of	NULL
GATA-3	NULL
antisense	NULL
oligonucleotides	NULL
on	NULL
GATA-3	NULL
expression	NULL
.	NULL

The	NULL
expression	NULL
of	NULL
GATA-3	NULL
,	NULL
OCT	NULL
-1	NULL
,	NULL
and	NULL
SP-1	NULL
transcription	NULL
factors	NULL
in	NULL
cellular	NULL
extracts	NULL
from	NULL
lung	NULL
cells	NULL
was	NULL
assessed	NULL
by	NULL
EMSA	NULL
using	NULL
specific	NULL
reference	NULL
binding	NULL
sites	NULL
.	NULL

Although	NULL
antisense	NULL
oligonucleotides	NULL
to	NULL
GATA-3	NULL
caused	NULL
a	NULL
marked	NULL
reduction	NULL
of	NULL
GATA-3	NULL
expression	NULL
,	NULL
they	NULL
had	NULL
no	NULL
such	NULL
effect	NULL
on	NULL
the	NULL
expression	NULL
of	NULL
OCT	NULL
-1	NULL
and	NULL
SP-1	NULL
.	NULL

The	NULL
expression	NULL
of	NULL
GATA-3	NULL
in	NULL
lung	NULL
extracts	NULL
was	NULL
finally	NULL
assessed	NULL
in	NULL
three	NULL
independent	NULL
experiments	NULL
using	NULL
EMSA	NULL
analysis	NULL
.	NULL

Quantification	NULL
of	NULL
the	NULL
EMSA	NULL
bands	NULL
in	NULL
these	NULL
three	NULL
experiments	NULL
is	NULL
depicted	NULL
on	NULL
the	NULL
right	NULL
(	NULL
signal	NULL
in	NULL
untreated	NULL
conditions	NULL
was	NULL
defined	NULL
as	NULL
100	NULL
%	NULL
)	NULL
.	NULL

Whereas	NULL
GATA-3	NULL
antisense	NULL
DNA	NULL
led	NULL
to	NULL
a	NULL
significant	NULL
(	NULL
P	NULL
<	NULL
0.01	NULL
)	NULL
reduction	NULL
of	NULL
GATA-3	NULL
expression	NULL
,	NULL
nonsense	NULL
DNA	NULL
had	NULL
no	NULL
such	NULL
effect	NULL
.	NULL

Mismatched	NULL
DNA	NULL
had	NULL
no	NULL
significant	NULL
effect	NULL
on	NULL
GATA-3	NULL
expression	NULL
,	NULL
although	NULL
a	NULL
reduction	NULL
in	NULL
the	NULL
average	NULL
GATA-3	NULL
signal	NULL
was	NULL
noted	NULL
.	NULL

**P	NULL
<	NULL
0.01	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Western	NULL
blot	NULL
analysis	NULL
for	NULL
GATA-3	NULL
and	NULL
B-actin	NULL
expression	NULL
in	NULL
the	NULL
lungs	NULL
of	NULL
OVA-immunized	NULL
mice	NULL
.	NULL

Extracts	NULL
from	NULL
lung	NULL
tissue	NULL
were	NULL
analyzed	NULL
using	NULL
a	NULL
GATA-3-specific	NULL
antibody	NULL
.	NULL

GATA-3	NULL
antisense	NULL
DNA	NULL
treatment	NULL
led	NULL
to	NULL
a	NULL
suppression	NULL
of	NULL
GATA-3	NULL
expression	NULL
,	NULL
whereas	NULL
control	NULL
nonsense	NULL
GATA-3	NULL
oligonucleotides	NULL
and	NULL
corticosteroids	NULL
had	NULL
no	NULL
such	NULL
effect	NULL
.	NULL

One	NULL
representative	NULL
out	NULL
of	NULL
three	NULL
lungs	NULL
per	NULL
group	NULL
is	NULL
shown	NULL
.	NULL

50	NULL
g	NULL
of	NULL
proteins	NULL
per	NULL
lane	NULL
was	NULL
loaded	NULL
.	NULL

Equal	NULL
loading	NULL
was	NULL
also	NULL
confirmed	NULL
after	NULL
5	NULL
min	NULL
staining	NULL
of	NULL
the	NULL
nitrocellulose	NULL
membrane	NULL
with	NULL
Ponceau	NULL
's	NULL
solution	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

AS	NULL
,	NULL
antisense	NULL
;	NULL
NS	NULL
,	NULL
nonsense	NULL
;	NULL
MM	NULL
,	NULL
mismatched	NULL
.	NULL

Antisense	NULL
DNA	NULL
to	NULL
GATA-3	NULL
Abrogates	NULL
Airway	NULL
Hyperresponsiveness	NULL
der	NULL
the	NULL
same	NULL
experimental	NULL
conditions	NULL
.	NULL

Treatment	NULL
with	NULL
mismatched	NULL
DNA	NULL
also	NULL
led	NULL
to	NULL
a	NULL
reduction	NULL
of	NULL
the	NULL
average	NULL
number	NULL
of	NULL
GAT	NULL
cells	NULL
and	NULL
IL-4	NULL
release	NULL
,	NULL
possibly	NULL
due	NULL
to	NULL
a	NULL
remaining	NULL
weak	NULL
hybridization	NULL
of	NULL
the	NULL
mismatched	NULL
DNA	NULL
to	NULL
the	NULL
GATA-3	NULL
target	NULL
mRNA	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

However	NULL
,	NULL
this	NULL
effect	NULL
was	NULL
less	NULL
pronounced	NULL
compared	NULL
with	NULL
the	NULL
antisense	NULL
DNA	NULL
effect	NULL
,	NULL
and	NULL
the	NULL
mismatched	NULL
DNA-induced	NULL
changes	NULL
were	NULL
not	NULL
statistically	NULL
significant	NULL
.	NULL

Furthermore	NULL
,	NULL
this	NULL
effect	NULL
was	NULL
not	NULL
seen	NULL
using	NULL
a	NULL
second	NULL
mismatched	NULL
control	NULL
oligonucleotide	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
H	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
antisense	NULL
oligonucleotides	NULL
to	NULL
GATA-3	NULL
cause	NULL
a	NULL
specific	NULL
suppression	NULL
of	NULL
GATA-3	NULL
expression	NULL
and	NULL
IL-4	NULL
production	NULL
by	NULL
cultured	NULL
T	NULL
cells	NULL
.	NULL

Intranasal	NULL
Administration	NULL
of	NULL
GATA-3	NULL
Antisense	NULL
Oligonucleotides	NULL
Decreases	NULL
Lung	NULL
GATA-3	NULL
Protein	NULL
Expression	NULL
in	NULL
a	NULL
Murine	NULL
Model	NULL
of	NULL
Asthma	NULL
.	NULL

Based	NULL
on	NULL
previous	NULL
studies	NULL
showing	NULL
a	NULL
key	NULL
role	NULL
for	NULL
GATA-3	NULL
in	NULL
Th2	NULL
cytokine	NULL
production	NULL
and	NULL
increased	NULL
Th2	NULL
cytokine	NULL
production	NULL
in	NULL
asthma	NULL
(	NULL
2	NULL
,	NULL
18	NULL
)	NULL
,	NULL
we	NULL
analyzed	NULL
in	NULL
a	NULL
consecutive	NULL
series	NULL
of	NULL
studies	NULL
the	NULL
expression	NULL
of	NULL
GATA-3	NULL
in	NULL
a	NULL
murine	NULL
model	NULL
of	NULL
asthma	NULL
(	NULL
37	NULL
)	NULL
associated	NULL
with	NULL
late	NULL
phase	NULL
allergic	NULL
pulmonary	NULL
inflammation	NULL
in	NULL
OVA-sensitized	NULL
mice	NULL
.	NULL

Accordingly	NULL
,	NULL
we	NULL
immunostained	NULL
lung	NULL
sections	NULL
from	NULL
OVA-treated	NULL
and	NULL
control	NULL
mice	NULL
with	NULL
anti-GATA-3	NULL
antibodies	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
OVA	NULL
immunization	NULL
caused	NULL
a	NULL
striking	NULL
increase	NULL
in	NULL
lung-infiltrating	NULL
cells	NULL
expressing	NULL
GATA-3	NULL
compared	NULL
with	NULL
saline	NULL
treatment	NULL
.	NULL

In	NULL
further	NULL
studies	NULL
,	NULL
we	NULL
wanted	NULL
to	NULL
directly	NULL
test	NULL
the	NULL
effects	NULL
of	NULL
GATA-3	NULL
antisense	NULL
phosphorothioate	NULL
oligonucleotides	NULL
on	NULL
the	NULL
expression	NULL
of	NULL
GATA-3	NULL
during	NULL
the	NULL
late	NULL
phase	NULL
allergic	NULL
asthmatic	NULL
reaction	NULL
in	NULL
vivo	NULL
.	NULL

Intranasal	NULL
delivery	NULL
of	NULL
FITC-labeled	NULL
GAT	NULL
antisense	NULL
oligonucleotides	NULL
led	NULL
to	NULL
a	NULL
DNA	NULL
uptake	NULL
by	NULL
GAT	NULL
A-3-expressing	NULL
lung	NULL
cells	NULL
in	NULL
vivo	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
C	NULL
and	NULL
F	NULL
)	NULL
.	NULL

This	NULL
finding	NULL
was	NULL
accompanied	NULL
by	NULL
a	NULL
significant	NULL
decrease	NULL
of	NULL
GATA-3	NULL
expression	NULL
in	NULL
the	NULL
lung	NULL
of	NULL
OVA-sensitized	NULL
mice	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
B	NULL
and	NULL
C	NULL
,	NULL
and	NULL
bottom	NULL
panel	NULL
)	NULL
,	NULL
while	NULL
control	NULL
nonsense	NULL
oligonucleotides	NULL
had	NULL
no	NULL
such	NULL
effect	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
E	NULL
,	NULL
and	NULL
bottom	NULL
panel	NULL
)	NULL
.	NULL

Mismatched	NULL
DNA	NULL
led	NULL
to	NULL
a	NULL
reduction	NULL
of	NULL
the	NULL
number	NULL
of	NULL
GATA-3-	NULL
positive	NULL
cells	NULL
in	NULL
the	NULL
lung	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
D	NULL
,	NULL
and	NULL
bottom	NULL
panel	NULL
)	NULL
,	NULL
although	NULL
this	NULL
effect	NULL
was	NULL
not	NULL
statistically	NULL
significant	NULL
.	NULL

In	NULL
additional	NULL
studies	NULL
,	NULL
we	NULL
performed	NULL
Western	NULL
blot	NULL
analysis	NULL
of	NULL
total	NULL
proteins	NULL
derived	NULL
from	NULL
the	NULL
lung	NULL
to	NULL
assess	NULL
local	NULL
GATA-3	NULL
expression	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
these	NULL
studies	NULL
confirmed	NULL
the	NULL
downregulation	NULL
of	NULL
GATA-3	NULL
protein	NULL
expression	NULL
in	NULL
antisense	NULL
GAT	NULL
A-3-treated	NULL
lungs	NULL
but	NULL
not	NULL
in	NULL
lungs	NULL
treated	NULL
with	NULL
control	NULL
nonsense	NULL
oligonucleotides	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
C	NULL
)	NULL
.	NULL

Simi-larly	NULL
,	NULL
analysis	NULL
of	NULL
lung	NULL
proteins	NULL
for	NULL
GATA-3	NULL
expression	NULL
by	NULL
gel	NULL
retardation	NULL
assays	NULL
(	NULL
EMSA	NULL
)	NULL
using	NULL
a	NULL
GATA-3	NULL
consensus	NULL
oligonucleotide	NULL
confirmed	NULL
the	NULL
downregulation	NULL
of	NULL
GATA-3	NULL
upon	NULL
antisense	NULL
treatment	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
A	NULL
)	NULL
.	NULL

Densitometric	NULL
analysis	NULL
of	NULL
the	NULL
EMSA	NULL
bands	NULL
showed	NULL
a	NULL
significant	NULL
downregulation	NULL
of	NULL
GATA-3	NULL
upon	NULL
antisense	NULL
DNA	NULL
treatment	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
B	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
transcription	NULL
factors	NULL
OCT	NULL
-1	NULL
and	NULL
SP-1	NULL
were	NULL
not	NULL
affected	NULL
by	NULL
GATA-3	NULL
antisense	NULL
DNA	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
B	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
nonsense	NULL
control	NULL
oligonucleotides	NULL
were	NULL
virtually	NULL
inactive	NULL
with	NULL
regard	NULL
to	NULL
GATA-3	NULL
expression	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
these	NULL
results	NULL
indicated	NULL
that	NULL
local	NULL
administration	NULL
of	NULL
1253	NULL
Finotto	NULL
et	NULL
al	NULL
.	NULL

:	NULL
``	NULL
RS	NULL
Ar	NULL
mA	NULL
Wak	NULL
(	NULL
G	NULL
:	NULL
e	NULL
att	NULL
b	NULL
yy	NULL
Â£9	NULL
Caf	NULL
ays	NULL
N	NULL
Figure	NULL
4	NULL
.	NULL

Histologic	NULL
evidence	NULL
of	NULL
airway	NULL
inflammation	NULL
in	NULL
OVA-sensitized	NULL
and	NULL
control	NULL
mice	NULL
;	NULL
effect	NULL
of	NULL
GATA-3	NULL
antisense	NULL
treatment	NULL
.	NULL

Lung	NULL
tissue	NULL
was	NULL
analyzed	NULL
from	NULL
untreated	NULL
(	NULL
C	NULL
and	NULL
D	NULL
)	NULL
and	NULL
antisense-treated	NULL
(	NULL
E	NULL
and	NULL
F	NULL
)	NULL
OVA-sensitized	NULL
mice	NULL
.	NULL

In	NULL
untreated	NULL
mice	NULL
,	NULL
a	NULL
massive	NULL
peribronchial	NULL
infiltration	NULL
with	NULL
eosinophils	NULL
,	NULL
thickening	NULL
of	NULL
the	NULL
basement	NULL
membrane	NULL
,	NULL
and	NULL
deepi-thelialization	NULL
were	NULL
seen	NULL
(	NULL
see	NULL
higher	NULL
magnification	NULL
in	NULL
D	NULL
:	NULL
X400	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
after	NULL
treatment	NULL
with	NULL
antisense	NULL
DNA	NULL
to	NULL
GATA-3	NULL
an	NULL
intact	NULL
bronchial	NULL
epithelial	NULL
layer	NULL
and	NULL
no	NULL
eosinophil	NULL
infiltration	NULL
were	NULL
seen	NULL
(	NULL
E	NULL
and	NULL
F	NULL
)	NULL
comparable	NULL
to	NULL
DEX	NULL
treatment	NULL
(	NULL
I	NULL
and	NULL
K	NULL
)	NULL
.	NULL

Lung	NULL
tissues	NULL
taken	NULL
from	NULL
sham	NULL
(	NULL
saline	NULL
)	NULL
-sensitized	NULL
mice	NULL
(	NULL
A	NULL
and	NULL
B	NULL
)	NULL
and	NULL
OVA-immunized	NULL
mice	NULL
treated	NULL
with	NULL
nonsense	NULL
DNA	NULL
(	NULL
G	NULL
and	NULL
H	NULL
)	NULL
are	NULL
shown	NULL
as	NULL
control	NULL
.	NULL

Lung	NULL
sections	NULL
were	NULL
stained	NULL
with	NULL
hematoxylin	NULL
and	NULL
eosin	NULL
and	NULL
examined	NULL
by	NULL
light	NULL
microscopy	NULL
.	NULL

Original	NULL
magnifications	NULL
:	NULL
(	NULL
A	NULL
,	NULL
C	NULL
,	NULL
E	NULL
,	NULL
G	NULL
,	NULL
and	NULL
H	NULL
)	NULL
X200	NULL
;	NULL
(	NULL
B	NULL
,	NULL
D	NULL
,	NULL
F	NULL
,	NULL
H	NULL
,	NULL
and	NULL
K	NULL
)	NULL
X400	NULL
.	NULL

specific	NULL
antisense	NULL
oligonucleotides	NULL
leads	NULL
to	NULL
specific	NULL
downregulation	NULL
of	NULL
pulmonary	NULL
GATA-3	NULL
expression	NULL
in	NULL
an	NULL
asthma	NULL
model	NULL
in	NULL
vivo	NULL
.	NULL

Inhibition	NULL
of	NULL
Allergen-induced	NULL
Airway	NULL
Inflammation	NULL
by	NULL
GAT	NULL
Antisense	NULL
Oligonucleotides	NULL
.	NULL

To	NULL
assess	NULL
the	NULL
histologic	NULL
effects	NULL
of	NULL
GATA-3	NULL
antisense	NULL
phosphorothioate	NULL
oligonucleotides	NULL
on	NULL
allergen-induced	NULL
airway	NULL
inflammation	NULL
,	NULL
we	NULL
analyzed	NULL
lung	NULL
tissues	NULL
24	NULL
h	NULL
after	NULL
the	NULL
last	NULL
of	NULL
three	NULL
sequential	NULL
OVA	NULL
challenges	NULL
(	NULL
days	NULL
25-27	NULL
)	NULL
on	NULL
day	NULL
28	NULL
.	NULL

In	NULL
untreated	NULL
OVA-sensitized	NULL
mice	NULL
,	NULL
an	NULL
infiltration	NULL
of	NULL
the	NULL
bronchial	NULL
interstitium	NULL
with	NULL
eosinophils	NULL
was	NULL
observed	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
C	NULL
and	NULL
D	NULL
)	NULL
.	NULL

Treatment	NULL
of	NULL
OV	NULL
A-sensitized	NULL
mice	NULL
with	NULL
nonsense	NULL
GAT	NULL
A-3	NULL
oligonucleotides	NULL
had	NULL
no	NULL
detectable	NULL
effects	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
G	NULL
and	NULL
H	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
no	NULL
inflammatory	NULL
signs	NULL
were	NULL
seen	NULL
in	NULL
OVA-sensitized	NULL
mice	NULL
upon	NULL
treatment	NULL
with	NULL
corticosteroids	NULL
or	NULL
GAT	NULL
A-3	NULL
antisense	NULL
oligonucleotides	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
I	NULL
,	NULL
K	NULL
,	NULL
E	NULL
,	NULL
and	NULL
F	NULL
)	NULL
.	NULL

A	NULL
Control	NULL
mice	NULL
were	NULL
treated	NULL
with	NULL
saline	NULL
complexed	NULL
with	NULL
alum	NULL
and	NULL
rechallenged	NULL
intranasally	NULL
with	NULL
saline	NULL
;	NULL
they	NULL
show	NULL
an	NULL
intact	NULL
airway	NULL
epithelium	NULL
and	NULL
no	NULL
sign	NULL
of	NULL
inflammation	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
A	NULL
and	NULL
B	NULL
)	NULL
.	NULL

Antisense	NULL
Oligonucleotides	NULL
to	NULL
GATA-3	NULL
Inhibit	NULL
Infiltration	NULL
of	NULL
Eosinophils	NULL
in	NULL
the	NULL
Lung	NULL
.	NULL

_	NULL
In	NULL
further	NULL
studies	NULL
on	NULL
the	NULL
potential	NULL
mechanisms	NULL
of	NULL
antisense-induced	NULL
suppression	NULL
of	NULL
lung	NULL
inflammation	NULL
,	NULL
we	NULL
assessed	NULL
allergen-induced	NULL
infiltration	NULL
of	NULL
eosinophils	NULL
in	NULL
the	NULL
lung	NULL
.	NULL

By	NULL
morphometric	NULL
analysis	NULL
,	NULL
the	NULL
influx	NULL
of	NULL
eosinophils	NULL
into	NULL
the	NULL
lung	NULL
interstitium	NULL
was	NULL
significantly	NULL
reduced	NULL
after	NULL
administration	NULL
of	NULL
GATA-3	NULL
antisense	NULL
oligonucleotides	NULL
compared	NULL
with	NULL
untreated	NULL
mice	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

Antisense-induced	NULL
suppression	NULL
of	NULL
the	NULL
number	NULL
of	NULL
eosinophils	NULL
in	NULL
the	NULL
BALF	NULL
was	NULL
comparable	NULL
to	NULL
that	NULL
induced	NULL
by	NULL
intranasal	NULL
DEX	NULL
treatment	NULL
(	NULL
BAL	NULL
cell	NULL
viability	NULL
77.5	NULL
+	NULL
9.8	NULL
%	NULL
)	NULL
.	NULL

However	NULL
,	NULL
no	NULL
difference	NULL
was	NULL
seen	NULL
in	NULL
cell	NULL
viability	NULL
in	NULL
the	NULL
Â©	NULL
``	NULL
&	NULL
.	NULL

T0	NULL
Â£1	NULL
m	NULL
L	NULL
.	NULL

53	NULL
3	NULL
``	NULL
!	NULL

E	NULL
I	NULL
â	NULL
L	NULL
-	NULL
Â£	NULL
I	NULL
Â§	NULL
2	NULL
&	NULL
&	NULL
``	NULL
|	NULL
8	NULL
``	NULL
|	NULL
Tsk	NULL
re	NULL
I	NULL
Ca	NULL
ees	NULL
Saline	NULL
OVA	NULL
__	NULL
OVA+AS-	NULL
OVA+NS-	NULL
OVA+MM-	NULL
_	NULL
DEX	NULL
GaTas	NULL
GATA3	NULL
Gata	NULL
B	NULL
u44	NULL
2500000	NULL
,	NULL
g	NULL
2000000	NULL
m	NULL
Â£	NULL
3	NULL
1500000	NULL
|-	NULL
ye	NULL
1000000	NULL
8	NULL
Â£	NULL
o	NULL
L	NULL
***	NULL
|	NULL
|	NULL
]	NULL
**	NULL
Saline	NULL
OVA	NULL
OVA	NULL
+	NULL
OVA	NULL
+	NULL
OVA	NULL
+	NULL
DEX	NULL
AS-	NULL
NS-	NULL
MMGATA3	NULL
GATA3	NULL
GATA3	NULL
C	NULL
16000	NULL
14000	NULL
bi	NULL
E	NULL
12000	NULL
=	NULL
40000	NULL
g	NULL
sooo	NULL
g	NULL
s000	NULL
#	NULL
$	NULL
4000	NULL
Ll	NULL
2000	NULL
a	NULL
o	NULL
-s	NULL
Saline	NULL
OVA	NULL
_	NULL
OVA+AS-	NULL
OVA+NS-	NULL
-	NULL
OVA+	NULL
DEX	NULL
GATA3	NULL
_	NULL
GATA3	NULL
MMGATA3	NULL
Figure	NULL
5	NULL
.	NULL

Infiltration	NULL
of	NULL
eosinophils	NULL
into	NULL
the	NULL
airways	NULL
is	NULL
abrogated	NULL
by	NULL
local	NULL
administration	NULL
of	NULL
GATA-3	NULL
antisense	NULL
oligonucleotides	NULL
(	NULL
significance	NULL
:	NULL
*P	NULL
<	NULL
0.05	NULL
;	NULL
**P	NULL
<	NULL
0.01	NULL
;	NULL
**P	NULL
<	NULL
0.001	NULL
)	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Eosinophils	NULL
in	NULL
the	NULL
BALF	NULL
were	NULL
detected	NULL
on	NULL
cytospins	NULL
after	NULL
staining	NULL
according	NULL
to	NULL
May-Griinwald	NULL
Giemsa	NULL
and	NULL
quantified	NULL
after	NULL
counting	NULL
of	NULL
200	NULL
cells	NULL
.	NULL

Data	NULL
are	NULL
reported	NULL
as	NULL
the	NULL
mean	NULL
percentage	NULL
of	NULL
eosinophils	NULL
in	NULL
the	NULL
BAL	NULL
*	NULL
SEM	NULL
(	NULL
r	NULL
=	NULL
4-5	NULL
animals	NULL
per	NULL
group	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Absolute	NULL
eosinophil	NULL
numbers	NULL
*	NULL
SEM	NULL
in	NULL
the	NULL
recovered	NULL
BALF	NULL
.	NULL

Results	NULL
were	NULL
obtained	NULL
by	NULL
multiplying	NULL
the	NULL
percentage	NULL
of	NULL
eosinophils	NULL
with	NULL
the	NULL
total	NULL
cell	NULL
number	NULL
per	NULL
milliliter	NULL
and	NULL
the	NULL
recovered	NULL
volume	NULL
of	NULL
the	NULL
BALF	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Three	NULL
representative	NULL
fields	NULL
around	NULL
peripheral	NULL
bronchi	NULL
of	NULL
similar	NULL
size	NULL
were	NULL
randomly	NULL
selected	NULL
from	NULL
lung	NULL
sections	NULL
and	NULL
eosinophils	NULL
were	NULL
counted	NULL
with	NULL
a	NULL
computerized	NULL
system	NULL
(	NULL
see	NULL
Materials	NULL
and	NULL
Methods	NULL
)	NULL
.	NULL

Data	NULL
are	NULL
reported	NULL
as	NULL
the	NULL
mean	NULL
number	NULL
of	NULL
eosinophils	NULL
per	NULL
mm	NULL
?	NULL

Â£	NULL
SEM	NULL
.	NULL

Significant	NULL
differences	NULL
compared	NULL
with	NULL
OVA	NULL
treatment	NULL
are	NULL
indicated	NULL
.	NULL

(	NULL
D-F	NULL
)	NULL
A	NULL
representative	NULL
field	NULL
of	NULL
the	NULL
BALF	NULL
from	NULL
a	NULL
saline-treated	NULL
mouse	NULL
(	NULL
D	NULL
)	NULL
and	NULL
an	NULL
OVA-sensitized	NULL
animal	NULL
with	NULL
(	NULL
F	NULL
)	NULL
or	NULL
without	NULL
(	NULL
E	NULL
)	NULL
antisense	NULL
GATA-3	NULL
DNA	NULL
treatment	NULL
are	NULL
shown	NULL
.	NULL

Cytospins	NULL
were	NULL
stained	NULL
with	NULL
May-Griinwald	NULL
Giemsa	NULL
.	NULL

AS	NULL
,	NULL
antisense	NULL
;	NULL
NS	NULL
,	NULL
nonsense	NULL
;	NULL
MM	NULL
,	NULL
mismatched	NULL
.	NULL

1254	NULL
Antisense	NULL
DNA	NULL
to	NULL
GATA-3	NULL
Abrogates	NULL
Airway	NULL
Hyperresponsiveness	NULL
BALF	NULL
after	NULL
antisense	NULL
treatment	NULL
in	NULL
OVA-sensitized	NULL
lungs	NULL
compared	NULL
with	NULL
saline	NULL
treatment	NULL
(	NULL
84.4	NULL
+	NULL
3.5	NULL
%	NULL
and	NULL
91.15	NULL
+	NULL
6.3	NULL
%	NULL
viability	NULL
,	NULL
respectively	NULL
,	NULL
as	NULL
assessed	NULL
by	NULL
trypan	NULL
blue	NULL
ex-clusion	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
treatment	NULL
with	NULL
control	NULL
mismatched	NULL
(	NULL
BAL	NULL
cell	NULL
viability	NULL
87.27	NULL
+	NULL
3.8	NULL
%	NULL
)	NULL
and	NULL
nonsense	NULL
oligonucleotides	NULL
(	NULL
BAL	NULL
cell	NULL
viability	NULL
79.15	NULL
+	NULL
5.45	NULL
%	NULL
)	NULL
had	NULL
no	NULL
significant	NULL
effect	NULL
on	NULL
the	NULL
OVA-induced	NULL
influx	NULL
of	NULL
eosinophils	NULL
in	NULL
the	NULL
airways	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

Antisense	NULL
Oligonucleotides	NULL
to	NULL
GATA-3	NULL
Inhibit	NULL
Th2	NULL
Cytokine	NULL
Production	NULL
and	NULL
Infiltration	NULL
of	NULL
Eosinophils	NULL
in	NULL
the	NULL
Lung	NULL
of	NULL
OVA-sensitized	NULL
Mice	NULL
.	NULL

-	NULL
Since	NULL
T	NULL
cell	NULL
cytokines	NULL
are	NULL
known	NULL
to	NULL
regulate	NULL
airway	NULL
inflammation	NULL
in	NULL
vivo	NULL
,	NULL
we	NULL
next	NULL
determined	NULL
Th1	NULL
and	NULL
Th2	NULL
cytokine	NULL
levels	NULL
in	NULL
the	NULL
BALF	NULL
of	NULL
OVA-sensitized	NULL
mice	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
neither	NULL
OVA	NULL
nor	NULL
antisense	NULL
treatment	NULL
altered	NULL
IFN-y	NULL
levels	NULL
in	NULL
the	NULL
BALF	NULL
compared	NULL
with	NULL
saline-treated	NULL
mice	NULL
.	NULL

However	NULL
,	NULL
IL-4	NULL
concentration	NULL
in	NULL
the	NULL
BAL	NULL
was	NULL
significantly	NULL
suppressed	NULL
(	NULL
P	NULL
<	NULL
0.05	NULL
)	NULL
by	NULL
GATA-3	NULL
antisense	NULL
DNA	NULL
treatment	NULL
,	NULL
suggesting	NULL
that	NULL
blockade	NULL
of	NULL
GATA-3	NULL
expression	NULL
selectively	NULL
inhibits	NULL
Th2	NULL
cytokine	NULL
levels	NULL
in	NULL
the	NULL
BAL	NULL
.	NULL

Nonsense	NULL
control	NULL
DNA	NULL
did	NULL
not	NULL
cause	NULL
significant	NULL
changes	NULL
in	NULL
IL-4	NULL
production	NULL
,	NULL
whereas	NULL
mismatched	NULL
oligonucleotides	NULL
led	NULL
to	NULL
downregulation	NULL
of	NULL
the	NULL
average	NULL
IL-4	NULL
production	NULL
.	NULL

However	NULL
,	NULL
this	NULL
effect	NULL
was	NULL
not	NULL
statistically	NULL
significant	NULL
.	NULL

Local	NULL
Treatment	NULL
with	NULL
Antisense	NULL
Oligonucleotides	NULL
Decreased	NULL
Alcian	NULL
Blue/PAS-positive	NULL
Cells	NULL
in	NULL
the	NULL
Airways	NULL
of	NULL
OVA-sensitized	NULL
Mice	NULL
.	NULL

Many	NULL
mucus-producing	NULL
cells	NULL
(	NULL
acidic	NULL
sulfated	NULL
and	NULL
neutral	NULL
mucosubstances	NULL
)	NULL
were	NULL
seen	NULL
in	NULL
the	NULL
airways	NULL
of	NULL
A	NULL
IL-4	NULL
BALF	NULL
(	NULL
pg/ml	NULL
!	NULL
)	NULL

3	NULL
Â§	NULL
$	NULL
$	NULL
S	NULL
wa	NULL
-	NULL
]	NULL
o	NULL
_o	NULL
mice	NULL
sensitized	NULL
to	NULL
OVA	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
compared	NULL
with	NULL
saline-treated	NULL
mice	NULL
(	NULL
saline	NULL
)	NULL
,	NULL
as	NULL
assessed	NULL
by	NULL
the	NULL
alcian	NULL
blue/PAS	NULL
reaction	NULL
.	NULL

These	NULL
inflammatory	NULL
changes	NULL
were	NULL
absent	NULL
in	NULL
mice	NULL
that	NULL
were	NULL
treated	NULL
with	NULL
GATA-3	NULL
antisense	NULL
DNA	NULL
(	NULL
AS-GATA-3	NULL
)	NULL
.	NULL

DEX	NULL
treatment	NULL
reduced	NULL
PAS-positive	NULL
cells	NULL
in	NULL
the	NULL
airways	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
no	NULL
changes	NULL
were	NULL
seen	NULL
after	NULL
treatment	NULL
with	NULL
nonsense	NULL
control	NULL
oligonucleotides	NULL
.	NULL

Local	NULL
Treatment	NULL
with	NULL
Antisense	NULL
Oligonucleotides	NULL
to	NULL
GATA-3	NULL
Suppresses	NULL
Airway	NULL
Hyperreactivity	NULL
in	NULL
OV	NULL
Mice	NULL
.	NULL

In	NULL
a	NULL
final	NULL
series	NULL
of	NULL
experiments	NULL
,	NULL
we	NULL
analyzed	NULL
whether	NULL
antisense	NULL
oligonucleotides	NULL
to	NULL
GAT	NULL
would	NULL
affect	NULL
airway	NULL
hyperreactivity	NULL
in	NULL
OVA-sensitized	NULL
mice	NULL
.	NULL

This	NULL
point	NULL
was	NULL
of	NULL
particular	NULL
importance	NULL
since	NULL
it	NULL
was	NULL
unclear	NULL
whether	NULL
modulation	NULL
of	NULL
the	NULL
function	NULL
of	NULL
GATA-3	NULL
would	NULL
not	NULL
only	NULL
affect	NULL
airway	NULL
inflammation	NULL
but	NULL
also	NULL
airway	NULL
hyperresponsiveness	NULL
.	NULL

In	NULL
initial	NULL
experiments	NULL
,	NULL
we	NULL
subjected	NULL
12	NULL
OVA-sensitized	NULL
mice	NULL
or	NULL
control	NULL
mice	NULL
per	NULL
group	NULL
to	NULL
treatment	NULL
with	NULL
antisense	NULL
oligonucleotides	NULL
,	NULL
control	NULL
nonsense	NULL
oligonucleotides	NULL
,	NULL
or	NULL
saline	NULL
and	NULL
assessed	NULL
airway	NULL
hyperreactivity	NULL
by	NULL
noninvasive	NULL
head-out	NULL
body	NULL
plethysmography	NULL
after	NULL
MCh	NULL
challenge	NULL
at	NULL
day	NULL
28	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

8	NULL
,	NULL
A	NULL
and	NULL
B	NULL
,	NULL
OVA-sensitized	NULL
mice	NULL
showed	NULL
an	NULL
increase	NULL
in	NULL
airway	NULL
hyperreactivity	NULL
compared	NULL
with	NULL
saline-treated	NULL
control	NULL
mice	NULL
after	NULL
challenge	NULL
.	NULL

Furthermore	NULL
,	NULL
it	NULL
was	NULL
found	NULL
that	NULL
antisense	NULL
oligonucleotides	NULL
to	NULL
GATA-3	NULL
lead	NULL
to	NULL
a	NULL
significant	NULL
reduction	NULL
of	NULL
airway	NULL
hyperreactivity	NULL
to	NULL
levels	NULL
comparable	NULL
to	NULL
saline-treated	NULL
control	NULL
mice	NULL
.	NULL

Finally	NULL
,	NULL
we	NULL
observed	NULL
that	NULL
control	NULL
nonsense	NULL
oligonucleotides	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
airway	NULL
hyperreactivity	NULL
in	NULL
OVA-sensitized	NULL
mice	NULL
.	NULL

Figure	NULL
6	NULL
.	NULL

GATA-3	NULL
antisense	NULL
treatment	NULL
selectively	NULL
reduces	NULL
Th2	NULL
cytokine	NULL
concentration	NULL
in	NULL
the	NULL
BALF	NULL
.	NULL

Analysis	NULL
of	NULL
Th1	NULL
and	NULL
Th2	NULL
cytokine	NULL
concentration	NULL
in	NULL
the	NULL
BAL	NULL
from	NULL
lungs	NULL
of	NULL
saline-treated	NULL
mice	NULL
(	NULL
PBS	NULL
;	NULL
n	NULL
=	NULL
4	NULL
)	NULL
,	NULL
OVA-sensitized	NULL
250	NULL
200	NULL
150	NULL
mice	NULL
(	NULL
n	NULL
=	NULL
4	NULL
)	NULL
,	NULL
and	NULL
OVA-sensitized	NULL
mice	NULL
treated	NULL
with	NULL
GATA-3	NULL
antisense	NULL
DNA	NULL
(	NULL
n	NULL
=	NULL
5	NULL
)	NULL
,	NULL
GATA-3	NULL
nonsense	NULL
DNA	NULL
(	NULL
n	NULL
=	NULL
4	NULL
)	NULL
,	NULL
GATA-3	NULL
mismatched	NULL
DNA	NULL
(	NULL
n	NULL
=	NULL
4	NULL
)	NULL
,	NULL
or	NULL
DEX	NULL
(	NULL
n	NULL
=	NULL
4	NULL
)	NULL
.	NULL

Cytokine	NULL
levels	NULL
(	NULL
IFN-y	NULL
,	NULL
IL-4	NULL
)	NULL
were	NULL
deter-T	NULL
mined	NULL
by	NULL
specific	NULL
ELISA	NULL
and	NULL
are	NULL
reported	NULL
as	NULL
mean	NULL
val	NULL
T.	NULL
if	NULL
IFN-gamma	NULL
BALF	NULL
(	NULL
pg/ml	NULL
)	NULL
100	NULL
OVA	NULL
_	NULL
AS	NULL
GATA3	NULL
NSGATA3	NULL
MMGATA3	NULL
1255	NULL
Finotto	NULL
et	NULL
al	NULL
.	NULL

ues	NULL
-	NULL
SEM	NULL
.	NULL

IFN-y	NULL
and	NULL
IL-4	NULL
levels	NULL
were	NULL
between	NULL
17	NULL
and	NULL
234	NULL
pg/ml	NULL
and	NULL
35	NULL
and	NULL
435	NULL
pg/ml	NULL
,	NULL
respectively	NULL
.	NULL

AS	NULL
GATA3	NULL
,	NULL
OVA-sensitized	NULL
mice	NULL
treated	NULL
with	NULL
GATA-3	NULL
antisense	NULL
DNA	NULL
;	NULL
MMGATA3	NULL
,	NULL
GATA-3	NULL
mismatched	NULL
DNA	NULL
;	NULL
NSGATA3	NULL
,	NULL
GATA-3	NULL
nonsense	NULL
DNA	NULL
;	NULL
OVA	NULL
,	NULL
OVA-sensitized	NULL
mice	NULL
.	NULL

Dex	NULL
4	NULL
Â£3	NULL
.	NULL

Â®	NULL
NS-GATA3	NULL
AS-GATA3	NULL
Las	NULL
(	NULL
a	NULL
\	NULL
MM-GATA3	NULL
DEX	NULL
saline	NULL
OVA	NULL
NS-GATA3	NULL
AS-GATA3	NULL
MM-GATA3	NULL
DEX	NULL
large	NULL
-	NULL
++	NULL
++	NULL
-	NULL
+	NULL
small	NULL
-	NULL
++	NULL
++	NULL
-	NULL
+	NULL
+/-airways	NULL
Figure	NULL
7	NULL
.	NULL

Mucus	NULL
occlusion	NULL
of	NULL
lower	NULL
airways	NULL
in	NULL
OVA-treated	NULL
mice	NULL
(	NULL
OVA	NULL
)	NULL
compared	NULL
with	NULL
saline-treated	NULL
mice	NULL
(	NULL
saline	NULL
)	NULL
.	NULL

The	NULL
acidic	NULL
and	NULL
neutral	NULL
mucosubstances	NULL
are	NULL
stained	NULL
in	NULL
magenta	NULL
by	NULL
the	NULL
alcian	NULL
blue/PAS	NULL
reaction	NULL
.	NULL

The	NULL
treatment	NULL
with	NULL
antisense	NULL
DNA	NULL
to	NULL
GATA-3	NULL
(	NULL
AS-GATA3	NULL
)	NULL
led	NULL
to	NULL
a	NULL
strong	NULL
reduction	NULL
of	NULL
the	NULL
PAS	NULL
reaction	NULL
in	NULL
the	NULL
airways	NULL
of	NULL
OVA-sensitized	NULL
mice	NULL
.	NULL

This	NULL
effect	NULL
was	NULL
comparable	NULL
to	NULL
DEX	NULL
treatment	NULL
.	NULL

No	NULL
effect	NULL
was	NULL
observed	NULL
after	NULL
nonsense	NULL
DNA	NULL
treatment	NULL
(	NULL
NS-GATA3	NULL
)	NULL
,	NULL
whereas	NULL
mismatched	NULL
DNA	NULL
(	NULL
MM-GATA3	NULL
)	NULL
led	NULL
to	NULL
a	NULL
small	NULL
reduction	NULL
in	NULL
mucus	NULL
production	NULL
.	NULL

The	NULL
differences	NULL
in	NULL
mucus	NULL
production	NULL
were	NULL
also	NULL
assessed	NULL
by	NULL
semiquantitative	NULL
analysis	NULL
of	NULL
mucosubstances	NULL
in	NULL
the	NULL
small	NULL
and	NULL
large	NULL
airways	NULL
of	NULL
four	NULL
to	NULL
five	NULL
mice	NULL
per	NULL
group	NULL
.	NULL

The	NULL
mean	NULL
values	NULL
are	NULL
shown	NULL
.	NULL

Antisense	NULL
DNA	NULL
to	NULL
GATA-3	NULL
led	NULL
to	NULL
an	NULL
abrogation	NULL
of	NULL
mucus	NULL
production	NULL
,	NULL
whereas	NULL
nonsense	NULL
DNA	NULL
had	NULL
no	NULL
effects	NULL
compared	NULL
with	NULL
OVA-sensitized	NULL
untreated	NULL
mice	NULL
.	NULL

Mismatched	NULL
DNA	NULL
led	NULL
to	NULL
a	NULL
detectable	NULL
reduction	NULL
in	NULL
mucus	NULL
production	NULL
,	NULL
although	NULL
this	NULL
effect	NULL
was	NULL
much	NULL
lower	NULL
compared	NULL
with	NULL
GATA-3	NULL
antisense	NULL
DNA	NULL
.	NULL

Bottom	NULL
table	NULL
:	NULL
-	NULL
,	NULL
no	NULL
mucosubstances	NULL
;	NULL
+	NULL
,	NULL
mucosubstances	NULL
detectable	NULL
;	NULL
++	NULL
,	NULL
high	NULL
amount	NULL
of	NULL
mucosubstances	NULL
.	NULL

1256	NULL
To	NULL
validate	NULL
our	NULL
findings	NULL
on	NULL
a	NULL
significant	NULL
downregulation	NULL
of	NULL
airway	NULL
hyperreactivity	NULL
upon	NULL
antisense	NULL
treatment	NULL
,	NULL
we	NULL
assessed	NULL
in	NULL
subsequent	NULL
studies	NULL
PenH	NULL
responses	NULL
of	NULL
OVA-sensitized	NULL
mice	NULL
in	NULL
a	NULL
body	NULL
plethysmograph	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
C	NULL
)	NULL
.	NULL

It	NULL
was	NULL
found	NULL
that	NULL
administration	NULL
of	NULL
antisense	NULL
oligonucleotides	NULL
to	NULL
GATA-3	NULL
results	NULL
in	NULL
a	NULL
significant	NULL
downregulation	NULL
of	NULL
MCh	NULL
responsiveness	NULL
,	NULL
whereas	NULL
nonsense	NULL
control	NULL
oligonucleotides	NULL
had	NULL
no	NULL
such	NULL
effect	NULL
.	NULL

Finally	NULL
,	NULL
to	NULL
assess	NULL
the	NULL
MCh	NULL
response	NULL
in	NULL
the	NULL
lower	NULL
airways	NULL
,	NULL
we	NULL
measured	NULL
RL	NULL
and	NULL
dose-response	NULL
curves	NULL
to	NULL
intravenous	NULL
MCh	NULL
in	NULL
anesthetized	NULL
OVA-treated	NULL
mice	NULL
by	NULL
body	NULL
plethysmography	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
D	NULL
)	NULL
.	NULL

These	NULL
experiments	NULL
demonstrated	NULL
a	NULL
significant	NULL
reduction	NULL
of	NULL
RL	NULL
in	NULL
OVA-sensitized	NULL
mice	NULL
upon	NULL
treatment	NULL
with	NULL
antisense	NULL
but	NULL
not	NULL
nonsense	NULL
control	NULL
oligonucleotides	NULL
.	NULL

Thus	NULL
,	NULL
using	NULL
three	NULL
independent	NULL
methods	NULL
to	NULL
assess	NULL
airway	NULL
hyperreactivity	NULL
,	NULL
these	NULL
data	NULL
showed	NULL
that	NULL
airway	NULL
hyperreactivity	NULL
was	NULL
significantly	NULL
suppressed	NULL
by	NULL
administration	NULL
of	NULL
antisense	NULL
oligonucleotides	NULL
to	NULL
GATA-3	NULL
.	NULL

Discussion	NULL
Recent	NULL
studies	NULL
in	NULL
transgenic	NULL
mice	NULL
have	NULL
revealed	NULL
that	NULL
expression	NULL
of	NULL
a	NULL
dominant	NULL
negative	NULL
form	NULL
of	NULL
GATA-3	NULL
can	NULL
prevent	NULL
allergic	NULL
airway	NULL
inflammation	NULL
(	NULL
38	NULL
)	NULL
,	NULL
indicating	NULL
that	NULL
GATA-3	NULL
plays	NULL
a	NULL
crucial	NULL
role	NULL
in	NULL
the	NULL
development	NULL
of	NULL
Th2-mediated	NULL
lung	NULL
inflammation	NULL
(	NULL
39	NULL
)	NULL
.	NULL

However	NULL
,	NULL
it	NULL
remains	NULL
unclear	NULL
whether	NULL
GATA-3	NULL
plays	NULL
a	NULL
role	NULL
in	NULL
the	NULL
effector	NULL
phase	NULL
of	NULL
allergic	NULL
airway	NULL
inflammation	NULL
and	NULL
whether	NULL
antagonizing	NULL
the	NULL
expression	NULL
and/or	NULL
function	NULL
of	NULL
GATA-3	NULL
can	NULL
be	NULL
used	NULL
for	NULL
the	NULL
therapy	NULL
of	NULL
allergic	NULL
airway	NULL
inflammation	NULL
and	NULL
hyperresponsiveness	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
potential	NULL
mechanisms	NULL
of	NULL
action	NULL
of	NULL
such	NULL
therapy	NULL
remain	NULL
to	NULL
be	NULL
elucidated	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
demonstrate	NULL
a	NULL
key	NULL
role	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
GATA-3	NULL
for	NULL
cytokine	NULL
production	NULL
of	NULL
T	NULL
cells	NULL
in	NULL
the	NULL
effector	NULL
phase	NULL
of	NULL
a	NULL
murine	NULL
asthma	NULL
model	NULL
induced	NULL
by	NULL
OVA	NULL
.	NULL

We	NULL
found	NULL
that	NULL
specific	NULL
blockade	NULL
of	NULL
GAT	NULL
expression	NULL
in	NULL
the	NULL
lung	NULL
by	NULL
antisense	NULL
oligonucleotides	NULL
leads	NULL
to	NULL
suppression	NULL
of	NULL
airway	NULL
inflammation	NULL
and	NULL
Th2	NULL
cytokine	NULL
production	NULL
both	NULL
in	NULL
the	NULL
BAL	NULL
and	NULL
in	NULL
the	NULL
interstitium	NULL
of	NULL
the	NULL
lung	NULL
.	NULL

Antisense-induced	NULL
blockade	NULL
of	NULL
GATA-3	NULL
was	NULL
at	NULL
least	NULL
as	NULL
effective	NULL
to	NULL
suppress	NULL
lung	NULL
inflammation	NULL
as	NULL
the	NULL
administration	NULL
of	NULL
corticosteroids	NULL
.	NULL

Furthermore	NULL
,	NULL
using	NULL
three	NULL
independent	NULL
methods	NULL
to	NULL
assess	NULL
airway	NULL
hyperresponsiveness	NULL
to	NULL
MCh	NULL
,	NULL
we	NULL
demonstrate	NULL
that	NULL
GATA-3	NULL
antisense	NULL
oligonucleotides	NULL
significantly	NULL
reduce	NULL
airway	NULL
hyperresponsiveness	NULL
in	NULL
a	NULL
model	NULL
of	NULL
allergic	NULL
asthma	NULL
,	NULL
suggesting	NULL
a	NULL
novel	NULL
function	NULL
of	NULL
GATA-3	NULL
as	NULL
a	NULL
key	NULL
regulator	NULL
of	NULL
airway	NULL
hyperresponsiveness	NULL
in	NULL
allergic	NULL
asthma	NULL
.	NULL

Taken	NULL
together	NULL
with	NULL
the	NULL
recently	NULL
described	NULL
increased	NULL
expression	NULL
of	NULL
GATA-3	NULL
mRNA	NULL
in	NULL
lung	NULL
CD3Â¢*	NULL
T	NULL
cells	NULL
of	NULL
patients	NULL
with	NULL
allergic	NULL
asthma	NULL
(	NULL
27	NULL
)	NULL
,	NULL
these	NULL
data	NULL
suggest	NULL
the	NULL
potential	NULL
therapeutic	NULL
utility	NULL
of	NULL
GATA-3	NULL
antisense	NULL
oligonucleotides	NULL
as	NULL
a	NULL
novel	NULL
molecular	NULL
approach	NULL
for	NULL
the	NULL
treatment	NULL
of	NULL
patients	NULL
with	NULL
allergic	NULL
asthma	NULL
in	NULL
humans	NULL
.	NULL

This	NULL
approach	NULL
has	NULL
the	NULL
potential	NULL
advantage	NULL
of	NULL
blocking	NULL
the	NULL
production	NULL
of	NULL
several	NULL
Th2	NULL
cytokines	NULL
simultaneously	NULL
rather	NULL
than	NULL
suppressing	NULL
the	NULL
activity	NULL
of	NULL
a	NULL
single	NULL
cytokine	NULL
.	NULL

The	NULL
GATA	NULL
family	NULL
of	NULL
zinc	NULL
finger	NULL
transcription	NULL
factors	NULL
has	NULL
pleiotropic	NULL
roles	NULL
in	NULL
cell	NULL
development	NULL
and	NULL
differentiation	NULL
.	NULL

Antisense	NULL
DNA	NULL
to	NULL
GATA-3	NULL
Abrogates	NULL
Airway	NULL
Hyperresponsiveness	NULL
A	NULL
120	NULL
D	NULL
500	NULL
/1	NULL
am	NULL
o	NULL
Â£	NULL
an	NULL
0	NULL
K	NULL
E	NULL
Â»	NULL
d	NULL
3	NULL
1	NULL
tn	NULL
0	NULL
$	NULL
E=	NULL
$	NULL
5	NULL
-Â©-as.cata	NULL
o	NULL
&	NULL
e	NULL
+	NULL
.	NULL

46	NULL
El	NULL
(	NULL
-+-	NULL
saline	NULL
100	NULL
___l+	NULL
ova	NULL
ova	NULL
|__	NULL
-=-	NULL
OVA/	NULL
AS	NULL
**	NULL
~-	NULL
OVA-NS	NULL
I	NULL
]	NULL
T	NULL
T	NULL
T	NULL
T	NULL
*	NULL
--	NULL
``	NULL
k	NULL
-	NULL
%	NULL
-	NULL
&	NULL
-g	NULL
saline	NULL
-	NULL
33ug/kg	NULL
100ug/kg	NULL
330ug/kg	NULL
1mg/kg	NULL
Methacholine	NULL
(	NULL
mgiml	NULL
B	NULL
Figure	NULL
8	NULL
.	NULL

-	NULL
Assessment	NULL
of	NULL
airway	NULL
reactivity	NULL
in	NULL
BALB/c	NULL
mice	NULL
after	NULL
GATA-3	NULL
antisense	NULL
100	NULL
treatment	NULL
using	NULL
three	NULL
independent	NULL
methods	NULL
to	NULL
assess	NULL
airway	NULL
hyperreactivity	NULL
in	NULL
vivo	NULL
.	NULL

(	NULL
A	NULL
)	NULL
12	NULL
BALB/c	NULL
mice	NULL
per	NULL
group	NULL
were	NULL
sensitized	NULL
to	NULL
OVA	NULL
accompanied	NULL
by	NULL
local	NULL
treatment	NULL
with	NULL
OVA	NULL
alone	NULL
(	NULL
PBS	NULL
,	NULL
OVA-sensitized	NULL
mice	NULL
)	NULL
,	NULL
OVA	NULL
followed	NULL
by	NULL
either	NULL
GATA-3	NULL
*	NULL
antisense	NULL
oligonucleotides	NULL
(	NULL
AS-GATA	NULL
)	NULL
,	NULL
or	NULL
GATA-3	NULL
nonsense	NULL
oligonucleotides	NULL
<	NULL
(	NULL
NS-GATA	NULL
)	NULL
.	NULL

Body	NULL
plethysmography	NULL
was	NULL
performed	NULL
24	NULL
h	NULL
after	NULL
the	NULL
last	NULL
local	NULL
treatment	NULL
g	NULL
75	NULL
in	NULL
all	NULL
12	NULL
mice	NULL
per	NULL
group	NULL
as	NULL
specified	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

Airway	NULL
reactivity	NULL
was	NULL
E	NULL
measured	NULL
in	NULL
nonanaesthetized	NULL
,	NULL
spontaneously	NULL
breathing	NULL
mice	NULL
simultaneously	NULL
during	NULL
wer	NULL
MCh	NULL
aerosol	NULL
exposure	NULL
.	NULL

Basal	NULL
values	NULL
were	NULL
measured	NULL
(	NULL
air	NULL
)	NULL
,	NULL
followed	NULL
by	NULL
measuring	NULL
the	NULL
â	NULL
O	NULL
,	NULL
response	NULL
to	NULL
aerosolized	NULL
saline	NULL
(	NULL
PBS	NULL
)	NULL
and	NULL
to	NULL
increasing	NULL
concentrations	NULL
of	NULL
MCh	NULL
(	NULL
25-150	NULL
5	NULL
mg/m1	NULL
)	NULL
.	NULL

Values	NULL
expressed	NULL
are	NULL
mean	NULL
*	NULL
SEM	NULL
of	NULL
tidal	NULL
volume	NULL
(	NULL
%	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Analysis	NULL
of	NULL
the	NULL
5	NULL
so	NULL
-	NULL
MCh	NULL
concentration	NULL
that	NULL
caused	NULL
a	NULL
50	NULL
%	NULL
reduction	NULL
in	NULL
expiratory	NULL
airflow	NULL
(	NULL
MCh50	NULL
;	NULL
refer	NULL
PBS	NULL
PBS	NULL
AS-GATA	NULL
NS-GATA	NULL
OVA-sensitized	NULL
mice	NULL
Â©	NULL
n.s	NULL
.	NULL

p	NULL
<	NULL
0.01	NULL
8	NULL
10	NULL
11	NULL
10	NULL
<	NULL
<	NULL
@	NULL
Â§	NULL
$	NULL
&	NULL
Â©	NULL
60Â°	NULL
$	NULL
$	NULL
Â®	NULL
_	NULL
Â®	NULL
<	NULL
Z	NULL
1	NULL
p	NULL
<	NULL
0.01	NULL
ence	NULL
33	NULL
)	NULL
in	NULL
the	NULL
plethysmography	NULL
experiments	NULL
described	NULL
in	NULL
A	NULL
.	NULL

Data	NULL
represent	NULL
mean	NULL
values	NULL
+1	NULL
SEM	NULL
.	NULL

*P	NULL
<	NULL
0.05	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Airway	NULL
responsiveness	NULL
in	NULL
OVA-	NULL
and	NULL
saline-treated	NULL
mice	NULL
was	NULL
assessed	NULL
by	NULL
analyzing	NULL
PenH	NULL
responses	NULL
in	NULL
a	NULL
body	NULL
plethysmograph	NULL
.	NULL

Mice	NULL
were	NULL
treated	NULL
with	NULL
saline	NULL
(	NULL
#	NULL
=	NULL
8	NULL
)	NULL
or	NULL
sensitized	NULL
to	NULL
OVA	NULL
followed	NULL
by	NULL
local	NULL
treatment	NULL
with	NULL
OVA	NULL
alone	NULL
(	NULL
OVA	NULL
;	NULL
n	NULL
=	NULL
10	NULL
)	NULL
,	NULL
GATA-3	NULL
antisense	NULL
oligonucleotides	NULL
(	NULL
AS-GATA	NULL
;	NULL
n	NULL
=	NULL
11	NULL
)	NULL
or	NULL
GATA-3	NULL
nonsense	NULL
oligonucleotides	NULL
(	NULL
NS-GATA	NULL
;	NULL
n	NULL
=	NULL
10	NULL
)	NULL
,	NULL
as	NULL
described	NULL
above	NULL
.	NULL

Measurements	NULL
of	NULL
MCh	NULL
responsiveness	NULL
were	NULL
made	NULL
after	NULL
exposure	NULL
for	NULL
5	NULL
min	NULL
to	NULL
200	NULL
mg/	NULL
ml	NULL
of	NULL
aerosolized	NULL
MCh	NULL
and	NULL
monitoring	NULL
PenH	NULL
.	NULL

Results	NULL
are	NULL
expressed	NULL
as	NULL
the	NULL
mean	NULL
peak	NULL
of	NULL
PenH	NULL
within	NULL
5	NULL
min	NULL
after	NULL
MCh	NULL
treatment	NULL
*	NULL
SEM	NULL
.	NULL

Data	NULL
were	NULL
pooled	NULL
from	NULL
two	NULL
independent	NULL
experiments	NULL
.	NULL

Whereas	NULL
treatment	NULL
with	NULL
antisense	NULL
oligonucleotides	NULL
to	NULL
GATA-3	NULL
caused	NULL
a	NULL
significant	NULL
reduction	NULL
of	NULL
PenH	NULL
values	NULL
(	NULL
P	NULL
<	NULL
0.01	NULL
)	NULL
,	NULL
treatment	NULL
with	NULL
nonsense	NULL
control	NULL
DNA	NULL
did	NULL
not	NULL
have	NULL
a	NULL
significant	NULL
effect	NULL
.	NULL

Furthermore	NULL
,	NULL
treatment	NULL
of	NULL
OVA-sensitized	NULL
mice	NULL
with	NULL
antisense	NULL
DNA	NULL
led	NULL
to	NULL
a	NULL
significant	NULL
reduction	NULL
of	NULL
PenH	NULL
values	NULL
(	NULL
P	NULL
<	NULL
0.01	NULL
)	NULL
compared	NULL
with	NULL
nonsense	NULL
,	NULL
control-treated	NULL
mice	NULL
.	NULL

(	NULL
D	NULL
)	NULL
Analysis	NULL
of	NULL
RL	NULL
in	NULL
anesthetized	NULL
,	NULL
OVA-	NULL
,	NULL
or	NULL
saline-treated	NULL
mice	NULL
by	NULL
body	NULL
plethysmography	NULL
.	NULL

Mice	NULL
were	NULL
treated	NULL
with	NULL
saline	NULL
(	NULL
#	NULL
=	NULL
8	NULL
)	NULL
or	NULL
sensitized	NULL
to	NULL
OVA	NULL
followed	NULL
by	NULL
local	NULL
treatment	NULL
with	NULL
OVA	NULL
alone	NULL
(	NULL
OVA/OVA	NULL
;	NULL
n	NULL
=	NULL
11	NULL
)	NULL
,	NULL
GATA-3	NULL
antisense	NULL
oligonucleotides	NULL
(	NULL
OVA/AS	NULL
;	NULL
n	NULL
=	NULL
11	NULL
)	NULL
,	NULL
or	NULL
GATA-3-nonsense	NULL
oligonucleotides	NULL
(	NULL
OVA/NS	NULL
;	NULL
n	NULL
=	NULL
12	NULL
)	NULL
.	NULL

Body	NULL
plethysmography	NULL
was	NULL
performed	NULL
24	NULL
h	NULL
after	NULL
the	NULL
last	NULL
local	NULL
treatment	NULL
in	NULL
all	NULL
mice	NULL
.	NULL

Dose-response	NULL
curves	NULL
to	NULL
MCh	NULL
were	NULL
obtained	NULL
after	NULL
administering	NULL
indicated	NULL
doses	NULL
of	NULL
intravenous	NULL
MCh	NULL
.	NULL

Data	NULL
were	NULL
pooled	NULL
from	NULL
two	NULL
independent	NULL
experiments	NULL
and	NULL
are	NULL
expressed	NULL
as	NULL
mean	NULL
values	NULL
of	NULL
RL	NULL
*	NULL
SEM	NULL
.	NULL

Multivariate	NULL
analysis	NULL
showed	NULL
a	NULL
significant	NULL
increase	NULL
of	NULL
RL	NULL
after	NULL
OVA	NULL
treatment	NULL
compared	NULL
with	NULL
saline	NULL
treatment	NULL
(	NULL
P	NULL
<	NULL
0.05	NULL
)	NULL
.	NULL

Treatment	NULL
with	NULL
antisense	NULL
oligonucleotides	NULL
to	NULL
GATA-3	NULL
led	NULL
to	NULL
a	NULL
significant	NULL
suppression	NULL
of	NULL
RL	NULL
values	NULL
compared	NULL
with	NULL
untreated	NULL
,	NULL
OVA-sensitized	NULL
mice	NULL
(	NULL
P	NULL
<	NULL
0.01	NULL
)	NULL
,	NULL
whereas	NULL
nonsense	NULL
control	NULL
DNA	NULL
did	NULL
not	NULL
have	NULL
a	NULL
significant	NULL
effect	NULL
.	NULL

Furthermore	NULL
,	NULL
treatment	NULL
of	NULL
OVA-sensitized	NULL
mice	NULL
with	NULL
antisense	NULL
DNA	NULL
caused	NULL
a	NULL
significant	NULL
suppression	NULL
of	NULL
RL	NULL
values	NULL
compared	NULL
with	NULL
nonsense-treated	NULL
,	NULL
OVA-sensitized	NULL
mice	NULL
(	NULL
P	NULL
<	NULL
0.05	NULL
)	NULL
.	NULL

While	NULL
GATA-1	NULL
and	NULL
GAT	NULL
A-2	NULL
are	NULL
involved	NULL
in	NULL
the	NULL
development	NULL
of	NULL
the	NULL
erythroid	NULL
and	NULL
megakaryocytic	NULL
lineages	NULL
,	NULL
GATA-3	NULL
is	NULL
highly	NULL
expressed	NULL
in	NULL
early	NULL
T	NULL
lymphocytes	NULL
and	NULL
controls	NULL
T	NULL
cell	NULL
receptor	NULL
gene	NULL
expression	NULL
and	NULL
thymocyte	NULL
development	NULL
(	NULL
17	NULL
,	NULL
14	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
within	NULL
mature	NULL
T	NULL
cells	NULL
GATA-3	NULL
was	NULL
found	NULL
to	NULL
be	NULL
selectively	NULL
expressed	NULL
in	NULL
naive	NULL
T	NULL
cells	NULL
and	NULL
to	NULL
control	NULL
Th2	NULL
T	NULL
cell	NULL
development	NULL
(	NULL
18	NULL
,	NULL
21	NULL
,	NULL
40	NULL
,	NULL
41	NULL
)	NULL
.	NULL

These	NULL
data	NULL
prompted	NULL
us	NULL
to	NULL
determine	NULL
the	NULL
expression	NULL
and	NULL
functional	NULL
role	NULL
of	NULL
GATA-3	NULL
in	NULL
a	NULL
murine	NULL
model	NULL
of	NULL
asthma	NULL
associated	NULL
with	NULL
Th2	NULL
cytokine	NULL
production	NULL
.	NULL

We	NULL
observed	NULL
that	NULL
OVA	NULL
sensitization	NULL
of	NULL
mice	NULL
caused	NULL
a	NULL
strong	NULL
upregulation	NULL
of	NULL
pulmonary	NULL
GATA-3	NULL
expression	NULL
.	NULL

This	NULL
finding	NULL
led	NULL
us	NULL
to	NULL
further	NULL
investigate	NULL
the	NULL
functional	NULL
role	NULL
of	NULL
this	NULL
factor	NULL
1257	NULL
Finotto	NULL
et	NULL
al	NULL
.	NULL

using	NULL
an	NULL
antisense	NULL
DNA	NULL
strategy	NULL
.	NULL

We	NULL
found	NULL
that	NULL
exposure	NULL
of	NULL
cultured	NULL
spleen	NULL
Th2	NULL
cells	NULL
to	NULL
an	NULL
antisense	NULL
GATA	NULL
oligonucleotide	NULL
suppressed	NULL
IL-4	NULL
expression	NULL
.	NULL

This	NULL
effect	NULL
on	NULL
IL-4	NULL
production	NULL
could	NULL
be	NULL
augmented	NULL
by	NULL
MACS-based	NULL
selection	NULL
of	NULL
antisense-transfected	NULL
T	NULL
cells	NULL
using	NULL
a	NULL
cotransfection	NULL
protocol	NULL
with	NULL
a	NULL
plasmid	NULL
expressing	NULL
a	NULL
truncated	NULL
H2-KÂ®	NULL
mole-cule	NULL
.	NULL

In	NULL
the	NULL
supernatant	NULL
of	NULL
antisense-treated	NULL
T	NULL
cells	NULL
,	NULL
we	NULL
could	NULL
not	NULL
see	NULL
any	NULL
decrease	NULL
in	NULL
IL-9	NULL
production	NULL
after	NULL
treatment	NULL
with	NULL
antisense	NULL
to	NULL
GATA-3	NULL
,	NULL
possibly	NULL
because	NULL
the	NULL
IL-9	NULL
promoter	NULL
has	NULL
no	NULL
binding	NULL
sites	NULL
for	NULL
GATA-3	NULL
(	NULL
42	NULL
)	NULL
.	NULL

Using	NULL
antisense	NULL
oligonucleotides	NULL
we	NULL
then	NULL
tested	NULL
the	NULL
potential	NULL
pathogenic	NULL
role	NULL
of	NULL
GATA-3	NULL
in	NULL
the	NULL
OVA-dependent	NULL
asthma	NULL
model	NULL
in	NULL
vivo	NULL
.	NULL

We	NULL
observed	NULL
that	NULL
intranasal	NULL
administration	NULL
of	NULL
FITC-labeled	NULL
GATA-3	NULL
antisense	NULL
phosphorothioate	NULL
oligonucleotides	NULL
causes	NULL
an	NULL
efficient	NULL
uptake	NULL
in	NULL
interstitial	NULL
lung	NULL
cells	NULL
that	NULL
coexpress	NULL
large	NULL
amounts	NULL
of	NULL
GATA-3	NULL
and	NULL
IL-4	NULL
upon	NULL
OVA	NULL
sensitization	NULL
.	NULL

This	NULL
uptake	NULL
was	NULL
followed	NULL
by	NULL
downregulation	NULL
of	NULL
lung	NULL
GATA-3	NULL
expression	NULL
(	NULL
compared	NULL
with	NULL
OV	NULL
A-sensitized	NULL
mice	NULL
without	NULL
treatment	NULL
)	NULL
within	NULL
24	NULL
h	NULL
after	NULL
the	NULL
last	NULL
antisense	NULL
administration	NULL
.	NULL

The	NULL
specificity	NULL
of	NULL
the	NULL
antisense	NULL
effect	NULL
on	NULL
GATA-3	NULL
expression	NULL
was	NULL
confirmed	NULL
according	NULL
to	NULL
several	NULL
previously	NULL
described	NULL
criteria	NULL
(	NULL
43	NULL
,	NULL
44	NULL
)	NULL
:	NULL
(	NULL
a	NULL
)	NULL
control	NULL
nonsense	NULL
oligonucleotides	NULL
did	NULL
not	NULL
have	NULL
an	NULL
effect	NULL
on	NULL
GATA-3	NULL
expression	NULL
;	NULL
(	NULL
b	NULL
)	NULL
the	NULL
antisense	NULL
oligonucleotide	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
a	NULL
nontargeted	NULL
protein	NULL
(	NULL
SP-1	NULL
,	NULL
OCT-1	NULL
)	NULL
;	NULL
and	NULL
(	NULL
c	NULL
)	NULL
direct	NULL
toxic	NULL
effects	NULL
of	NULL
the	NULL
GATA-3	NULL
antisense	NULL
oligonucleotide	NULL
were	NULL
excluded	NULL
by	NULL
cell	NULL
viability	NULL
tests	NULL
.	NULL

Interestingly	NULL
,	NULL
mismatched	NULL
control	NULL
DNA	NULL
led	NULL
to	NULL
a	NULL
reduction	NULL
of	NULL
GATA-3	NULL
expression	NULL
and	NULL
IL-4	NULL
production	NULL
in	NULL
T	NULL
cells	NULL
,	NULL
probably	NULL
due	NULL
to	NULL
a	NULL
remaining	NULL
weak	NULL
hybridization	NULL
of	NULL
the	NULL
mismatched	NULL
DNA	NULL
to	NULL
the	NULL
GATA-3	NULL
target	NULL
mRNA	NULL
.	NULL

However	NULL
,	NULL
these	NULL
changes	NULL
were	NULL
less	NULL
pronounced	NULL
compared	NULL
with	NULL
the	NULL
antisense	NULL
DNA	NULL
effect	NULL
and	NULL
did	NULL
not	NULL
reach	NULL
statistical	NULL
significance	NULL
.	NULL

The	NULL
antisense-induced	NULL
suppression	NULL
of	NULL
GATA-3	NULL
expression	NULL
was	NULL
accompanied	NULL
by	NULL
a	NULL
suppression	NULL
of	NULL
Th2	NULL
cytokine	NULL
synthesis	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
and	NULL
the	NULL
accumulation	NULL
of	NULL
eosinophils	NULL
in	NULL
the	NULL
airways	NULL
,	NULL
whereas	NULL
treatment	NULL
with	NULL
control	NULL
nonsense	NULL
oligonucleotides	NULL
had	NULL
no	NULL
such	NULL
effects	NULL
.	NULL

Mucus	NULL
occlusion	NULL
of	NULL
the	NULL
airway	NULL
lumen	NULL
in	NULL
the	NULL
OVA-treated	NULL
mice	NULL
was	NULL
present	NULL
24	NULL
h	NULL
after	NULL
the	NULL
last	NULL
intravenous	NULL
OVA	NULL
administration	NULL
on	NULL
day	NULL
28	NULL
.	NULL

Furthermore	NULL
,	NULL
in	NULL
vivo	NULL
noninvasive	NULL
pulmonary	NULL
function	NULL
tests	NULL
using	NULL
body	NULL
plethysmography	NULL
showed	NULL
that	NULL
the	NULL
OVA-immunized	NULL
challenged	NULL
mice	NULL
reproducibly	NULL
developed	NULL
increased	NULL
airway	NULL
responsiveness	NULL
to	NULL
MCh	NULL
that	NULL
could	NULL
be	NULL
completely	NULL
reversed	NULL
by	NULL
treatment	NULL
with	NULL
antisense	NULL
DNA	NULL
to	NULL
GAT	NULL
but	NULL
not	NULL
by	NULL
control	NULL
nonsense	NULL
DNA	NULL
.	NULL

This	NULL
is	NULL
an	NULL
important	NULL
novel	NULL
information	NULL
that	NULL
highlights	NULL
GATA-3	NULL
as	NULL
a	NULL
key	NULL
regulator	NULL
of	NULL
both	NULL
T	NULL
cell	NULL
effector	NULL
function	NULL
and	NULL
airway	NULL
hyperresponsiveness	NULL
in	NULL
allergic	NULL
airway	NULL
inflammation	NULL
.	NULL

It	NULL
should	NULL
be	NULL
noted	NULL
that	NULL
the	NULL
above	NULL
finding	NULL
on	NULL
antisense-induced	NULL
suppression	NULL
of	NULL
airway	NULL
hyperresponsiveness	NULL
was	NULL
validated	NULL
by	NULL
two	NULL
additional	NULL
independent	NULL
methods	NULL
using	NULL
assessment	NULL
of	NULL
PenH	NULL
responses	NULL
and	NULL
of	NULL
RL	NULL
in	NULL
anesthetized	NULL
mice	NULL
.	NULL

All	NULL
three	NULL
methods	NULL
demonstrated	NULL
a	NULL
significant	NULL
downregulation	NULL
of	NULL
OVA-induced	NULL
airway	NULL
hyperresponsiveness	NULL
upon	NULL
administration	NULL
of	NULL
antisense	NULL
oligonucleotides	NULL
to	NULL
GATA-3	NULL
,	NULL
definitively	NULL
demonstrating	NULL
for	NULL
the	NULL
first	NULL
time	NULL
a	NULL
critical	NULL
regulatory	NULL
role	NULL
of	NULL
GAT	NULL
in	NULL
airway	NULL
hyperresponsiveness	NULL
in	NULL
allergic	NULL
asthma	NULL
.	NULL

The	NULL
potential	NULL
relevance	NULL
of	NULL
this	NULL
GATA-3	NULL
antisense-based	NULL
approach	NULL
to	NULL
inhibit	NULL
Th2	NULL
cytokine	NULL
production	NULL
is	NULL
underlined	NULL
by	NULL
various	NULL
functional	NULL
studies	NULL
showing	NULL
a	NULL
key	NULL
regulatory	NULL
role	NULL
for	NULL
both	NULL
IL-4	NULL
and	NULL
IL-5	NULL
in	NULL
asthma	NULL
.	NULL

For	NULL
instance	NULL
,	NULL
studies	NULL
in	NULL
transgenic	NULL
and	NULL
knockout	NULL
mice	NULL
showed	NULL
that	NULL
the	NULL
Th2	NULL
cytokine	NULL
IL-4	NULL
is	NULL
important	NULL
for	NULL
IgE	NULL
mRNA	NULL
production	NULL
in	NULL
allergic	NULL
asthmatic	NULL
reactions	NULL
(	NULL
45	NULL
,	NULL
46	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
studies	NULL
in	NULL
a	NULL
knockout	NULL
model	NULL
for	NULL
the	NULL
IL-4-dependent	NULL
STAT-6	NULL
have	NULL
shown	NULL
that	NULL
suppression	NULL
of	NULL
IL-4	NULL
signal	NULL
transduction	NULL
profoundly	NULL
inhibits	NULL
influx	NULL
of	NULL
eosinophils	NULL
into	NULL
the	NULL
lung	NULL
(	NULL
47	NULL
)	NULL
.	NULL

Finally	NULL
,	NULL
suppression	NULL
of	NULL
IL-5	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
prevent	NULL
allergic	NULL
inflammation	NULL
in	NULL
an	NULL
animal	NULL
model	NULL
(	NULL
48	NULL
)	NULL
,	NULL
possibly	NULL
due	NULL
to	NULL
suppression	NULL
of	NULL
IL-5-dependent	NULL
activation	NULL
of	NULL
eosinophils	NULL
(	NULL
49	NULL
)	NULL
.	NULL

1258	NULL
Recent	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
studies	NULL
have	NULL
shown	NULL
that	NULL
various	NULL
transcription	NULL
factors	NULL
such	NULL
as	NULL
c-maf	NULL
,	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
c1-4	NULL
,	NULL
NIP	NULL
45	NULL
,	NULL
STAT-6	NULL
,	NULL
and	NULL
GATA-3	NULL
are	NULL
important	NULL
for	NULL
Th2-type	NULL
cytokine	NULL
production	NULL
in	NULL
T	NULL
cells	NULL
(	NULL
14	NULL
,	NULL
50	NULL
)	NULL
.	NULL

Here	NULL
,	NULL
we	NULL
show	NULL
that	NULL
local	NULL
GATA-3	NULL
antisense	NULL
DNA	NULL
treatment	NULL
directly	NULL
affects	NULL
Th2	NULL
cytokine	NULL
production	NULL
and	NULL
lung	NULL
inflammation	NULL
in	NULL
asthma	NULL
,	NULL
although	NULL
the	NULL
oligonucleotides	NULL
lack	NULL
CpG	NULL
motifs	NULL
.	NULL

These	NULL
data	NULL
support	NULL
and	NULL
significantly	NULL
extend	NULL
data	NULL
from	NULL
a	NULL
very	NULL
recent	NULL
report	NULL
(	NULL
38	NULL
)	NULL
showing	NULL
that	NULL
expression	NULL
of	NULL
a	NULL
dominant	NULL
negative	NULL
mutant	NULL
of	NULL
GATA-3	NULL
in	NULL
T	NULL
cells	NULL
from	NULL
transgenic	NULL
mice	NULL
leads	NULL
to	NULL
profound	NULL
attenuation	NULL
of	NULL
OV	NULL
A-induced	NULL
eosinophilia	NULL
and	NULL
Th2	NULL
cytokine	NULL
production	NULL
.	NULL

However	NULL
,	NULL
we	NULL
demonstrate	NULL
in	NULL
this	NULL
study	NULL
for	NULL
the	NULL
first	NULL
time	NULL
that	NULL
GAT	NULL
plays	NULL
a	NULL
role	NULL
in	NULL
the	NULL
effector	NULL
phase	NULL
of	NULL
allergic	NULL
airway	NULL
inflammation	NULL
using	NULL
mice	NULL
with	NULL
a	NULL
normal	NULL
immune	NULL
system	NULL
.	NULL

Furthermore	NULL
,	NULL
we	NULL
show	NULL
that	NULL
blockade	NULL
of	NULL
GATA-3	NULL
expression	NULL
can	NULL
be	NULL
used	NULL
as	NULL
a	NULL
therapeutic	NULL
approach	NULL
to	NULL
suppress	NULL
lung	NULL
inflammation	NULL
and	NULL
mucus	NULL
production	NULL
in	NULL
a	NULL
murine	NULL
model	NULL
of	NULL
asthma	NULL
in	NULL
vivo	NULL
.	NULL

Finally	NULL
,	NULL
we	NULL
have	NULL
found	NULL
that	NULL
GATA-3	NULL
is	NULL
a	NULL
critical	NULL
factor	NULL
for	NULL
the	NULL
maintenance	NULL
of	NULL
airway	NULL
hyperresponsiveness	NULL
in	NULL
allergic	NULL
airway	NULL
inflammation	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
these	NULL
data	NULL
suggest	NULL
that	NULL
antisense	NULL
DNA	NULL
treatment	NULL
to	NULL
GATA-3	NULL
is	NULL
a	NULL
novel	NULL
selective	NULL
way	NULL
to	NULL
simultaneously	NULL
suppress	NULL
the	NULL
production	NULL
of	NULL
several	NULL
Th2	NULL
type	NULL
cytokines	NULL
in	NULL
asthmatic	NULL
reactions	NULL
in	NULL
vivo	NULL
.	NULL

Furthermore	NULL
,	NULL
we	NULL
have	NULL
demonstrated	NULL
here	NULL
that	NULL
GAT	NULL
A-3	NULL
antisense	NULL
DNA	NULL
treatment	NULL
of	NULL
asthma	NULL
is	NULL
at	NULL
least	NULL
as	NULL
effective	NULL
as	NULL
corticosteroid	NULL
treatment	NULL
,	NULL
suggesting	NULL
that	NULL
antisense	NULL
oligonucleotides	NULL
to	NULL
GATA-3	NULL
may	NULL
be	NULL
a	NULL
novel	NULL
molecular	NULL
approach	NULL
for	NULL
the	NULL
treatment	NULL
of	NULL
inflammatory	NULL
disorders	NULL
such	NULL
as	NULL
asthma	NULL
in	NULL
humans	NULL
.	NULL

The	NULL
authors	NULL
would	NULL
like	NULL
to	NULL
thank	NULL
ChongQing	NULL
Liu	NULL
for	NULL
his	NULL
technical	NULL
help	NULL
with	NULL
the	NULL
body	NULL
plethysmography	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
authors	NULL
greatly	NULL
acknowledge	NULL
Professor	NULL
R.	NULL
Buhl	NULL
(	NULL
University	NULL
of	NULL
Mainz	NULL
)	NULL
for	NULL
his	NULL
support	NULL
in	NULL
this	NULL
study	NULL
.	NULL

The	NULL
research	NULL
of	NULL
M.F	NULL
.	NULL

Neurath	NULL
and	NULL
S.	NULL
Finotto	NULL
was	NULL
supported	NULL
by	NULL
grants	NULL
from	NULL
the	NULL
Innovationsstiftung	NULL
Rheinland-Pfalz	NULL
,	NULL
the	NULL
MAIFOR	NULL
program	NULL
,	NULL
the	NULL
Deutsche	NULL
Forschungsgemeinschaft	NULL
(	NULL
Ne	NULL
490/1-1	NULL
,	NULL
Ne	NULL
490/2-1	NULL
)	NULL
and	NULL
the	NULL
Gerhard	NULL
Hess	NULL
program	NULL
of	NULL
the	NULL
Deutsche	NULL
Forschungsgemeinschaft	NULL
(	NULL
Ne	NULL
490/3-1	NULL
)	NULL
.	NULL

Submitted	NULL
:	NULL
2	NULL
August	NULL
2000	NULL
Revised	NULL
:	NULL
19	NULL
March	NULL
2001	NULL
Accepted	NULL
:	NULL
16	NULL
April	NULL
2001	NULL
References	NULL
1	NULL
.	NULL

Kon	NULL
,	NULL
O.M	NULL
.	NULL

,	NULL
and	NULL
A.B	NULL
.	NULL

Kay	NULL
.	NULL

1999	NULL
.	NULL

T	NULL
cells	NULL
and	NULL
chronic	NULL
asthma	NULL
.	NULL

Int	NULL
.	NULL

Arch	NULL
.	NULL

Allergy	NULL
Immunol	NULL
.	NULL

118:133-135	NULL
.	NULL

2	NULL
.	NULL

Kaliner	NULL
,	NULL
M.A	NULL
.	NULL

1996	NULL
.	NULL

Pathogenesis	NULL
of	NULL
asthma	NULL
.	NULL

In	NULL
Clinical	NULL
Im-munology	NULL
.	NULL

R.R	NULL
.	NULL

Rich	NULL
,	NULL
editor	NULL
.	NULL

Mosby	NULL
,	NULL
St.	NULL
Louis	NULL
.	NULL

909-923	NULL
.	NULL

3	NULL
.	NULL

Gelfand	NULL
,	NULL
EW	NULL
.	NULL

1998	NULL
.	NULL

Essential	NULL
role	NULL
of	NULL
T	NULL
lymphocytes	NULL
in	NULL
the	NULL
development	NULL
of	NULL
allergen-driven	NULL
airway	NULL
hyperresponsiveness	NULL
.	NULL

Allergy	NULL
Asthma	NULL
Proc	NULL
.	NULL

19:365-369	NULL
.	NULL

4	NULL
.	NULL

Holgate	NULL
,	NULL
S.T	NULL
.	NULL

1999	NULL
.	NULL

The	NULL
epidemic	NULL
of	NULL
allergy	NULL
and	NULL
asthma	NULL
.	NULL

Nature	NULL
.	NULL

402	NULL
(	NULL
Suppl	NULL
.	NULL
)	NULL

:	NULL
B2-B4	NULL
.	NULL

5	NULL
.	NULL

Zhu	NULL
,	NULL
Z.	NULL
,	NULL
R.J.	NULL
Horner	NULL
,	NULL
Z.	NULL
Wang	NULL
,	NULL
Q.	NULL
Chen	NULL
,	NULL
G.P	NULL
.	NULL

Geba	NULL
,	NULL
J.	NULL
Wang	NULL
,	NULL
Y.	NULL
Zhang	NULL
,	NULL
and	NULL
J.A	NULL
.	NULL

Elias	NULL
.	NULL

1999	NULL
.	NULL

Pulmonary	NULL
expression	NULL
of	NULL
interleukin-13	NULL
causes	NULL
inflammation	NULL
,	NULL
mucus	NULL
hypersecretion	NULL
,	NULL
subepithelial	NULL
fibrosis	NULL
,	NULL
physiologic	NULL
abnormalities	NULL
,	NULL
and	NULL
eo-taxin	NULL
production	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

103:779-788	NULL
.	NULL

Antisense	NULL
DNA	NULL
to	NULL
GATA-3	NULL
Abrogates	NULL
Airway	NULL
Hyperresponsiveness	NULL
6	NULL
.	NULL

8	NULL
.	NULL

10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

Brusselle	NULL
,	NULL
G.G	NULL
.	NULL

,	NULL
J.C.	NULL
Knips	NULL
,	NULL
J.H	NULL
.	NULL

Tavernier	NULL
,	NULL
J.G	NULL
.	NULL

van	NULL
der	NULL
Heyden	NULL
,	NULL
C.A	NULL
.	NULL

Cuvelier	NULL
,	NULL
R.A.	NULL
Pauwels	NULL
,	NULL
and	NULL
H.	NULL
Bluethmann	NULL
.	NULL

1994	NULL
.	NULL

Attenuation	NULL
of	NULL
allergic	NULL
airway	NULL
inflammation	NULL
in	NULL
IL-4-deficient	NULL
mice	NULL
.	NULL

Clin	NULL
.	NULL

Exp	NULL
.	NULL

Allergy	NULL
.	NULL

24:73-80.	NULL
.	NULL

Corry	NULL
,	NULL
D.B	NULL
.	NULL

,	NULL
H.G	NULL
.	NULL

Folkesson	NULL
,	NULL
M.L	NULL
.	NULL

Warnock	NULL
,	NULL
D.J	NULL
.	NULL

Erle	NULL
,	NULL
M.A	NULL
.	NULL

Matthay	NULL
,	NULL
J.P.	NULL
Wiener-Kronish	NULL
,	NULL
and	NULL
R.M	NULL
.	NULL

Locksley	NULL
.	NULL

1996	NULL
.	NULL

Interleukin	NULL
4	NULL
,	NULL
but	NULL
not	NULL
interleukin	NULL
5	NULL
or	NULL
eosinophils	NULL
,	NULL
is	NULL
required	NULL
in	NULL
a	NULL
murine	NULL
model	NULL
of	NULL
acute	NULL
airway	NULL
hyperreactivity	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

183:109-117	NULL
.	NULL

Griinig	NULL
,	NULL
G.	NULL
,	NULL
M.	NULL
Warnock	NULL
,	NULL
A.E	NULL
.	NULL

Wakil	NULL
,	NULL
R.	NULL
Venkayya	NULL
,	NULL
F.	NULL
Brom-bacher	NULL
,	NULL
D.M	NULL
.	NULL

Rennick	NULL
,	NULL
D.	NULL
Sheppard	NULL
,	NULL
M.	NULL
Mohrs	NULL
,	NULL
D.D	NULL
.	NULL

Donaldson	NULL
,	NULL
R.M	NULL
.	NULL

Locksley	NULL
,	NULL
and	NULL
D.B	NULL
.	NULL

Corry	NULL
.	NULL

1998	NULL
.	NULL

Requirement	NULL
for	NULL
IL-13	NULL
independently	NULL
of	NULL
IL-4	NULL
in	NULL
experimental	NULL
asthma	NULL
.	NULL

Science	NULL
.	NULL

282:2261-2263.	NULL
.	NULL

Himmelrich	NULL
,	NULL
H.	NULL
,	NULL
C.	NULL
Parra-Lopez	NULL
,	NULL
F.	NULL
Tacchini-Cottier	NULL
,	NULL
J.A	NULL
.	NULL

Louis	NULL
,	NULL
and	NULL
P.	NULL
Launois	NULL
.	NULL

1998	NULL
.	NULL

The	NULL
IL-4	NULL
rapidly	NULL
produced	NULL
in	NULL
BALB/c	NULL
mice	NULL
after	NULL
infection	NULL
with	NULL
Leishmania	NULL
major	NULL
downregulates	NULL
IL-12	NULL
receptor	NULL
B-2	NULL
chain	NULL
expression	NULL
on	NULL
CD4*	NULL
T	NULL
cells	NULL
resulting	NULL
in	NULL
a	NULL
state	NULL
of	NULL
unresponsiveness	NULL
to	NULL
IL-12	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

161:6156-6163	NULL
.	NULL

Hamid	NULL
,	NULL
Q.A	NULL
.	NULL

,	NULL
and	NULL
E.M.	NULL
Minshall	NULL
.	NULL

2000	NULL
.	NULL

Molecular	NULL
pathology	NULL
of	NULL
allergic	NULL
disease	NULL
.	NULL

I	NULL
.	NULL

Lower	NULL
airway	NULL
disease	NULL
.	NULL

J	NULL
.	NULL

Allergy	NULL
Clin	NULL
.	NULL

Immunol	NULL
.	NULL

105:20-36	NULL
.	NULL

Shi	NULL
,	NULL
H.Z	NULL
.	NULL

,	NULL
J.M	NULL
.	NULL

Deng	NULL
,	NULL
H.	NULL
Xu	NULL
,	NULL
Z.X	NULL
.	NULL

Nong	NULL
,	NULL
C.Q	NULL
.	NULL

Xiao	NULL
,	NULL
Z.M	NULL
.	NULL

Liu	NULL
,	NULL
S.M	NULL
.	NULL

Qin	NULL
,	NULL
HL	NULL
.	NULL

Jiang	NULL
,	NULL
G.N	NULL
.	NULL

Liu	NULL
,	NULL
and	NULL
Y.Q	NULL
.	NULL

Chen	NULL
.	NULL

1998	NULL
.	NULL

Effect	NULL
of	NULL
inhaled	NULL
interleukin-4	NULL
on	NULL
airway	NULL
hyperreactivity	NULL
in	NULL
asthmatics	NULL
.	NULL

Am	NULL
.	NULL

Rev	NULL
.	NULL

Resp	NULL
.	NULL

Dis	NULL
.	NULL

157:1818-1821	NULL
.	NULL

Teran	NULL
,	NULL
LM	NULL
.	NULL

,	NULL
M.	NULL
Mochizuki	NULL
,	NULL
J.	NULL
Bartels	NULL
,	NULL
E.L.	NULL
Valencia	NULL
,	NULL
T.	NULL
Na-kajima	NULL
,	NULL
K.	NULL
Hirai	NULL
,	NULL
and	NULL
J.M	NULL
.	NULL

Schroeder	NULL
.	NULL

1999	NULL
.	NULL

Th1-	NULL
and	NULL
Th2-type	NULL
cytokines	NULL
regulate	NULL
the	NULL
expression	NULL
and	NULL
production	NULL
of	NULL
eo-taxin	NULL
and	NULL
RANTES	NULL
by	NULL
human	NULL
lung	NULL
fibroblasts	NULL
.	NULL

Am	NULL
.	NULL

J.	NULL
Respir	NULL
.	NULL

Cell	NULL
Mol	NULL
.	NULL

Biol	NULL
.	NULL

20:1044-1549	NULL
.	NULL

Pandolfi	NULL
,	NULL
P.P	NULL
.	NULL

,	NULL
M.E	NULL
.	NULL

Roth	NULL
,	NULL
A.	NULL
Karis	NULL
,	NULL
M.W	NULL
.	NULL

Leonard	NULL
,	NULL
E.	NULL
Dzierzak	NULL
,	NULL
F.G.	NULL
Grosveld	NULL
,	NULL
J.D	NULL
.	NULL

Engel	NULL
,	NULL
and	NULL
M.H	NULL
.	NULL

Lindenbaum	NULL
.	NULL

1995	NULL
.	NULL

Targeted	NULL
disruption	NULL
of	NULL
the	NULL
GATA-3	NULL
gene	NULL
causes	NULL
severe	NULL
abnormalities	NULL
in	NULL
the	NULL
nervous	NULL
system	NULL
and	NULL
in	NULL
fetal	NULL
liver	NULL
hae-matopoiesis	NULL
.	NULL

Nat	NULL
.	NULL

Genet	NULL
.	NULL

11:10-44	NULL
.	NULL

Ho	NULL
,	NULL
.C	NULL
.	NULL

,	NULL
P.	NULL
Vorhees	NULL
,	NULL
N.	NULL
Marin	NULL
,	NULL
B.	NULL
Karpinsky-Oakley	NULL
,	NULL
S.F	NULL
.	NULL

Tsai	NULL
,	NULL
S.H	NULL
.	NULL

Orkin	NULL
,	NULL
and	NULL
J.M	NULL
.	NULL

Leiden	NULL
.	NULL

1993	NULL
.	NULL

Human	NULL
GATA-3	NULL
:	NULL
a	NULL
lineage-restricted	NULL
transcription	NULL
factor	NULL
that	NULL
regulates	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
T	NULL
cell	NULL
receptor	NULL
a	NULL
gene	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

10:1187-1191	NULL
.	NULL

Ting	NULL
,	NULL
C.N	NULL
.	NULL

,	NULL
M.C	NULL
.	NULL

Olson	NULL
,	NULL
K.P	NULL
.	NULL

Barton	NULL
,	NULL
and	NULL
J.M	NULL
.	NULL

Leiden	NULL
.	NULL

1996	NULL
.	NULL

Transcription	NULL
factor	NULL
GATA-3	NULL
is	NULL
required	NULL
for	NULL
development	NULL
of	NULL
the	NULL
T-cell	NULL
lineage	NULL
.	NULL

Nature	NULL
.	NULL

384:474-478	NULL
.	NULL

Pedone	NULL
,	NULL
P.V	NULL
.	NULL

,	NULL
J.G	NULL
.	NULL

Omichinski	NULL
,	NULL
P.	NULL
Nony	NULL
,	NULL
C.	NULL
Trainor	NULL
,	NULL
A.M.	NULL
Gronenborn	NULL
,	NULL
G.M	NULL
.	NULL

Clore	NULL
,	NULL
and	NULL
G.	NULL
Felsenfeld	NULL
.	NULL

1997	NULL
.	NULL

The	NULL
N-terminal	NULL
fingers	NULL
of	NULL
chicken	NULL
GATA-2	NULL
and	NULL
GATA-3	NULL
are	NULL
independent	NULL
sequence-specific	NULL
DNA	NULL
binding	NULL
domains	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

16:2874-2882	NULL
.	NULL

Hendriks	NULL
,	NULL
R.W	NULL
.	NULL

,	NULL
M.C	NULL
.	NULL

Nawijn	NULL
,	NULL
J.D	NULL
.	NULL

Engel	NULL
,	NULL
H.	NULL
van	NULL
Door-ninck	NULL
,	NULL
F.	NULL
Grosveld	NULL
,	NULL
and	NULL
A.	NULL
Karis	NULL
.	NULL

1999	NULL
.	NULL

Expression	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
GATA-3	NULL
is	NULL
required	NULL
for	NULL
the	NULL
development	NULL
of	NULL
the	NULL
earliest	NULL
T	NULL
cell	NULL
progenitors	NULL
and	NULL
correlates	NULL
with	NULL
stages	NULL
of	NULL
cellular	NULL
proliferation	NULL
in	NULL
the	NULL
thymus	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

29	NULL
:	NULL
1912-1918	NULL
.	NULL

Zheng	NULL
,	NULL
W.	NULL
,	NULL
and	NULL
R.A.	NULL
Flavell	NULL
.	NULL

1997	NULL
.	NULL

The	NULL
transcription	NULL
factor	NULL
GATA-3	NULL
is	NULL
necessary	NULL
and	NULL
sufficent	NULL
for	NULL
Th2	NULL
cytokine	NULL
gene	NULL
expression	NULL
in	NULL
CD4*	NULL
T	NULL
cells	NULL
.	NULL

Cell	NULL
.	NULL

89:587-596	NULL
.	NULL

Ouyang	NULL
,	NULL
W.	NULL
,	NULL
S.H	NULL
.	NULL

Ranganath	NULL
,	NULL
K.	NULL
Weindel	NULL
,	NULL
D.	NULL
Bhattacharya	NULL
,	NULL
T.L	NULL
.	NULL

Murphy	NULL
,	NULL
W.C.	NULL
Sha	NULL
,	NULL
and	NULL
K.M	NULL
.	NULL

Murphy	NULL
.	NULL

1998	NULL
.	NULL

Inhibition	NULL
of	NULL
Th1	NULL
development	NULL
mediated	NULL
by	NULL
GATA-3	NULL
through	NULL
an	NULL
IL-4-independent	NULL
mechanism	NULL
.	NULL

Immunity	NULL
.	NULL

9:745-755	NULL
.	NULL

1259	NULL
Finotto	NULL
et	NULL
al	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

Lee	NULL
,	NULL
HJ	NULL
.	NULL

,	NULL
A.	NULL
O'Garra	NULL
,	NULL
K.	NULL
Arai	NULL
,	NULL
and	NULL
N.	NULL
Arai	NULL
.	NULL

1998	NULL
.	NULL

Characterization	NULL
of	NULL
cis-regulatory	NULL
elements	NULL
and	NULL
nuclear	NULL
factors	NULL
conferring	NULL
Th2-specific	NULL
expression	NULL
of	NULL
the	NULL
IL-5	NULL
gene	NULL
:	NULL
a	NULL
role	NULL
for	NULL
a	NULL
GATA-binding	NULL
protein	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

160:2343-2352	NULL
.	NULL

Zhang	NULL
,	NULL
D.H.	NULL
,	NULL
L.	NULL
Cohn	NULL
,	NULL
P.	NULL
Ray	NULL
,	NULL
K.	NULL
Bottomly	NULL
,	NULL
and	NULL
A.	NULL
Ray	NULL
.	NULL

1997	NULL
.	NULL

Transcription	NULL
factor	NULL
GATA-3	NULL
is	NULL
differentially	NULL
expressed	NULL
in	NULL
murine	NULL
Th1	NULL
and	NULL
Th2	NULL
cells	NULL
and	NULL
controls	NULL
Th2-specific	NULL
expression	NULL
of	NULL
the	NULL
interleukin-5	NULL
gene	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

272:21597-21603	NULL
.	NULL

Ranganath	NULL
,	NULL
S.	NULL
,	NULL
W.	NULL
Ouyang	NULL
,	NULL
D.	NULL
Bhattarcharya	NULL
,	NULL
W.C.	NULL
Sha	NULL
,	NULL
A.	NULL
Grupe	NULL
,	NULL
G.	NULL
Peltz	NULL
,	NULL
and	NULL
K.M	NULL
.	NULL

Murphy	NULL
.	NULL

1998	NULL
.	NULL

GATA-3-depen-dent	NULL
enhancer	NULL
activity	NULL
in	NULL
IL-4	NULL
gene	NULL
regulation	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

161:3822-3826	NULL
.	NULL

Miaw	NULL
,	NULL
S.C.	NULL
,	NULL
A.	NULL
Choi	NULL
,	NULL
E.	NULL
Yu	NULL
,	NULL
H.	NULL
Kishikawa	NULL
,	NULL
and	NULL
I.C	NULL
.	NULL

Ho	NULL
.	NULL

2000	NULL
.	NULL

ROG	NULL
,	NULL
repressor	NULL
of	NULL
GATA	NULL
,	NULL
regulates	NULL
the	NULL
expression	NULL
of	NULL
cytokine	NULL
genes	NULL
.	NULL

Immunity	NULL
.	NULL

12:323-333	NULL
.	NULL

Ferber	NULL
,	NULL
L.A.	NULL
,	NULL
H.J	NULL
.	NULL

Lee	NULL
,	NULL
F.	NULL
Zonin	NULL
,	NULL
V.	NULL
Heath	NULL
,	NULL
A.	NULL
Mui	NULL
,	NULL
N.	NULL
Arai	NULL
,	NULL
and	NULL
A.	NULL
O'Garra	NULL
.	NULL

1999	NULL
.	NULL

GATA-3	NULL
significantly	NULL
downregulates	NULL
IFN-y	NULL
production	NULL
from	NULL
developing	NULL
Th1	NULL
cells	NULL
in	NULL
addition	NULL
to	NULL
inducing	NULL
IL-4	NULL
and	NULL
IL-5	NULL
levels	NULL
.	NULL

Clin	NULL
.	NULL

Immunol	NULL
.	NULL

91:134-144	NULL
.	NULL

Kurata	NULL
,	NULL
H.	NULL
,	NULL
H.J	NULL
.	NULL

Lee	NULL
,	NULL
A.	NULL
O'Garra	NULL
,	NULL
and	NULL
N.	NULL
Arai	NULL
.	NULL

1999	NULL
.	NULL

Ectopic	NULL
expression	NULL
of	NULL
activated	NULL
STAT-6	NULL
induces	NULL
the	NULL
expression	NULL
of	NULL
TH2-specific	NULL
cytokines	NULL
and	NULL
transcription	NULL
factors	NULL
in	NULL
developing	NULL
THA	NULL
cells	NULL
.	NULL

Immunity	NULL
.	NULL

11:677-688	NULL
.	NULL

Ouyang	NULL
,	NULL
W.	NULL
,	NULL
M.	NULL
Lohning	NULL
,	NULL
Z.	NULL
Gao	NULL
,	NULL
M.	NULL
Assenmacher	NULL
,	NULL
S.	NULL
Ranganath	NULL
,	NULL
A.	NULL
Radbruch	NULL
,	NULL
and	NULL
K.M	NULL
.	NULL

Murphy	NULL
.	NULL

2000	NULL
.	NULL

Stat6-independent	NULL
GATA-3	NULL
autoactivation	NULL
directs	NULL
IL-4-independent	NULL
Th2	NULL
development	NULL
and	NULL
commitment	NULL
.	NULL

Immunity	NULL
.	NULL

12:27-37	NULL
.	NULL

Nakamura	NULL
,	NULL
Y.	NULL
,	NULL
O.	NULL
Ghaffar	NULL
,	NULL
R.	NULL
Olivenstein	NULL
,	NULL
R.A.	NULL
Taha	NULL
,	NULL
A.	NULL
Soussi-Gounni	NULL
,	NULL
D.H.	NULL
Zhang	NULL
,	NULL
A.	NULL
Ray	NULL
,	NULL
and	NULL
Q.	NULL
Hamid	NULL
.	NULL

1999	NULL
.	NULL

Gene	NULL
expression	NULL
of	NULL
the	NULL
GATA-3	NULL
transcription	NULL
factor	NULL
is	NULL
increased	NULL
in	NULL
atopic	NULL
asthma	NULL
.	NULL

J	NULL
.	NULL

Allergy	NULL
Clin	NULL
.	NULL

Immunol	NULL
.	NULL

103:215-222	NULL
.	NULL

Henderson	NULL
,	NULL
WR	NULL
.	NULL

,	NULL
Jr.	NULL
,	NULL
EY	NULL
.	NULL

Chi	NULL
,	NULL
R.J.K	NULL
.	NULL

Albert	NULL
,	NULL
A.J	NULL
.	NULL

Chu	NULL
,	NULL
W.J.E	NULL
.	NULL

Lamm	NULL
,	NULL
Y.	NULL
Rochon	NULL
,	NULL
M.	NULL
Jonas	NULL
,	NULL
P.E	NULL
.	NULL

Christi	NULL
,	NULL
and	NULL
J.M	NULL
.	NULL

Harlan	NULL
.	NULL

1997	NULL
.	NULL

Blockade	NULL
of	NULL
CD49d	NULL
(	NULL
@	NULL
4-integrin	NULL
)	NULL
on	NULL
intrapulmonary	NULL
but	NULL
not	NULL
circulating	NULL
leukocytes	NULL
inhibits	NULL
airway	NULL
inflammation	NULL
and	NULL
hyperresponsiveness	NULL
in	NULL
a	NULL
mouse	NULL
model	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

100:3083-3092	NULL
.	NULL

Finotto	NULL
,	NULL
S.	NULL
,	NULL
K.	NULL
Krieglstein	NULL
,	NULL
A.	NULL
Schober	NULL
,	NULL
F.	NULL
Deimling	NULL
,	NULL
K.	NULL
Lindner	NULL
,	NULL
B.	NULL
Bruhl	NULL
,	NULL
K.	NULL
Beier	NULL
,	NULL
J.	NULL
Metz	NULL
,	NULL
J.E	NULL
.	NULL

Garcia-Arraras	NULL
,	NULL
J.L	NULL
.	NULL

Roig-Lopez	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1999	NULL
.	NULL

Analysis	NULL
of	NULL
mice	NULL
carrying	NULL
targeted	NULL
mutations	NULL
of	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
gene	NULL
argues	NULL
against	NULL
an	NULL
essential	NULL
role	NULL
of	NULL
glucocorticoid	NULL
signaling	NULL
for	NULL
generating	NULL
adrenal	NULL
chromaffin	NULL
cells	NULL
.	NULL

Development	NULL
.	NULL

126:2935-2944	NULL
.	NULL

Finotto	NULL
,	NULL
S.	NULL
,	NULL
Y.A	NULL
.	NULL

Mekori	NULL
,	NULL
and	NULL
D.D	NULL
.	NULL

Metcalfe	NULL
.	NULL

1997	NULL
.	NULL

Gluco-corticoids	NULL
decrease	NULL
tissue	NULL
mast	NULL
cell	NULL
number	NULL
by	NULL
reducing	NULL
the	NULL
production	NULL
of	NULL
the	NULL
c-kit	NULL
ligand	NULL
,	NULL
stem	NULL
cell	NULL
factor	NULL
,	NULL
by	NULL
resident	NULL
cells	NULL
.	NULL

In	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
evidence	NULL
in	NULL
murine	NULL
systems	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

99:1721-1729	NULL
.	NULL

Atreya	NULL
,	NULL
R.	NULL
,	NULL
J.	NULL
Mudter	NULL
,	NULL
S.	NULL
Finotto	NULL
,	NULL
J.	NULL
Mullberg	NULL
,	NULL
T.	NULL
Jostock	NULL
,	NULL
S.	NULL
Wirtz	NULL
,	NULL
M.	NULL
Schutz	NULL
,	NULL
B.	NULL
Bartsch	NULL
,	NULL
M.	NULL
Holtmann	NULL
,	NULL
C.	NULL
Becker	NULL
,	NULL
et	NULL
al	NULL
.	NULL

2000	NULL
.	NULL

Blockade	NULL
of	NULL
IL-6	NULL
trans-signaling	NULL
abrogates	NULL
established	NULL
experimental	NULL
colitis	NULL
in	NULL
mice	NULL
by	NULL
suppression	NULL
of	NULL
T	NULL
cell	NULL
resistance	NULL
against	NULL
apoptosis	NULL
.	NULL

Nat	NULL
.	NULL

Med	NULL
.	NULL

6:583-588	NULL
.	NULL

Wirtz	NULL
,	NULL
S.	NULL
,	NULL
S.	NULL
Finotto	NULL
,	NULL
S.	NULL
Kanzler	NULL
,	NULL
A.W	NULL
.	NULL

Lohse	NULL
,	NULL
M.	NULL
Blessing	NULL
,	NULL
H.A	NULL
.	NULL

Lehr	NULL
,	NULL
P.R	NULL
.	NULL

Galle	NULL
,	NULL
and	NULL
M.F	NULL
.	NULL

Neurath	NULL
.	NULL

1999	NULL
.	NULL

Chronic	NULL
intestinal	NULL
inflammation	NULL
in	NULL
STAT-4	NULL
transgenic	NULL
mice	NULL
:	NULL
characterization	NULL
of	NULL
disease	NULL
and	NULL
adoptive	NULL
transfer	NULL
by	NULL
TNF-	NULL
plus	NULL
IFN-y-producing	NULL
CD4*	NULL
T	NULL
cells	NULL
that	NULL
respond	NULL
to	NULL
bacterial	NULL
antigens	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

162:1884-1888	NULL
.	NULL

Neuhaus-Steinmetz	NULL
,	NULL
U.	NULL
,	NULL
T.	NULL
Glaab	NULL
,	NULL
A.	NULL
Daser	NULL
,	NULL
A.	NULL
Braun	NULL
,	NULL
M.	NULL
34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

Lommatzsch	NULL
,	NULL
U.	NULL
Herz	NULL
,	NULL
J.	NULL
Kips	NULL
,	NULL
Y.	NULL
Alarie	NULL
,	NULL
and	NULL
H.	NULL
Renz	NULL
.	NULL

2000	NULL
.	NULL

Sequential	NULL
development	NULL
of	NULL
airway	NULL
hyperresponsiveness	NULL
and	NULL
acute	NULL
airway	NULL
obstruction	NULL
in	NULL
a	NULL
mouse	NULL
model	NULL
of	NULL
allergic	NULL
inflammation	NULL
.	NULL

Int	NULL
.	NULL

Arch	NULL
.	NULL

Allergy	NULL
Immunol	NULL
.	NULL

121:57-67	NULL
.	NULL

Hamelmann	NULL
,	NULL
E.	NULL
,	NULL
J.	NULL
Schwarze	NULL
,	NULL
K.	NULL
Takeda	NULL
,	NULL
A.	NULL
Oshiba	NULL
,	NULL
G.L	NULL
.	NULL

Larsen	NULL
,	NULL
C.G	NULL
.	NULL

Irvin	NULL
,	NULL
and	NULL
E.W	NULL
.	NULL

Gelfand	NULL
.	NULL

1997	NULL
.	NULL

Noninvasive	NULL
measurement	NULL
of	NULL
airway	NULL
responsiveness	NULL
in	NULL
allergic	NULL
mice	NULL
using	NULL
barometric	NULL
plethysmography	NULL
.	NULL

Am	NULL
.	NULL

J.	NULL
Respir	NULL
.	NULL

Crit	NULL
.	NULL

Care	NULL
Med	NULL
.	NULL

156:766-775	NULL
.	NULL

De	NULL
Sanctis	NULL
,	NULL
G.T	NULL
.	NULL

,	NULL
A.	NULL
Itoh	NULL
,	NULL
F.H.Y	NULL
.	NULL

Green	NULL
,	NULL
S.	NULL
Qin	NULL
,	NULL
T.	NULL
Kimura	NULL
,	NULL
J.K.	NULL
Grobholz	NULL
,	NULL
TR	NULL
.	NULL

Martin	NULL
,	NULL
T.	NULL
Maki	NULL
,	NULL
and	NULL
J.M	NULL
.	NULL

Drazen	NULL
.	NULL

1997	NULL
.	NULL

T-lymphocytes	NULL
regulate	NULL
genetically	NULL
determined	NULL
airway	NULL
hyperresponsiveness	NULL
in	NULL
mice	NULL
.	NULL

Nat	NULL
.	NULL

Med	NULL
.	NULL

3:460-462	NULL
.	NULL

De	NULL
Sanctis	NULL
,	NULL
G.T	NULL
.	NULL

,	NULL
M.	NULL
Merchant	NULL
,	NULL
D.R	NULL
.	NULL

Beier	NULL
,	NULL
RD	NULL
.	NULL

Dredge	NULL
,	NULL
J.K.	NULL
Grobholz	NULL
,	NULL
TR	NULL
.	NULL

Martin	NULL
,	NULL
E.S	NULL
.	NULL

Lander	NULL
,	NULL
and	NULL
J.M	NULL
.	NULL

Drazen	NULL
.	NULL

1995	NULL
.	NULL

Quantitative	NULL
locus	NULL
analysis	NULL
of	NULL
airway	NULL
hyperresponsiveness	NULL
in	NULL
A/J	NULL
and	NULL
C57BL/6J	NULL
mice	NULL
.	NULL

Nat	NULL
.	NULL

Genet	NULL
.	NULL

11:150-154	NULL
.	NULL

Henderson	NULL
,	NULL
WR	NULL
.	NULL

,	NULL
D.B	NULL
.	NULL

Lewis	NULL
,	NULL
RK	NULL
.	NULL

Albert	NULL
,	NULL
Y.	NULL
Zhang	NULL
,	NULL
W.J.E	NULL
.	NULL

Lamm	NULL
,	NULL
G.K.S	NULL
.	NULL

Chiang	NULL
,	NULL
F.	NULL
Jones	NULL
,	NULL
P.	NULL
Eriksen	NULL
,	NULL
Y.	NULL
Tien	NULL
,	NULL
M.	NULL
Jonas	NULL
,	NULL
and	NULL
E.Y	NULL
.	NULL

Chi	NULL
.	NULL

1996	NULL
.	NULL

The	NULL
importance	NULL
of	NULL
leuko-trienes	NULL
in	NULL
airway	NULL
inflammation	NULL
in	NULL
a	NULL
mouse	NULL
murine	NULL
model	NULL
of	NULL
asthma	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

184:1483-1494	NULL
.	NULL

Zhang	NULL
,	NULL
D.H.	NULL
,	NULL
L.	NULL
Yang	NULL
,	NULL
L.	NULL
Cohn	NULL
,	NULL
L.	NULL
Parkyn	NULL
,	NULL
R.	NULL
Homer	NULL
,	NULL
P.	NULL
Ray	NULL
,	NULL
and	NULL
A.	NULL
Ray	NULL
.	NULL

1999	NULL
.	NULL

Inhibition	NULL
of	NULL
allergic	NULL
airway	NULL
inflammation	NULL
in	NULL
a	NULL
murine	NULL
model	NULL
of	NULL
asthma	NULL
by	NULL
expression	NULL
of	NULL
a	NULL
dominant	NULL
negative	NULL
mutant	NULL
of	NULL
GATA-3	NULL
.	NULL

Immunity	NULL
.	NULL

11:473-482	NULL
.	NULL

Ray	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
L.	NULL
Cohn	NULL
.	NULL

1999	NULL
.	NULL

Th2	NULL
cells	NULL
and	NULL
GATA-3	NULL
in	NULL
asthma	NULL
:	NULL
new	NULL
insights	NULL
into	NULL
the	NULL
regulation	NULL
of	NULL
airway	NULL
inflammation	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

104:985-993	NULL
.	NULL

Rodriguez-Palmero	NULL
,	NULL
M.	NULL
,	NULL
T.	NULL
Hara	NULL
,	NULL
A.	NULL
Thumbs	NULL
,	NULL
and	NULL
T.	NULL
Hunig	NULL
.	NULL

1999	NULL
.	NULL

Triggering	NULL
of	NULL
T	NULL
cell	NULL
proliferation	NULL
through	NULL
CD28	NULL
induces	NULL
GATA-3	NULL
and	NULL
promotes	NULL
T	NULL
helper	NULL
type	NULL
2	NULL
differentiation	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

29:14-24	NULL
.	NULL

Blumenthal	NULL
,	NULL
S.G.	NULL
,	NULL
G.	NULL
Aichele	NULL
,	NULL
T.	NULL
Wirth	NULL
,	NULL
A.P	NULL
.	NULL

Czernilofsky	NULL
,	NULL
A.	NULL
Nordheim	NULL
,	NULL
and	NULL
J.	NULL
Dittmer	NULL
.	NULL

1999	NULL
.	NULL

Regulation	NULL
of	NULL
the	NULL
human	NULL
interleukin-5	NULL
promoter	NULL
by	NULL
Ets	NULL
transcription	NULL
factors	NULL
.	NULL

Ets1	NULL
and	NULL
Ets2	NULL
,	NULL
but	NULL
not	NULL
EIf-1	NULL
,	NULL
cooperate	NULL
with	NULL
GATA3	NULL
and	NULL
HTLV-I	NULL
1260	NULL
42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

Tax1	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

274:12910-12916	NULL
.	NULL

Zhu	NULL
,	NULL
Y.X	NULL
.	NULL

,	NULL
L.	NULL
Y.	NULL
Kang	NULL
,	NULL
W.	NULL
Luo	NULL
,	NULL
C.C	NULL
.	NULL

Li	NULL
,	NULL
L.	NULL
Yang	NULL
,	NULL
and	NULL
Y.C	NULL
.	NULL

Yang	NULL
.	NULL

1996	NULL
.	NULL

Multiple	NULL
transcription	NULL
factors	NULL
are	NULL
required	NULL
for	NULL
activation	NULL
of	NULL
human	NULL
interleukin	NULL
9	NULL
gene	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

271:26	NULL
.	NULL

Wagner	NULL
,	NULL
R.W	NULL
.	NULL

1994	NULL
.	NULL

Gene	NULL
inhibition	NULL
using	NULL
antisense	NULL
oli-godeoxynucleotides	NULL
.	NULL

Nature	NULL
.	NULL

372:333-335	NULL
.	NULL

Wakatsuki	NULL
,	NULL
Y.	NULL
,	NULL
M.F	NULL
.	NULL

Neurath	NULL
,	NULL
E.E	NULL
.	NULL

Max	NULL
,	NULL
and	NULL
W.	NULL
Strober	NULL
.	NULL

1994	NULL
.	NULL

The	NULL
B	NULL
cell	NULL
specific	NULL
transcription	NULL
factor	NULL
BSAP	NULL
regulates	NULL
B	NULL
cell	NULL
proliferation	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

179:1099-1108	NULL
.	NULL

Kopf	NULL
,	NULL
M.	NULL
,	NULL
G.	NULL
LeGros	NULL
,	NULL
M.	NULL
Bachmann	NULL
,	NULL
M.C	NULL
.	NULL

Lamers	NULL
,	NULL
H.	NULL
Bluethmann	NULL
,	NULL
and	NULL
G.	NULL
Koehler	NULL
.	NULL

1993	NULL
.	NULL

Disruption	NULL
of	NULL
the	NULL
murine	NULL
IL-4	NULL
gene	NULL
blocks	NULL
Th2	NULL
cytokine	NULL
responses	NULL
.	NULL

Nature	NULL
.	NULL

362	NULL
:	NULL
245-248	NULL
.	NULL

Tepper	NULL
,	NULL
RL	NULL
.	NULL

,	NULL
D.A	NULL
.	NULL

Levinson	NULL
,	NULL
B.Z	NULL
.	NULL

Stanger	NULL
,	NULL
J.	NULL
Campos-Torres	NULL
,	NULL
A.K	NULL
.	NULL

Abbas	NULL
,	NULL
and	NULL
P.	NULL
Leder	NULL
.	NULL

1990	NULL
.	NULL

IL-4	NULL
induces	NULL
aller-gic-like	NULL
inflammatory	NULL
disease	NULL
and	NULL
alters	NULL
T	NULL
cell	NULL
development	NULL
in	NULL
transgenic	NULL
mice	NULL
.	NULL

Cell	NULL
.	NULL

62:457-467	NULL
.	NULL

Miyata	NULL
,	NULL
S.	NULL
,	NULL
T.	NULL
Matsuyama	NULL
,	NULL
T.	NULL
Kodama	NULL
,	NULL
Y.	NULL
Nishioka	NULL
,	NULL
K.	NULL
Kuribayashi	NULL
,	NULL
K.	NULL
Takeda	NULL
,	NULL
S.	NULL
Akira	NULL
,	NULL
and	NULL
M.	NULL
Sugita	NULL
.	NULL

1999	NULL
.	NULL

STAT-6	NULL
deficiency	NULL
in	NULL
a	NULL
mouse	NULL
model	NULL
of	NULL
allergen-induced	NULL
airways	NULL
inflammation	NULL
abolishes	NULL
eosinophilia	NULL
but	NULL
induces	NULL
infiltration	NULL
of	NULL
CD8+*	NULL
T	NULL
cells	NULL
.	NULL

Clin	NULL
.	NULL

Exp	NULL
.	NULL

Allergy	NULL
.	NULL

29:114-123	NULL
.	NULL

Danzig	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
F.	NULL
Cuss	NULL
.	NULL

1997	NULL
.	NULL

Inhibition	NULL
of	NULL
interleukin-5	NULL
with	NULL
a	NULL
monoclonal	NULL
antibody	NULL
attenuates	NULL
allergic	NULL
inflammation	NULL
.	NULL

Allergy	NULL
.	NULL

52:787-794	NULL
.	NULL

Robinson	NULL
,	NULL
D.S	NULL
.	NULL

,	NULL
J	NULL
.	NULL

North	NULL
,	NULL
K.	NULL
Zeibecoglou	NULL
,	NULL
S.	NULL
Ying	NULL
,	NULL
Q.	NULL
Meng	NULL
,	NULL
S.	NULL
Rankin	NULL
,	NULL
Q.	NULL
Hamid	NULL
,	NULL
J.	NULL
Tavernier	NULL
,	NULL
and	NULL
A.B	NULL
.	NULL

Kay	NULL
.	NULL

1999	NULL
.	NULL

Eosinophil	NULL
development	NULL
and	NULL
bone	NULL
marrow	NULL
and	NULL
tissue	NULL
eosinophils	NULL
in	NULL
atopic	NULL
asthma	NULL
.	NULL

Int	NULL
.	NULL

Arch	NULL
.	NULL

Allergy	NULL
Immunol	NULL
.	NULL

118	NULL
:	NULL
98-100	NULL
.	NULL

Ranger	NULL
,	NULL
A.M.	NULL
,	NULL
M.R	NULL
.	NULL

Hodge	NULL
,	NULL
EM	NULL
.	NULL

Gravallese	NULL
,	NULL
M.	NULL
Oukka	NULL
,	NULL
L.	NULL
Davidson	NULL
,	NULL
FW	NULL
.	NULL

Alt	NULL
,	NULL
F.C	NULL
.	NULL

Brousse	NULL
,	NULL
T.	NULL
Hoey	NULL
,	NULL
M.	NULL
Grusby	NULL
,	NULL
and	NULL
L.H	NULL
.	NULL

Glimcher	NULL
.	NULL

1998	NULL
.	NULL

Delayed	NULL
lymphoid	NULL
repopulation	NULL
with	NULL
defects	NULL
in	NULL
IL-4-driven	NULL
responses	NULL
produced	NULL
by	NULL
inactivation	NULL
of	NULL
NF-ATc	NULL
.	NULL

Immunity	NULL
.	NULL

8:125-134	NULL
.	NULL

Antisense	NULL
DNA	NULL
to	NULL
GATA-3	NULL
Abrogates	NULL
Airway	NULL
Hyperresponsiveness	NULL

